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RESUMEN:  
 
1.   INTRODUCCIÓN: 
 
RAS, es uno de los oncogenes más mutados en cáncer. Hoy en día sabemos que las proteínas 
RAS de la membrana plasmática están presentes en diferentes microdominios, como en las 
balsas lipídicas (BL) o en membrana desordenada (MD), y su distribución está modulada por 
la depalmitoilasa, APT-1. Además, RAS también se localiza en diferentes organelos 
intracelulares siendo los más comunes el Retículo Endoplasmático (RE) y el Complejo de 
Golgi (CG) donde también es funcional, contrastando con una idea inicial de una sola fuente 
de las señales de RAS. Sin embargo, poco se ha sabe de cómo la sublocalización de RAS 
afectan a su potencial oncogénico.  
 
Es bien conocido que las mutaciones de RAS en distintos tipos de cánceres humanos y el 
cáncer de tiroides es uno de ellos. De hecho, los carcinomas papilares de tiroides presentan 
un 26% de mutaciones en RAS, los carcinomas foliculares de tiroides sobre un 40% y los 
carcinomas anaplásicos, los más agresivos, sobre un 53%. Sin embargo, las mutaciones de RAS 
también ocurren en un 20-25% de los adenomas benignos tiroideos. En consecuencia, a pesar 
de que en la última década se ha realizado un esfuerzo considerable en asociar la presencia de 
RAS con el manejo clínico de los nódulos tiroideos y del cáncer de tiroides. Sin embargo, la 
gran mayoría de los nódulos tiroideos positivos para RAS son clasificados como 
indeterminados. Además, debido al papel incierto de RAS en la evolución clínica del cáncer 
de tiroides, ha sido difícil usar las mutaciones de RAS para ayudar al manejo de estos tumores. 
En consecuencia, nuevos conceptos son necesarios para descartar la malignidad y predecir la 
agresividad en los cánceres de tiroides ya que las nuevas guías clínicas se están encaminando 
a aproximaciones más conservadoras. 
                                                                                                                                                                                                                                         
Además, en los últimos años ha surgido una nueva faceta de RAS en cáncer, ya que se ha visto 
que RAS tiene un papel importante en la biogénesis, mantenimiento, secreción y modificación 
del contenido de los exosomas. Los exosomas son vesículas extracelulares que tienen 
diferentes tipos de contenido, incluyendo proteínas, mRNA, miRNA, DNA y nlRNA. Estas 
vesículas afectan fundamentalmente la evolución de diferentes tipos de cáncer como 
melanoma y colorectal entre otros afectando al crecimiento tumoral, a la angiogénesis, la 
invasión y la metástasis. 
 
Por tanto, hipotetizamos que el cambiante comportamiento de RAS en el cáncer de tiroides 
es debido a los efectos diferenciales de RAS en función de su diferente localización en la 
célula. 
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2.  OBJETIVOS:  
-Estudiar cómo RAS en sus diferentes sublocalizaciones contribuye al cáncer de tiroides 
-Encontrar nuevos marcadores para descartar malignidad en los nódulos de tiroides mutados 
en RAS y determinar agresividad en cáncer de tiroides. 
- Elucidar la relevancia de los exosomas en la carcinogénesis de tiroides mediada por RAS en 
sus diferentes sublocalizaciones.  
  
3.   MATERIALES Y MÉTODOS:  
Para explorar el papel de las sublocalizaciones de RAS en el cáncer de tiroides elegimos las 
células PCCL3 que no tienen mutaciones conocidas, y las transfectamos con vectores de 
pCEFL hemaglutinina (HA) que contienen las señales diana M1, LCK, CD8α y KDELr 
unidas a H-, N- o K-RASv12. Éstas señales dirigen a RAS a retículo endoplásmico, balsas 
lipídicas, membrana desordenada y aparato de Golgi, respectivamente. Además, usamos el 
modelo de metástasis espontanea del embrión de pollo para analizar los efectos de estas 
células en el crecimiento tumoral y metástasis y determinar los efectos de diferentes proteínas. 
Los exosomas fueron aislado por cromatografía de exclusión por tamaño y sus efectos fueron 
probados in vitro y en el modelo de pollo. 
 
4.   RESULTADOS Y DISCUSIÓN:  
Para analizar los efectos de las sublocalizaciones de RAS en el cáncer de tiroides utilizamos 
las células PCCL3 expresando H- o N-RASv12 en retículo endoplasmático (RE), balsas 
lipídicas (BL), membrana desordenada (MD) y complejo de Golgi (CG). Para K-RASv12 RE 
y MD. Cuando analizamos sus efectos in vitro observamos que no había diferencias entre las 
sublocalizaciones de RAS en la proliferación, pero sí en la migración, induciéndola RAS en 
MD y GC. Además, RAS era capaz de inducir apoptosis desde todas las localizaciones 
celulares excepto desde BL y más notablemente desde CG, lo que puede estar relacionado 
por los efectos de RAS en la inestabilidad genómica y su posible inducción de una catástrofe 
mitótica.  
Al mirar el papel de RAS in vivo en el modelo de metástasis del embrión de pollo, vimos que 
los tumores más pequeños, generados por RAS en MD y CG, eran los más metastáticos. 
Además, para confirmar que esto también sucedía en líneas celulares con H-RAS endógeno 
mutado analizamos la locación de RAS en BL y MD, los cuales exhibieron efectos opuestos, 
en las células tumorales de cáncer anaplásico de tiroides C643 y HTH83. Fuimos capaces de 
ver que las células C643 tenían H-RAS en BL y las células HTH83 en MD y que su localización 
estaba modulada por los niveles de APT-1. Cuando se determinó el potencial tumoral de estas 
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células en el modelo de pollo pudimos observar que las células HTH83, con H-RAS mutado, 
esta vez endógeno, en MD, generó tumores más pequeños con mayor potencial metastático 
en comparación con las células C643. Además, la alteración de APT-1 fue capaz de promover 
la translocación de H-RAS, modificando los efectos en crecimiento tumoral y metástasis de 
las dos líneas celulares. Al ver que los niveles altos de APT-1 estaba relacionado con la 
localización de H-RAS en BL que exhibe mayores tumores, pero con poca capacidad de 
colonización a distancia, quisimos ver qué sucedía en tumores de pacientes. Para ello usamos 
la herramienta cBioPortal en la que seleccionamos una base de datos de mutaciones y 
alteraciones en niveles de mRNA y proteína de 507 pacientes con carcinomas papilares de 
tiroides. En este caso no encontramos ninguna co-ocurrencia entre las mutaciones de H-RAS 
y APT-1 aunque todos los pacientes con amplificaciones o ganancias de función en APT-1 
exhiben un 100% de supervivencia. Esto sugiere que incluso la modulación de RAS wt por 
APT-1 podría estar ejerciendo un efecto en el proceso carcinogénico. Además, al analizar 
también alteraciones de APT-1 en melanoma, en el cuál si existían co-ocurrencias con 
mutaciones en H-RAS, observamos un aumento de supervivencia de casi un año en esos casos 
con altos niveles de APT-1 mientras que al mirar los efectos de su deleción o perdida de 
expresión observamos lo contrario. Por tanto, esto sugiere que APT-1 puede ser un buen 
marcador pronóstico en cáncer de tiroides y melanoma. 
Al observar inmunohistologicamente los tumores generados por RAS en sus diferentes 
sublocalizaciones observamos que RAS en RE y BL, las localizaciones en las que RAS 
generaba los tumores más grandes, pero con menos capacidad de metastatizar, parecían 
presentar gotas lipídicas, lo cual confirmamos usando una tinción de red oil. Además, fuimos 
capaces de relacionar el acúmulo de lípidos con los niveles de VEGF-B, un miembro de la 
familia de VEGF con poca capacidad angiogénica. Cuando añadimos VEGF-B a los tumores 
formados por las otras sublocalizaciones de RAS, MD y CG, observamos que esta proteína 
era capaz de aumentar el tamaño tumoral y disminuir la metástasis. Por tanto, VEGF-B al 
estar presente a altos niveles en los tumores menos metastáticos podría ser un posible 
marcador de invasividad en tumores de tiroides.  
En cuanto a los efectos de las sublocalizaciones de RAS en la biogénesis, secreción y cargo de 
los exosomas, fuimos capaces de determinar que las sublocalizaciones de RAS pueden 
modular diferencialmente el tamaño, la cantidad y el cargo de los exosomas. 
Sorprendentemente hemos demostrado que los exosomas secretados por células con RAS en 
MD y CG son capaces de transferir su potencial metastático a otras células lo que sugiere que 
podrían estar modulando la intravasación, la supervivencia celular en el torrente sanguíneo 
y/o el nicho pre-metastático. 
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5.   CONCLUSIONES: 
En resumen, hemos encontrado que el tamaño de los tumores generados por H-RAS y N-
RAS en sus diferentes sublocalizaciones no se correlaciona con su potencial metastático. 
Además, hemos visto que la modificación de los niveles de APT-1 afecta la proliferación y el 
potencial metastático de los tumores de tiroides al regular la presencia de RAS en los 
diferentes microdominios de la membrana plasmática. 
Por otro lado, los tumores formados por H-RAS en RE y BL presentan gotas lipídicas cuya 
acumulación se relaciona con los niveles de VEGF-B el cuál es capaz de aumentar el tamaño 
tumoral, pero disminuir la metástasis. Debido a ello, tanto APT-1 como VEGF-B podrían ser 
propuesto como posibles marcadores a estudiar para determinar la posibilidad de colonización 
a distancia.  
Además, los exosomas secretados por células expresando H-RASv12 en sus diferentes 
localizaciones celulares son diferentes en tamaño, se secretan en diferente cantidad, presentan 
diferentes marcadores y presentan efectos diferenciales en proceso carcinogénico. 
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1. INTRODUCTION 
1.1   Ras superfamily of small GTPases 
The Ras superfamily are small G proteins of approximately 21 kDa that share a main 
biochemical feature that defines them. This property is their ability to act as molecular binary 
switches cycling between an active GTP bound form and inactive GDP-bound form, being able 
to couple extracellular signals to intracellular signaling networks.  
The research about these proteins began in 1964 when Jennifer Harvey discovered that a 
leukemia virus isolated from a rat, was able to produce sarcomas in young rodents (1). The 
oncogene behind the tumorigenic activity was named Harvey RAS, from “Rat sarcoma”, 
nowadays known as H-RAS. Moreover, in 1974 another sarcoma virus, the Kirsten murine 
sarcoma virus, was identified and named K-RAS (2). In addition, by 1983, N-RAS was 
described as the third member of the RAS gene family after being isolated from two human 
sarcoma cells lines (3, 4). These proteins were found to have intrinsic capacity to bind guanine 
nucleotides and were reported to be GTPases. It was also described that their ability to 
maintain their GTP-bound state was higher in the proteins encoded by transforming alleles 
than normal ones and H-RAS was isolated as the first oncogene in a bladder cancer cell line 
(5-8). In 1993, 50 proteins similar to RAS had been described and they were all reported to 
have key functions regulating processes such as proliferation and cell cycle control (9). 
Nowadays, in humans, there are more than 160 members of the Ras superfamily identified. 
Conserved orthologs are found throughout the evolutionary scale (10). 
 
The Ras superfamily is divided, depending on their sequence and function, into five major 
subfamilies: Ras, Rho, Rab, Ran and Arf (Fig.1.1). (From now on lowercase will be used to 
refer to the families, capital letter will denote specific proteins and italics will be used to refer 
to genes).  
Ras family is composed by 36 members that regulate multiple cytoplasmic signaling networks 
and control cell proliferation, survival and differentiation among other cellular functions (11). 
(it will be further described in section 2)  
Rho (Ras homologous) family has 20 members being RHOA, RAC1 and CDC42 the best 
studied. They mainly regulate the actin cytoskeleton, regulating cell movement, shape as well 
as vesicular mediated processes. RHOA is particularly involved in focal adhesion dynamics 
and mainly regulates actomyosin, RAC1 controls lamellipodium assembly and membrane 
ruffing, and CDC42 promotes the formation of actin structures such as filopodia and micro 
spikes. However, they all have been implicated in a wide variety of function such as regulation 
of phagocytosis or polarity regulation. Moreover, RHO GTPases mutations have been 
proposed to be pro-tumorigenic since they are linked to cell survival, metabolism control as 
well as with metastasis (11-13). 
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Rab (Ras-like proteins in brain) subfamily is the largest one, with 61 members. RAB GTPases 
are key regulators of membrane endocytic and secretory processes and membrane budding by 
controlling actin- and tubulin-dependent vesicle movement and membrane fusions (11, 14). 
Ran (Ras-like nuclear) family is involve in nucleus-to-cytosol protein trafficking and its 
function, unlike the others depends, on the spatial gradient of its active form (11). 
Arf (ADP-ribosylation factor) subfamily is involved in coated vesicles biogenesis, vesicular 
trafficking and actin regulation (11).  
Figure 1.1: Cladogram of human Ras superfamily members and functions. Subfamilies of proteins are 
indicated by colored arcs: RAS (pink), RHO (green), Gα (brown), ARF (yellow), and RAB (blue). 
Adapted from Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE. 
2004;2004(250):RE13. Published 2004 Sep 7. doi:10.1126/stke.2502004re13 
 
1.1.1   STRUCTURE AND FUNCTION OF RAS GTPASES 
RAS small GTPases act as biological switches cycling between GTP-bound and GDP-bound 
state affecting almost all cellular processes (Fig 1.2 B). Their protein structure is conserved 
among all Ras subfamilies, as well as other GTPases. They share a five α-helix surrounding a 
six-stranded β-sheet structure in a Rossman-type fold structure (15, 16). The structure of H-
RAS p21 protein in the triphosphate conformation (17) shows that is made up of five 
conserved motifs (G1-G5): The G1 motif (I), GXXXXGKS/T, containing the P-loop that is 
the phosphate binding site. This motif also binds to the purine nucleotide. The G2 motif E, T, 
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is the major effector binding component. The G3 motif (III), DXXGQ/H/T, is the one that 
recognize the nucleotide-related Mg2+; G4 motif (IV), T/NKXD, brings close the guanine ring 
and the G5 motif (V), C/SAK/L/T, makes indirect associations with the guanine nucleotide 
(11) (18) (Fig. 1.2 A). However, despite this common structure some members of the family 
exhibit some differences in their structure. For instance, ARF proteins present additional N-
terminal sequences (19), whereas RAN has them in the C-terminus determining 
conformational changes during the GDP/GTP binding cycle (20). 
Figure 1.2: Ras family protein sequence and structure. (A) Ras superfamily functional domains 
representation. The core G-domains, corresponding to RAS residues 4-166 contains the nucleotide 
binding domains (G1-G5) and the switch regions. (B) Small GTPases crystal structure in their active 
GTP-form and inactive GDP-form. Figure adapted from (21). 
  
Small GTPases activity depends on their GTP/GDP binding status. When they bind GDP they 
are in their inactive form and are unable to trigger any signaling pathway. To become activated 
they need to exchange GDP for GTP. This causes a conformational change in their switch I 
(30-40 residues) and switch II (60-76 residues) regions allowing the repositioning of the 
terminal extension enabling regulator/effector interactions (22). 
Figure 1.3: Small GTPases activation 
cycle. RAS proteins function as 
molecular switches, cycling 
between the GDP-bound (‘off’) and 
the GTP-bound (‘on’) states and 
exist predominantly in the GDP-
bound state. Upon exogenous 
stimulation, GEFs catalyze the 
exchange of GTP for GDP. RAS 
proteins are inactivated by GAPs, 
which accelerate the cleavage of 
the terminal inorganic phosphate 
(Pi) group of GTP(23). 
 
A. B. 
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This cycle is regulated by Guanine-Nucleotide-Exchange factors (GEFs) that promote 
formation of the active, GTP-bound form (24), and GTPases-Activating Proteins (GAPs), 
which enhance the intrinsic GTPase activity promoting hydrolysis of GTP, leading to the 
inactive GDP-bound form (25). Moreover, there is another group of proteins, called 
Guanosine Nucleotide Dissociation Inhibitors (GDIs), which kidnap GTPases in the cytosol 
avoiding them to anchor to the membrane and to bind to different effectors (26) (Fig. 1.3). 
 
1.2   RAS family 
1.2.1   GENERAL OVERVIEW AND DESCRIPTION 
Besides RAS classical proteins (H-RAS, N-RAS, K-RAS4A and K-RAS4B), R-RAS (R-
Ras2/TC21, R-RAS3/M-RAS) is the only one with transforming capability. There are several 
non-transforming members such as RAS-Like (RAL) proteins (RAL-A y RAL-B) and RAS 
Proximal (RAP) proteins (RAP1A, RAP1B, RAP2A and RAP2B), RHEB, RAS like protein 
In Neurons (RIN) and RAS like protein in tissue (RIT) (27). This thesis will only be referring 
to the classical RAS proteins (H-Ras, N-Ras, K-Ras4A and K-Ras4B). 
 
These proteins are encoded by three different genes (H-RAS, N-RAS and K-RAS) located in 
chromosome 11 (11p15.1-p15.5), chromosome 1 (1p22-p32) and chromosome 12 (12p12.1-p-
terminal) respectively. All of them are composed by four coding exons and a non-codifying 
fifth one, giving rise to the different RAS proteins. For K-RAS there is an exon four alternative 
splicing that encodes for two different K-RAS isoforms (K-RAS4A and K-RAS4B) (28, 29). 
K-RAS4B is a 188 amino acid protein whereas the other isoforms are 189 amino acids. These 
proteins, as they are GTPases, are comprised of two main domains: the G domain and the 
hypervariable region (HVR). In the N-terminus the G domain (residues 1–166) presents an 
effector lobe (residues 1–86) and an allosteric lobe (87–166). RAS effector lobe is crucial for 
the interaction with its effectors such as RAF, PI3K and RalGEFs, whereas the allosteric lobe 
allows intra-protein communication, where it connects the active site of the effector lobe to 
membrane-interacting residues (22, 30-32). When RAS is activated, conformational changes 
occur in the switch I (aa 30–40) and switch II (aa 60–76) regions to allow for effector 
interactions and signalling (Fig. 1.2 B). The RAS proteins, share 90% identity in their G 
domain, with conserved structural and biochemical properties (22). More importantly, each 
protein has a unique HVR (Fig. 1.4) containing specific sites for posttranslational 
modifications resulting in differences in membrane trafficking, localization and function (32, 
33). 
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Figure 1.4: Divergent C-terminal membrane targeting domains in RAS proteins. The four RAS 
proteins: N-RAS, H-RAS, K-RAS4A and K-RAS4B share a conserved core domain (‘G-Domain’) 
which confers GTPase and effector binding. However, they diverge in C-terminal where they present a 
hypervariable region (‘HVR’), that contains different membrane targeting signals such as a (CAAX) 
motif (denoted by pink box).  
 
1.2.2 RAS POSTTRANSLATIONAL MODIFICATIONS 
 
RAS proteins are all synthesized on free polysomes, as hydrophilic proteins that remain 
scattered throughout the cytoplasm. However, it is well known that these proteins need to be 
anchored to different membranes by their carboxy-terminus in order to be active. Therefore, 
a variety of posttranslational modifications in their HVR are necessary in order to increase 
their hydrophobicity and binding to different types of membranes (33). 
 
All nascent RAS isoforms are firstly farnesylated at Cysteine (C)186 (C185 in K-Ras4B), in 
the cytosol on their CAAX motif (where C is cysteine, A is an aliphatic amino acid, and X is 
serine or methionine) by farnesyl protein transferases (34) forcing them to transiently 
accumulate on the cytoplasmic face of the Endoplasmic Reticulum (ER). They are further 
modified at the ER by RAS Converting Enzyme 1 (RCE1), a protease that eliminates the last 
three amino acids, AAX (35) to form, a carboxy-terminal S farnesyl cysteine carboxylmethyl 
ester. Also, at the ER, the Isoprenyl-Carboxymethyl Transferase (ICMT) adds a 
carboxymethyl group on the C-terminal cysteine residue (36-38). This allows RAS to weakly 
bind the plasma membrane, but it also needs a second modification to strengthen membrane 
interactions that it is takes place at the Golgi Complex (GC). It is been proposed that RAS, 
once it leaves the ER, enters into the cytoplasmic fluid phase, rebinding then to Golgi 
membranes (39).  
Membrane targeting 
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The second mandatory anchor component results of the mono-palmitoylation, that is the 
addition of palmitate, a satured (acyl) fatty acid, to N-RAS at C181 and K-RAS4A at Cys180, 
or a bi-palmitoylation of H-RAS at C181 and C184, through the covalent attachment of a 16-
carbon palmitoyl chain (40). RAS palmytoilation is catabolized by a Palmytoil Acyltransferase 
(PAT) localized at the GC, which consist in a heterodimeric complex formed by DHHC9 and 
GCP16, transmembrane proteins that have a conserved aspartate-histidine-histidine-cysteine 
(DHHC) motif (Fig. 1.5). However, the possibility that some of the other 20 members of the 
DHHC family can perform this task at other sublocations cannot be discarded. K-RAS4B, the 
most prevalent splice form of K-RAS has a polybasic region (residues 175-180) that allows it 
to bind to membranes enriched acidic phospholipids (41-44).  
 
Figure 1.5: H-RAS posttranslational modifications and palmitoylation cycle.  H-RAS is synthesized on 
cytosolic free polysomes as a globular hydrophilic protein. Nascent RAS is farnesylated by a 
farnesyltransferase (FTase) in the cytosol and transported to membranes of the endoplasmic reticulum 
(ER) where it encounters the subsequent CAAX-processing enzymes RAS-converting enzyme 1 
(RCE1) and isoprenyl cysteine carboxylmethyl transferase (ICMT). Following CAAX modification H-
RAS proceed to the cytosolic face of the Golgi apparatus, where is duo-palmitoylated by DHHC9–
GCP16 allowing it to traffic via vesicular transport to the plasma membrane, locating at disordered 
membrane (DM). Then, duo-palmitoylated H-RAS can be partially depalmytoilated by APT-1 
provoking H-RAS segregation to lipids rafts (LR). Duo- and mono-palmitoylated H-RAS can also be 
dissociated from the membrane by depalmitoylation, which translocates it by retrograde transport to 
the Golgi for another round of palmitoylation. 
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Additionally, RAS proteins are subject to other posttranslational modifications including 
phosphorylation, ubiquitination, acetylation, and S-nitrosylation. The G-P peptidyl-prolyl 
bond of H-RAS at position 178–179 undergoes cis-trans isomerization catalyzed by FKBP12 
(45). Protein kinase C (PKC) phosphorylates K-RAS4B on serine 181 negatively regulating its 
association with the plasma membrane (46). Cysteine 118, which is conserved in all RAS 
isoforms, can be S-nitrosylated facilitating guanine nucleotide exchange and therefore 
promoting efficient RAS activation (47). RAS proteins can also be acetylated at lysine 104 
decreasing RAS activity (48). Furthermore, H-RAS and K-RAS can be mono- and di-
ubiquitinated on several lysines (K), K117, K147 and K170, by the E3 ligase Rabex-5 affecting 
the activation state of the GTPase and the subcellular localization of the proteins, that it is 
also modified by phosphorylation (49). In addition,  monoubiquitinated RAS in lysine 147 
impairs GTP dependent binding interactions with the p120 GAP catalytic domain, PI3K and 
both CRAF- and RALGDS RBDs, but displays significantly enhanced binding to the CRAF 
RBD in its GDP bound state what it is thought to promote RAF signaling (50, 51). Finally, 
last year was described that RAS proteins can be modified by SUMOylation in Lysine 42 by 
SUMO-E3 ligase PIASγ but little is known about its implications yet (52).  
 
1.2.3   RAS PALMITOYLATION CYCLE  
RAS palmitoylation, unlike farnesylation, is a reversible labile process creating a cycle of 
palmitoylation/depalmitoylation that controls H-RAS and N-RAS membrane attachment and 
maintenance on their specific sub-cellular localizations. As a result, when farnesylated N-RAS 
and H-RAS are palmitoylated in the Golgi, they become stably associated with membranes 
and packaged into transport vesicles for delivery to the cell surface. RAS proteins 
palmitoylation affects their distribution in GC. N-RAS and K-RAS4A, which are 
monopalmitoylated, are polarized toward the cis Golgi whereas H-RAS, that is 
duopalmitoylated, is found to be homogeneously distributed throughout the Golgi stacks. The 
differential palmitoylation states of N-RAS and H-RAS determine their distinct Golgi Sub-
compartment localizations (53). This, has been proposed to affect Golgi mediated transport 
to the plasma membrane of N-RAS but no H-RAS (53, 54), suggesting that N-RAS might be 
transported through a pathway consistent with the recently proposed ‘rapid partitioning’ 
model of Golgi trafficking (55, 56). On the other hand, H-RAS seems to traffic by the classical 
trans-Golgi vesicular transport to the plasma membrane. Once in the plasma membrane, their 
half-lives of residency are estimated to be <30 min for N-RAS, which has just a single 
palmitoyl-modification therefore cycling faster; and <1 h for H-RAS, which must undergo a 
double depalmitoylation (57).  
Acyl thioesterases (ATs) are the enzymes that control depalmitoylation and subsequently H-
RAS, N-RAS and K-RAS4A translocation from the plasma membrane to the GC. 
Furthermore, Acyl Protein Thioesterase 1 (APT1) (originally designated lysophospholipase I 
(LYPLA1)), previously thought to be a lysophospholipase,  was found to depalmitoylate H-
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RAS and Gαi (inhibitory G-protein alpha subunit) in vitro (58, 59). APT1 is a conserved α/β 
hydrolase that contains a S-H-D catalytic triad and a G-X-S-X-G motif (59, 60). It has a wider 
variety of substrates such as the Endothelial Nitric Oxide Synthase (eNOS), the Synaptosomal-
Associated Protein 23 (SNAP-23) and some viral proteins (61-64) and is in charge for H-RAS 
segregation between plasma membrane microdomains, from disordered membrane to lipids 
rafts (Fig. 1.5).   
The phosphodiesterase delta (PDEδ), acting as a chaperone, has been found to increase the 
diffusion of farnesylated RAS, via a non-vesicular route, in the cytosol facilitating its recycling 
back to the Golgi complex (GC) where it undergoes re‐palmitoylation, permitting a new 
palmitoylation cycle of trafficking back to the plasma membrane (65). Besides them, FKBP12, 
a cis-trans prolyl isomerase, has been recently shown to be involved in depalmitoylation, 
specifically of H-RAS but nor N-RAS or K-RAS (45). In addition, for N-RAS, ABHD17 
proteins have been proposed as novel protein depalmitoylases (66).  
Since Golgi and  PM pools of H/N-RAS activate different downstream signaling cascades (67), 
the regulation of their localization affects signaling. Thus, RAS depalmitoylation cycle is 
crucial for its correct localization since it regulates both RAS macro-localization, and its 
localization within plasma membrane subdomains. Overall, this cycle affects different cellular 
processes and its inhibition can be exploited for therapeutic approaches in different human 
cancers (68).  
 
1.2.4   RAS SIGNALING AND ITS REGULATORS 
 
1.2.4.1 RAS effectors and signaling pathways 
 
 
1.2.4.1.1 RAS effectors  
 
For a protein to be considered a RAS effector needs to be able to mainly associate to RAS 
active form (RAS-GTP) through regions called the Ras Binding Domain (RBD) and Ras 
Association Domain (RAD), with a βαβαβ structure (69). There are several RAS effectors 
such as RAF Interactor 1 (RIN1), T Cell Lymphoma Invasion and Metastasis 1 (TIAM1), 
Phospholipase C Epsilon (PLCε) and AF6 but the best characterized are RAF family kinases, 
the p110 catalytic subunit of class I phosphatidylinositol-3 kinase (PI3K) and a RAL-GEFs 
exchange factors (70-72) (Fig. 1.6). 
 
1.2.4.1.2 MAPK pathway 
 
The MAPK (Mitogen-Activated Protein Kinase) pathway is one of the primordial signaling 
systems that exists in all eukaryotes, and controls such fundamental cellular processes as 
proliferation, differentiation, survival and apoptosis. Mammalian MAPK can be divided into 
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four groups based on their structure and function: Extracellular signal-Regulated Kinases 
(ERK), p38 MAPKs , c-Jun NH2-terminal Kinases (JNKs) and Extracellular signal-
Regulated Kinase-5 (ERK-5) (73, 74). Activation of these MAPKs occurs through a cascade 
of upstream kinases; a MAPKKKs (MAPK Kinase Kinase) first phosphorylates a dual-
specificity protein kinase MAPKK (MAPK Kinase), which in turn phosphorylates the MAPK. 
This set-up provides not only for signal amplification, but, maybe even more importantly, for 
additional regulatory interfaces that allow the kinetics, duration and amplitude of the activity 
to be precisely tuned (74, 75).  
 The MAPK /ERK is one of the best characterized and its signaling cascade is activated by a 
wide variety of receptors involved in growth and differentiation including GPCRs (G-Protein 
Coupled Receptors), RTKs (Receptor Tyrosine Kinases), Integrins, and Ion channels. The 
specific components of the cascade vary greatly among different stimuli, but the architecture 
of the pathway usually includes a set of adaptors like SHC and GRB2 (Growth Factor 
Receptor Bound protein-2), linking the receptor to a GEF, like SOS (Son of Sevenless) or 
CDC25, transducing the signal to RAS which in turn activate the core unit of the cascade 
composed of a MAPKKK (RAF), a MAPKK (MEK1/2 (MAPK/ERK Kinase-1/2)) 
and MAPK (ERK). An activated ERK dimer can regulate targets in the cytosol and ERK also 
translocate, as monomer, to the nucleus where it phosphorylates a variety of transcription 
factors regulating gene expression (74, 76-78). 
 
Figure 1.6: RAS effectors. 
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1.2.4.1.3 PI3K/AKT signaling pathway 
 
Another well studied signaling pathway is the PI3K/Protein Kinase B (AKT), which plays 
important roles as modulator of RAS-mediated cell survival and proliferation (70, 79). Upon 
ligand stimulating of a Receptor Tyrosine Kinase (RTK) RAS interacts with lipid kinases, like 
Class I PI3K 110 subunits (p110α, p110β, p110γ, and p110δ) independently of its p85 
regulatory subunit. This interaction allows the conversion of phosphatidylinositol (4,5)-
bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 then binds 
the Pleckstrin Homology (PH) domain of Phosphoinositide-Dependent Kinase 1 (PDK1), 
which allows PDK1 mediated activation of AKT by its phosphorylation at residue threonine 
308 (80-82). AKT can promote cell survival by inhibiting proapoptotic Bcl-2 family members 
BAD and BAX (83, 84), negatively regulating the transcription factor NF-κB which leads to 
antiapoptotic and pro-survival signals (85).  Moreover, AKT also promotes RHEB activation 
which in turn stimulates the Mammalian Target Of Rapamycin (mTOR), leading to increased 
p70 S6 kinase activity. This finally results in an increase in protein synthesis by phosphorylation 
of the eukaryotic initiation factor 4E and the ribosomal S6 protein (86). Moreover, mTORC2 
contributes to complete AKT activation by phosphorylating AKT on serine 473 (87, 88) (Fig. 
1.7).   
 
Figure 1.7: Schematic diagram of the most representative signaling of the PI3K/AKT pathway. 
The tumor suppressor phosphatase and tensing homolog (PTEN) meanwhile 
dephosphorylates PIP3 to PIP2, thereby terminating PI3K-dependent signaling (80).  
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Additionally, RAS also interacts with the RAS GTPase family RALGEF (RalGDS, RGL, 
RGL2 and RGL3) promoting activation of the RALA and RALB small GTPases (89). The 
biological function of these proteins is not yet fully understood, although there is evidence that 
they play a role in RAS-mediated transformation and tumorigenesis in vivo (90).  
 
1.2.4.2 RAS sub-cellular localizations 
Initially, it was thought that RAS proteins, in order to be functional, needed to be in the inner 
leafled of the plasma membrane where GEFs would be active (91). However, today we know 
that RAS is also present and functional in different subcellular localizations, contradicting the 
initial concept of a single source of RAS signals. 
 
For instance, in 1980 when Willigham and colleagues first pointed that RAS needed to be in 
the plasma membrane (PM) in order to be active, they were considering PM as a simple and 
homogeneous lipid bilayer, the “fluid mosaic model”(92). Nowadays, we are aware that the 
plasma membrane is highly asymmetric and laterally compartmentalized  (93, 94). Due to its 
different lipid components, the plasma membrane can be divided into lipid rafts, defined as 
liquid-ordered domains enriched in sphingolipids, cholesterol and in caveolin proteins; and 
disordered membrane, also known as bulk membrane, a liquid disordered domain, due to the 
high concentration of highly unsaturated phospholipids and lacking caveolin (95, 96). It was 
years later that Hancock and colleagues showed that RAS proteins are in different 
microdomains within the plasma membrane. It was then shown that at a steady-state H-RAS 
and N-RAS localized mainly in caveolin rich lipids raft from where they diffuse to the bulk 
plasma membrane after activation, on the other hand K-RAS was located in disordered 
membrane but not lipids rafts (57, 97-99) (Fig. 1.8).   
 
Years later, our group described that the presence of H-RAS at different PM microdomains 
was not only due to H-RAS activation state, but also regulated by its palmitoylation levels. 
This depends on the level of palmitoylation in a specific cell type. It was proposed that H-RAS 
double palmitoylation (C181, C184) will direct H-RAS to disordered membrane but when 
single palmitoylated H-RAS (C181) will be present in lipids rafts. Moreover, we saw that 
double palmitoylated H-RAS can loss one of its palmitic groups, at C184, due to high levels of 
APT-1 activity, causing H-RAS lateral diffusion from disordered membrane to lipids raft. 
Also, fully depalmitoylation of H-RAS causes its diffusion back to the Golgi complex (100) 
(Fig. 1.5). 
 
RAS isoforms can also be present in different endomembranes where they display different 
degrees of association (N-RAS>H-RAS>K-RAS) to the Golgi Apparatus, ER, mitochondria 
and a variety of endosomes (101) (Fig. 1.8). For instance, non-palmitoylated RAS proteins can 
be found in ER where they can trigger different signaling pathways. Moreover, once N-RAS 
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RAS isoforms can also be present in different endomembranes where they display different 
degrees of association (N-RAS>H-RAS>K-RAS) to Golgi Apparatus, ER, mitochondria 
and a variety of endosomes (101) (Fig. 1.8). For instance, non-palmitoylated RAS proteins can 
be found in ER where they can trigger different signaling pathways. Moreover, once N-RAS 
and H-RAS are steadily palmitoylated they can also be found in GC coming from either ER 
or through the retrograde pathway from the PM, closing the palmytoilation cycle (102). 
Additionally, as pointed before N-RAS seems to be only in cis-Golgi whereas H-RAS is 
thought to be dispersed throughout the whole complex (103-105).  
Figure 1.8: RAS locations within the cell. In the plasma membrane, H- and N-RAS can be located at 
lipids rafts and disordered membrane, whereas K-RAS is only present at disordered membrane. H- and 
N-RAS can be present and signal from the Golgi Complex but K-RAS is not found in this organelle. 
Moreover, H- and N-RAS once ubiquitinated can locate at endosomes and K-RAS needs to bind 
calmodulin in other to locate in them. Moreover, phosphorylated K-RAS can be found at mitochondria. 
Besides from being substrate to depalmytoilation, RAS proteins at the PM can be translocated 
to endomembranes (endosomes/ER/Golgi) by endocytosis. Strikingly, H-RAS, in order to be 
present in the recycling endosomes (RE), needs to be bi-palmytoilated, and H-RAS mono and 
diubiquitination seems to stabilize endosomal interactions and impedes reclycling (51, 106, 
107). Therefore, this locates H-RAS and N-RAS to endosomes regulating RAF-1 activation 
(108). Additionally, K-RAS was shown to be internalized in a clathrin-dependent fashion and 
to be transported along early endosomes, late endosomes and eventually into lysosomes, 
displaying only a minor and transient association with endosomes (109).   
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1.2.4.2.1 Effectors in different RAS sublocalizations 
 
Since RAS is present in different locations is not a surprise that RAS sublocalizations has 
functional consequences. 
 
Previous studies from our group using H-RASv12 constructs specifically tethered to the 
different compartments where RAS is known to be active (Disordered membrane, lipids raft, 
Endoplasmic Reticulum and Golgi Aparatus) showed that RAS compartmentalization 
determines effector usage (Fig. 1.9). This way, RAS is able to activate different effector 
signaling pathways and tightly regulate their amplitude, intensity and substrate specificity 
consequently affecting gene expression patterns. Our group showed that H-RASv12 at lipids 
rafts and ER was able to strongly activate ERK and the PI3K/AKT pathway, while from 
disordered membrane it displayed lower ERK and AKT activation. The activation of these 
pathways was almost negligible from the Golgi Complex. However, RAL-GDS was mainly 
activated at this organelle. Consequently, H-RASv12 could induce NIH3T3 cells proliferation 
and transformation from all sublocalizations except from the Golgi Complex. Conversely, 
other groups have found that RAS from GC is also able to strongly induce ERK and 
PI3K/AKT activation (104, 110-113). These site-specific differences are thought to be 
mediated by different space related mechanism that probably include kinase tiers (GEFs and 
GAPs), scaffold proteins and protein dimerization. 
Figure 1.9: RAS site-specific signals. Main signaling pathways activated by RAS at its different 
subcellular locations (Bigger letters represents more activation) and the total and specific number of 
genes regulated by RAS from the different sublocalizations. 
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These site-specific differences are thought to be mediated by different space related 
mechanism that probably include kinase tiers (GEFs and GAPs) (114, 115), scaffold proteins 
(116-118) and protein dimerization (119, 120).  
1.2.4.2.2 Role of RAS sublocalizations in vivo 
 
RAS sublocalizations role in in vivo carcinogenesis has been mostly explored in melanoma. In 
this respect, H-RASv12 signals emanating from all locations but GC are able to induce tumors 
in a zebrafish melanoma model. In this model H-RASv12 signals from GC, specifically from 
cis Golgi, strongly induce apoptotic signals and is not able to induce tumor formation. These 
results are related with TP53 mutated status and PTPRk levels (121). However, little is known 
about their effects in other tumoral types.  
 
1.3 VEGF FAMILY 
The human vascular endothelial growth factor family is composed by VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E and placental growth factor (PLGF), that bind a family of 
cognate protein tyrosine kinase receptors (VEGFRs)(122, 123). For instance, VEGF-A binds 
to VEGFR2 and VEGFR1; VEGF-B to VEGFR1 and NEUROPILIN-1; VEGF-C and 
VEGF-D to VEGFR2 and VEGFR3; VEGF-E only to VEGFR2; and PLGF to VEGFR1 
and NEUROPILIN-1 and -2 (122-125).  
Human VEGF genes are characterized by a highly conserved seven exon structure, with the 
exception of VEGF-A, which has eight exons that gives rise to at least six different transcripts 
and VEGF-B that gives rise to two transcripts (78, 124). VEGF-B167 and VEGF-B186 are two 
VEGF-B isoforms. Both bind VEGFR1 and its coreceptor neuropilin-1 and are expressed in 
most tissues and organs (126).  
VEGF-A is the best studied member. VEGF-A is crucial for angiogenesis and therefore for 
embryonic vascular development. A single VEGF-A allele in mice causes embryoinic death 
(127, 128). Moreover, many tumors have taken advantage of VEGF-A, which promotes 
formation of new vessels from pre-existing ones feeding the tumor. Nowadays, an specific 
humanized monoclonal antibody to this molecule, Avastin (Bevacizumab), is approved for 
treatment of metastatic colorectal cancer, metastatic renal cell carcinoma, recurrent 
glioblastoma and non-squamous non-small cell lung, cancer among others  (129-133).  
In contrast to VEGF-A, VEGF-B genetic deletion in mice seemed to be harmless. 
However, these mice have trouble recovering from ischemic myocarditis. Although 
substantial efforts have been focused to relate VEGF-B to angiogenic activities little has 
been found in this matter (134, 135). Nevertheless, VEGF-B167 can increase blood vessel 
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density in ischemic and infarcted hearts but not under normal conditions, and VEGF-B186 
induced myocardium specific angiogenesis and arteriogenesis. This suggest that VEGF-B 
has only angiogenic activity in the heart (126, 136).  
More surprisingly, Eriksson´group has recently showed that VEGF-B is crucial for energy 
metabolism, by regulating fatty acid uptake and transportation across the endothelium, 
using fatty acid transporter proteins (FATPs) (135, 137, 138). Moreover, VEGF-B was 
shown to induce blood vessel stabilization and survival and to inhibit VEGF-A induced 
pathological angiogenesis (136). Although VEGF-B has been seen to promote cancer 
metastasis through a VEGF-A independent mechanism in human melanomas (139), and its 
expression is associated with lymph node metastasis in human primary breast cancers (140), 
little is known about its effects in cancer. 
 
1.4 Extracellular vesicles 
Besides all these types of RAS signalling modulators regulating its role in cancer development 
and metastasis, there is a new aspect in the control of RAS-mediated cancer effects. A new 
hot topic in cancer has emerged in the last years, focusing on Extracellular Vesicles (EVs). 
These were initially considered to be extracellular debris but have been identified as key 
mediators in cell-to-cell communication. This has added a new layer of complexity to our still 
poor knowledge of tumor cell physiology.  
 
1.4.1 EVS DEFINITION  
EVs are lipid bilayer-enclosing membranes containing a variety of cargoes protected from 
enzymatic degradation and serve as vehicles of biological information. The term EVs was 
proposed as a generic term for all types of secreted membrane vesicles, regardless of their 
differences in biogenesis and composition. Although EVs have been differently defined by 
different criteria, the general and accepted one classify EV subpopulations based on their 
biogenesis. EVs are then broadly classified into: Exosomes (EXOs), Microvesicles (MVs) and 
apoptotic bodies (141). 
 
1.4.2 EXOSOME BIOGENESIS  
Exosome biogenesis is initiated as an endocytic event driven by the Endosomal Sorting 
Complex Required for Transport (ESCRT), including: ESCRT I-III, ALG-2-Interacting 
Protein X (ALIX), which connects the SYNTENIN–SYNDECAN complexes to the ESCRT 
machinery, and Tumor Suspectibility 101 (TSG101), involving inward invagination of the 
plasma membrane. This leads to the formation of early endosomes that after maturation, 
promote Intraluminal Vesicles (ILVs) formation in late endosomal Multivesicular Bodies 
(MVBs) (142-144). These vesicles size is 40-120 nm and are composed of a wide variety of 
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cytosolic components, containing molecules from the phospholipid bilayer, endoplasmic 
reticulum, cytosol, and Golgi apparatus; including transmembrane proteins as tetraspanins, 
such as CD81, CD63 and CD9; signal transduction proteins; biogenesis factors such as 
TSG101, ALIX and SYNTENIN; nucleic acids (messenger Ribonucleic Acid (mRNA), 
microRNA (miRNA), other non-coding RNA, Deoxyribonucleic acid (DNA) (and histones)); 
enzymes, chaperones and several lipids (Table 1.1). The exosomal membrane cargoes are 
known to reach endosomes from the Golgi Apparatus, or are internalized from the plasma 
membrane before being sorted to ILVs, during endosome maturation (145-147). RAB 
GTPases, among others, modulate lysosomal MVBs degradation in a ubiquitin-dependent 
manner and their secretion in an ubiquitin-independent manner (148-150). After that, and 
among other proteins, N-ethylmaleimide-sensitive Factor Attachment Protein Receptors 
(SNAREs), orchestrate the fusion of MVBs with the plasma-membrane, releasing exosomes 
to the extracellular space. However, this is a not a fully-understood process yet (151, 152). 
Alternatively, another ESCRT-independent mechanism for exosome biogenesis, dependent 
on sphingolipid ceramide has been proposed. Ceramide contributes to the inward budding of 
the plasma membrane, generating another ILV population destined for secretion as EXOs 
(153).  
 
EV type and Size Biogenesis Enriched Markers Content 
Exosomes  
(40-120 nm) 
Endosomal pathway 
vesicle maturation 
in MVB 
ALIX, Syntenin, 
TSG101, CD63, 
CD9, CD81 
Proteins (cytoplasmic 
and membrane), 
mRNA, miRNA, 
DNA, noncoding 
RNA 
Microvesicles 
(120-1000 nm) 
Outward budding of 
plasma membrane 
Integrins, 
metalloproteinases, 
CD-40 ligand, 
ARF6 phosphatidyl-
serine 
Proteins (cytoplasmic 
and membrane), 
mRNA, miRNA, 
DNA, noncoding 
RNA 
Apoptotic bodies 
(50-5000 nm) 
Cell surface. 
Release from 
cellular blebs during 
apoptosis 
Phophatidyl-serine Nuclear fractions, cell 
organelles 
Table 1.1. Extracellular vesicles characteristics, biogenesis, content and useful markers for their 
detection.  
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1.4.3 MICROVESICLES  
Microvesicles (120-1000 nm) originate by an outward budding of the plasma membrane and 
are released to the extracellular space (154). During membrane budding, lipid rafts containing 
ceramide, regulatory proteins, and cytoskeleton elements, can promote membrane curvature 
and extensive cytoskeletal changes, promoting the formation of MVs (155, 156). Due to its 
origin, they have different lipid, cytoplasmic and membrane components, only presenting 
tetraspanins CD9, CD81 and CD82 but not CD63; biogenesis factors as ALIX, TSG101 but 
not SYNTENIN, nucleic acids and signaling molecules; also presenting cytoleskeletal 
molecules such as ACTIN and TUBULIN and extracellular matrix adhesion proteins (Table 
1.1) (145, 157). 
 
1.4.4 APOPTOTIC BODIES 
Apoptotic bodies, containing fragmented nuclear and cytoplasmic components from the dying 
cell, range from 50-5000 nm and are formed during programmed cell death, and have been 
shown to promote apoptosis of adjacent cells (Table 1.1) (141, 158).   
 
1.4.5 EVs IN CANCER 
The nature and abundance of extracellular vesicle cargoes are cell-type-specific and are often 
influenced by the physiological or pathological state of the donor cell, the stimuli that 
modulate their production and release, and the molecular mechanisms that leads to their 
biogenesis (157). When EVs are released to the extracellular space they can exert their 
functions in proximity or they can travel in different biofluids such as blood. Moreover, they 
can be internalized by cells delivering their cargo, by either fusion (159, 160), energy-
dependent receptor-mediated endocytosis (161, 162), macropinocytosis (163) or phagocytosis 
(164), thus participating in cell-to-cell communication (165).  
Several studies have recently pointed out that cancer cells are able to secrete a high amount 
of EVs and that they are critical messenger in tumor progression and metastasis, contributing 
to the acquisition of all of the cancer hallmarks delineated by Hanahan and Weinberg such as 
tumor growth, angiogenesis, invasion and metastasis (166) (Fig. 1.10). Cancer cell-derived 
EVs have been found to transfer oncogenic molecules among the cells in the primary tumor 
as well as to neighbouring stromal cells. These cells can also intervein secreting EVs mediating 
bi-directional communication, thus, influencing tumor progression and shaping of tumor 
microenvironment (157). Moreover, tumor-derived EVs from several types of tumors such as 
melanoma (167), renal cancer (168) and breast cancer (169) among others, are able to shape 
distant organs environment. This process, known as premetastatic niche (PMN) conditioning, 
allows primary tumor survival and outgrowth once tumor cells scape blood circulation. 
Moreover, due to surface protein specific composition, tumor-derived EVs may be directed to 
specific tissues (170, 171). Furthermore, tumor-derived EVs could be future targets for 
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anticancer therapies, since they are found in blood and urine, and are promising emerging 
biomarkers to monitor cancer progression and treatment response (157, 172). 
 
Figure 1.10: Representation of the hallmarks of cancer acquired during tumor progression. by Hanahan 
and Weinberg, Cell 2011. The hallmarks of cancer where EVs have been shown to participate are 
marked in yellow. The functions marker in grey are the ones where EVs effects are still poorly 
understood. In red, we show that enabling replicative immortality has not been related to EVs yet.  
 
1.4.6 RAS AND EXTRACELLULAR VESICLES  
  
Since cancer-derived EVs can mediate in horizontal transformation of normal cells, it is not a 
surprise that RAS presence in EVs, as well as RAS mutated cells derived EVs, have risen 
researcher´s attention.  
 
RAS networks have been shown to play a critical role in exosome biogenesis, maintenance, 
secretion and even cargo loading (173) (Fig. 1.11). Some studies have shown that tumor cell-
derived EVs can functionally transfer fragments of genomic DNA (174). Indeed, double 
stranded genomic DNA for mutated K-RAS (G12V and G12D) has been found in serum isolated 
EVs from patients with colon cancer and pancreatic cancer (175, 176). Moreover, Shi and 
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Colleagues have also found genomic RAS in exosomes isolated from the blood of a cervical 
cancer mouse model and that it was related with higher tumor aggressiveness (177). Also, rat 
epithelial cells transformed by H-RASv12 secreted EVs containing chromatin-associated 
double-stranded genomic DNA for H-RASv12, which in turn were able to transiently 
transform fibroblast and endothelial cells (178). Furthermore, apoptotic bodies have been 
found to mediate H-RAS genomic DNA transfer, inducing tumor formation of non-
tumorogenic fibroblasts (179, 180).  
 
Additionally, farnesylated RAS proteins have been found in Glioblastoma extracellular 
vesicles associated with ESCRT proteins, what suggests that RAS plays a crucial role in 
exosomes biogenesis (181). K-RAS has also been found in non-small cell lung cancer-derived 
EVs (182). 
In addition, RAS can modulate EVs cargo by promoting the packing of different molecules. 
For instance, H-RAS overexpression in Madin-Darby canine kidney epithelial cells leads to 
the incorporation of different mesenchymal markers such a as vimentin and MMPs into EVs 
that are thought to induce epithelial to mesenchymal transition (EMT) in recipient cells (183). 
Furthermore, MK4 cells transformed by H-RASv12, increased exosome-like microvesicle 
release compared with their normal counterparts (184).  
Figure 1.11: Role of RAS pathway proteins in exosome biogenesis, cargo selection and release. Adapted 
from (173). 
 
Other group has seen that mutant K-RAS CRC cells exosomes contained higher levels of the 
EGFR ligand amphiregulin (AREG) than K-RAS wild type ones, enhancing invasiveness by 
 1.   Introduction  
 
 
58 
 
recipient cancer cells (185). Moreover, Beckler and colleagues showed that exosomes isolated 
from mutant K-RASG13D-expressing colon cancer cells enhanced the invasiveness of recipient 
cells in comparison to exosomes purified from wt K-RAS-expressing cells which leads to 
hypothesize that mutant K-RAS might affect neighboring and distant cells by regulating 
exosome composition and behavior (186) (Fig. 1.11).  
 
Finally, active RAS isolated from human and mouse glioblastoma extracellular nanovesicles 
lysates coprecipitates with ESCRT-associated exosome proteins VSP4a and ALIX (181). 
Furthermore, H-RASv12 expression in fibroblasts was associated with higher levels of 
tetraspanins, involved in vesicle formation (187). There are also several RAS effectors, such 
as RHO family GTPases or RAL GTPases that have been shown to promote protein sorting 
into exosomes and to be regulators of MVB formation and exosome release (173, 188, 189). 
Additionally, Small GTPases have also been documented in stabilizing 
the phospholipases present in the exosome bilayer and ERKs have been reported to play a 
role in facilitating exosome uptake (173). 
 
1.5   Thyroid lesions and cancer 
1.5.1   THE THYROID GLAND 
 
The thyroid is a highly vascularized gland located anteriorly in the lower neck. It has two 
symmetrical lobules connected by an isthmus. These lobules are irrigated by the superior 
thyroid artery, that arises from the external carotid artery, and the inferior thyroid artery that 
is a branch of the subclavian artery (190, 191). The thyroid is covered by a thin true capsule 
that penetrates the parenchyma of the gland dividing it into several lobules containing 20-40 
follicles. These follicles are the structural units of the gland and consist of a colloid-filled cavity 
surrounded by a layer of polarized epithelial cells, also called follicular cells, that are the main 
component of the gland (Fig. 1.12)  (191, 192). The colloid serves as a storage for the thyroid 
hormones precursor, iodo-thyroglobulin, while follicular cells are able to incorporate iodine, 
through a 2Na+/I- symporter (NIS) located in their basolateral membrane (193), in response 
to the Thyroid Stimulating Hormone (TSH) (194). This process finally results in the synthesis 
of the two thyroid hormones, triiodothyronine (T3) and thyroxine (T4), which are crucial for 
children growth and nervous system maturation and for a correct metabolism control in adults 
(191, 194). 
Parafollicular cells, also known as C cells, are the other component of the gland. They are 
found among follicles and their main function is the production of Calcitonin, a hormone that 
decrease ionic calcium and phosphorus in blood preventing bone resorption (191, 192, 195). 
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A broad plethora of diseases affect this gland, the most common ones being  autoimmune 
diseases (196, 197), followed by inflammatory diseases (198) and cancer, which can arise from 
alterations on follicular and C cells (199).  
Figure 1.12: Thyroid gland anatomy and histology showing the structural units of the gland, the 
follicules, and its epithelial cells, follicular cells and parafollicular cells. 
 
1.5.2 THYROID CANCER INCIDENCE 
Thyroid cancer is the most common endocrine malignancy worldwide accounting for ~ 2.1% 
of all cancer diagnoses. Almost 3 out of 4 cases are women. Last year, the American Cancer 
Society accounted an estimated 53 990 new diagnoses in the United States, a figure 
significantly higher than 10 years ago (200). Thyroid cancer incidence continues to rise, mostly 
due to overdiagnosis as a consequence to an increased use of improved diagnostic imaging and 
surveillance (201) (Fig. 1.13). However, big tumors diagnosis suggests that other factors 
besides overdiagnosis, such as an increase in the most prevalent environmental factors, obesity 
and cigarette smoking, could drive the initiation of new tumors (202-204). Noticeably,   
Figure 1.13: Thyroid cancer incidence and mortality. For the National Cancer Institute © (2019) Terese 
Winslow LLC, U.S. Govt. has certain rights 
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although incidence is rising steadily, mortality has not changed significantly over the past fifty 
years (205) (Fig. 1.13). This is thanks to the standard Radioactive Iodine (RAI) ablation, TSH 
suppressive therapy and surgery that allow thyroid cancer patients to have an overall survival 
rate of 95% after 5 years. However, locoregional recurrence is frequent, affecting up to 20% 
of patients, and 10% of them will also develop distant metastasis after 10 years (206, 207). 
Right now, there are several challenges that face clinicians, but the main goal is not to 
overtreat patients with low risk disease or benign thyroid nodules, and to identify those 
patients with a high risk disease, in order to treat them fast and more aggressively (201). 
 
1.5.3   CLINICAL PRESENTATIONS 
1.5.3.1   Thyroid nodules 
 
Thyroid nodules are defined as any lump within the thyroid gland that is ultrasonographically 
distinct from the surrounding parenchyma (207). The vast majority, around 90%, are small, 
non-palpable, benign lesions that have no clinical significance. Their size or the presence of 
more than one nodule are not predictive of malignancy. For example, cancer is no less frequent 
in nodules smaller than 10 mm, or when there are several nodules. However, generally, only 
nodules >1 cm are evaluated, since they are consider to harbor a greater potential to be 
clinically significant cancers (208).  
 
Nowadays, to be able to discern between low-risk and high-risk patients, a good familiar 
history, a proper physical examination, neck ultrasonography (US) (table 1.2), TSH laboratory 
determination and Fine-Needle Aspiration (FNA), in > 1cm suspicious nodules or > 2 cm 
low suspicion sonographic pattern nodules, in the correct patients, are fundamental (201).  
 
US feature Relative risk 
Microcalcifications 4.97 
Hypoechogenicity 1.92 
Irregular margins or no halo 16.83 
Solid 4.2 
Intranodule vascularity 14.29 
More tall than wide 10.5 
Table 1.2. Summary of key ultrasonographical (US) features in thyroid nodules and their relative risk 
for thyroid cancer. 
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FNA cytology is classified by the 2017 Bethesda System for Reporting Thyroid Cytopathology 
(Table 1.3), into seven different categories that predict their risk of malignancy and posterior 
management (209).  
Diagnostic Category Risk of malignancy Management 
I.Nondiagnostic/unsatisfactory 5-10% Repeat FNA under US 
guidance 
II. Benign 0-3% Clinical and US follow-up 
until two negative 
III. Atypia of undetermined 
significance/follicular lesion of 
undetermined significance 
10-30% Repeat FNA, molecular 
testing or lobectomy 
IV. Follicular 
neoplasm/suspicious for a 
follicular neoplasm 
25-40% Molecular testing and 
lobectomy 
V. Suspicious for malignancy 50-75% Lobectomy or near total 
thyroidectomy 
VII. Malignant 
Papillary thyroid carcinoma 
Follicular thyroid carcinoma 
Poorly differentiated 
carcinoma 
Anaplastic carcinoma 
Squamous cell carcinoma 
Carcinoma with mixed 
features 
Metastatic malignancy 
Non-Hodgkin lymphoma 
Others 
97-99% Lobectomy or near total 
thyroidectomy 
Table 1.3: Bethesda System for Reporting Thyroid Cytopathology 
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Although the Bethesda system is able to determine the risk of malignancy, about 15-40% of 
FNA samples are included in Bethesda group III or IV which are indeterminate lesions (210, 
211). As pointed in table 1.3 10-40% these lesions are malignant and originally, repeat FNA 
and diagnostic lobectomy were recommended for these lesions (210). Nevertheless, around 
80% of samples from lobectomy patients classified as Bethesda III and IV lesions are 
ultimately benign. 
Therefore, much research has been centered on better identifying high risk patients classified 
as Bethesda III and IV, to avoid unnecessary surgery or to perform more aggressive treatment 
in case they are predicted to be an aggressive tumor.  
The 2015 ATA guidelines have proposed three novel molecular diagnostic tools in order to 
further stratify the risk of those patients with undetermined lesions. One of the most 
affordable molecular testing, consists in the evaluation of a seven gene panel of mutations and 
rearrangements that includes BRAFv600e, H-RAS, N-RAS and K-RAS  as well as Rearranged 
during transfection / Papillary carcinoma type I and III, (RET/PTC1, RET/PTC3) and Paired 
box gene 8 / Peroxisome proliferator-activated receptor gamma-1 (PAX8/PPARγ) 
rearrangements (207, 212). In indeterminate cytology nodules, the sensitivity of the seven-
gene mutational panel testing is variable, with reports ranging from 44% to 100% (213-215). 
For instance, using the 7-gene panel RAS and BRAF mutations were the most commonly 
detected. Interestingly, in a series of 67 prospectively identified RAS-positive thyroid nodules, 
cytology was malignant in 3%, benign in 3%, and indeterminate in 94% of the cases. Positive 
testing for BRAF, RET/PTC or PAX8/PPARγ was specific for a malignant outcome in almost 
100% of cases, although BRAF mutation sensitivity is too low to reliably rule out the presence 
of malignancy. Therefore, only these last nodules are classified as cytologically-diagnosed 
thyroid carcinoma (207).  
Regarding RAS mutations, it has been seen that their presence relates to an 80% risk of cancer 
and a 20% chance of benign follicular adenoma in Bethesda III and IV patients, which makes 
difficult to determine their risk of malignancy. In consequence, they are considered in a similar 
risk category to cytologically suspicious for malignancy, which can lead to an undertreatment 
of patient with highly aggressive RAS mutations, or to an overtreatment of other more benign 
forms (207, 216). There is evidence that the risk of malignancy varies with the RAS isoform 
that is mutated. One group demonstrated that the specific isoform of RAS that was mutated 
in follicular neoplasms (Bethesda IV) determined the relative risk of malignancy, being 
greatest with H-RAS (80-90%), compared to N-RAS (75-85%) and K-RAS (41-61%) (217) 
(218). By contrast, there are several series demonstrating predominance of N-RAS mutations 
(219-221).   
 
Nowadays, no genetic test is able to discern between high or low risk RAS mutations, since 
the same mutation can lead to the development of a thyroid carcinoma or not. Neither this is 
an indicator that will define their risk of distant spreading. If molecular testing is either not 
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performed or inconclusive, surgical excision may be considered for removal and definitive 
diagnosis of these thyroid nodule. Nodules lacking all of these mutations still have a substantial 
cancer risk (222). To assess nodules risk of malignancy, another tests have been tried, such as 
the 167 GEC, that analyzes the mRNA expression of 167 genes (223) and galectin-3 
immunohistochemistry (224) but, currently, there is no single optimal molecular test that can 
definitively rule in or rule out malignancy in those cases of indeterminate cytology, and, 
importantly, in RAS mutated ones. Therefore, long-term outcome data with clinical utility is 
necessary to draw conclusions. 
 
1.5.3.2   Thyroid cancer  
 
Thyroid malignant lesions can mainly arise from either follicular cells, being the most common 
ones, or from C cells. Tumors that have other origin are exceptional. 
There are different follicular-derived thyroid cancers that include: differentiated thyroid 
cancer, poorly differentiated carcinoma and anaplastic thyroid cancer, the most aggressive 
form (225) (Fig. 1.14). Tumors arising from C cells of neuroendocrine origin are known as 
medullary thyroid carcinomas (226). This thesis will focus exclusively in follicular-derived 
thyroid cancers.  
Figure 1.14: follicular-derived thyroid cancers and incidence. 
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1.5.3.2.1  Differentiated thyroid cancers 
 
These types of thyroid cancers are the most common, accounting for more than 95% of the 
cases. They can be divided depending on their level of differentiation into well differentiated, 
under this category are Papillary Thyroid Cancer (PTC) and Follicular Thyroid Cancer (FTC), 
where we can include its less common variant: the Hürthle cell thyroid cancer (227).  
 
1.5.3.2.1.1 Papillary carcinoma  
 
PTC is a well-differentiated adenocarcinoma, often multifocal (20%) and is the major subtype 
accounting for 80-85% of thyroid cancers (228). There are different variants, including: 
papillary carcinoma, follicular variant of PTC, encapsulated variant of PTC, papillary 
microcarcinoma, columnar cell variant of PTC and oncocytic variant of PTC (229). They have 
been highly associated to ionizing radiation and they have the best overall prognosis as they 
tend to grow and metastasize slowly and generally in cervical lymph nodes (20-50%), and, 
more exceptionally, in lungs. Moreover, unlike other tumors PTC excellent prognosis is not 
affected by the extension of this cancer to lymph nodes, where micrometastases (<2 mm) can 
be present in 90% cases, and more than 95% of patients diagnosed with this cancer are alive 
after 10 years (201, 230, 231).  
These tumors are histologically complex, branching with papillary structures, a fibrous tail 
surrounded by neoplastic tissue, and display characteristic nuclear alterations such as; 
eosinophilic intranuclear inclusions; finely dispersed optically clear chromatin also called 
ground glass and Orphan Annie nuclei or micronucleoli. Moreover, Psammoma bodies, 
present in 50% of tumors, are round concentric collections of calcium and are almost 
pathognomonic for PTC (229). 
 
1.5.3.2.1.2 Follicular thyroid carcinomas (FTC) 
 
FTC is defined as a differentiated, malignant, follicular epithelial tumor that does not have 
the PTC typical nuclear alterations. It represents 10–15% of all the thyroid carcinomas and its 
overall survival is around 85% in 10 years. Rarely they are multifocal and they do not usually 
colonize locoregional ganglion, although they are more likely to spread to distant organs, 
mainly lungs and bones in around 70% of the cases. Their main risk factor is insufficient 
dietary iodine and due to that their incidence, unlike PTC, is decreasing (201, 206, 232). There 
are three types that are: minimally invasive follicular carcinoma (with capsular invasion only), 
encapsulated angioinvasive and widely invasive. Patients diagnosed with FTC are mainly 
women (75%) and the peak age is higher than in papillary carcinoma. Histologically, they are 
highly variable (from well-formed follicles to solid or trabecular growth) not being their 
cellular characteristics or cytoarquitecture exclusive for malignant lesions. Then, the only 
difference between them is their invasive capacity (capsular and/or vascular) (229).  
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Hürthle cell carcinoma derives from oncocytic follicular cells, that are polygonal cells with 
granular and eosinophilic cytoplasm, full of mitochondria. These tumors can be poorly or 
highly invasive. Nevertheless, it is usually more aggressive than other differentiated cancers 
and is associated to higher rates of distant metastases (233, 234).   
  
1.5.3.2.1.3 Differentiated thyroid cancer treatment 
 
 The basic goals of initial therapy for patients with DTC are to improve overall and disease-
specific survival, reduce the risk of persistent/recurrent disease and associated morbidity, and 
permit accurate disease staging and risk stratification, while minimizing treatment-related 
morbidity and unnecessary therapy.  
 
The new 2015 American Thyroid Association (ATA) guidelines have changed the surgical 
management recommendations of patients with biopsy proven for differentiated thyroid 
cancer (DTC). In the old guidelines all patients with a >1 cm nodule diagnosed with DTC 
were recommended to undergo total thyroidectomy as the primary treatment option. 
However, since thyroid surgery is not without risk, the mostly indolent course of these tumors 
and some recent studies demonstrating that in properly selected patients, clinical outcomes 
are very similar after hemithyroidectomy and total thyroidectomy (235-238), the new 2015 
ATA guidelines have suggested hemithyroidectomy as an acceptable option for malignant 
nodules 1–4 cm in diameter without extrathyroidal extension, and without clinical evidence of 
any lymph node metastases (cN0) (207). This measure has been the most controversial change 
since they suggest that hemithyroidectomy is equivalent to total thyroidectomy for low risk 
cancer between 1-4 cm in diameter (239).  
 
1.5.3.2.2 Poorly differentiated and anaplastic thyroid carcinomas 
 
Poorly Differentiated Thyroid Carcinoma (PDTC) and Anaplastic Thyroid Carcinoma (ATC) 
account 5-10% of thyroid cancers and represent a major clinical challenge since they are very 
aggressive and have a mean survival of 3.2 and 0.5 years, respectively, from the time of 
diagnosis. Particularly, anaplastic cancers have an almost 95% mortality in 5 years and have 
no available treatment options (240, 241).  
PDTC is a malignant follicular neoplasm with limited follicular cell differentiation and with 
an intermediate clinical behavior between well differentiated and anaplastic carcinoma 
(62) (242). It is more common in older patients, mean age 55-63 years, and it is relatively more 
usual in Europe and South America than in Unites States. These tumors usually extend to 
perithyroidal soft tissue, 60-70% of cases; undergo vascular invasion in 60-90% cases; with a 
distant metastasis rate of 40-70%, mainly to lungs and bone, and nodal invasion rate between 
15-65%. This results in 3 years survival rate of the 38% of patients with nodal and 
hematogenous metastases (62). 
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The histology description follows the Turin consensus diagnostic criteria that includes: solid, 
trabecular or insular growth pattern, no nuclear features of papillary carcinoma and the 
presence of at least one of the following: convoluted nuclei, >3 mitotic figures/10 high power 
field or tumor necrosis. It stains positive for keratin, Thyroid Transcription Factor (TTF1) and 
Ki67 (10-30%) and negative for calcitonin and Parathyroid Hormone (PTH) (64). 
 
ATC is an undifferentiated, high grade, follicular cell carcinoma of the thyroid gland and it 
usually presents as a rapidly enlarging, bulky neck mass that invades adjacent structures 
causing hoarseness, dysphagia and dyspnea. The mean age is 70 years and it is often presented 
with local and distant metastases in lungs, bone and with lower frequency in liver and brain, 
being all considered since diagnosis high stage (IV) tumors (243). The etiology is unknown 
although 50% arise from prior multinodular goiter suggesting a possible relationship with 
iodine deficiency. 
Histologically there are three patters that can be seen singly or in any combination:  
- Sarcomatioid: Malignant spindle cells are present, and it resembles high grade 
pleomorphic sarcoma. 
- Giant cell: highly pleomoporphic tumors with some tumor giant cells and might have 
blood vessel structures that resemble aneurysmal bone cysts. 
- Epithelial: squamous tumors nests with occasional focal keratinization are present. 
Moreover, necrosis, vascular invasion, high mitosis, heterologous differentiation, acute 
inflammation and some other less common variants such as the paucicellular one can be found. 
It stains positive for Paired Box Gene 8 (PAX8), Keratin, vimentin, p53, increased KI-67 and 
Proliferation Cell Nuclear Antigen (PCNA). It is negative for calcitonin, thyroglobulin and 
TTF1 (64). 
 
1.5.3.2.2.1 PDTC and ATC treatment 
Patients with PDTC and ATC must undergo total thyroidectomy and neck dissection in order 
to remove any lymph node affected. Moreover, RAI is used when possible and suppressive 
thyroxine therapy is fundamental too (244).  
 
1.5.4   Thyroid cancer genetics  
 
Thyroid cancer it is thought to undergo a multistep carcinogenesis model, accumulating 
mutations, that promote progression through a dedifferentiation process. Firstly, this causes 
well-differentiated carcinomas as PTC and FTC eventually giving rise to PDTC, thought to be 
an intermediate tumor that can derive later to the most aggressive form, the ATC (245, 246).  
However, some evidences supporting ATC arising de novo has nurtured a novel less studied 
theory: the fetal cell carcinogenesis theory. This theory propose that cancer cells arise from 
fetal thyroid cells remnants instead of normal adult thyroid follicular cells (247).  
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The Cancer Genome Atlas of the Thyroid (TCGA) shows that PTC has 11 non-synonymous 
mutations per tumor, that is: 0.41 mutation per Mb on average, which is one of the lowest 
among solid tumors (248). In contrast, ATC shows 90 non-synonymous mutation per tumor, 
around 3 per Mb, that is a much higher mutation rate supporting the multistep carcinogenesis 
model (249, 250).  
 
The DNA sequencing studies in thyroid carcinomas have disclosed accumulation of mutations 
affecting genes encoding: growth factors and cell cycle regulators plus genetic and epigenetic 
alterations of multiple genes. However, there is a signaling pathway that harbor most of 
thyroid cancer mutations and drives nearly 70% of thyroid tumors, the well-known RAS-ERK 
signaling pathway. This pathway, key for thyroid cancer initiation, is essential to transmit 
growth factor external signals from the plasma membrane to the nucleus, a process that is 
crucial for regulating cellular proliferation (166, 250, 251). Another pathway that has seen to 
be crucial is the PI3K/AKT, which is fundamental for thyroid cancer progression along with 
P53 alterations and TERT mutations (201) (Fig. 1.15). 
 
Figure 1.15: Thyroid cancer pathways. Image shows the fundamental signaling pathways involved in 
thyroid cancer. The left box shows the most mutated one, that is the MAPK signaling pathway, which 
has been thought to initiate thyroid cancer development by altering gene expression, which promotes 
cell proliferation, cell growth, angiogenesis, and loss of differentiation. The right box shows pathways 
that promote tumor progression and are altered in advanced thyroid cancers. This includes the PI3K–
mTOR pathway and alterations in p53 tumor suppressor, and in the promoter for TERT (201). 
mTOR=mammalian target of rapamycin. PI3K=phosphatidylinositol-3-kinase. TERT=telomerase 
reverse transcriptase. 
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Many PTC tumor initiating events have been identified and all of them involve a single 
pathway: the RTK/RAS/RAF/MAPK pathway, obeying an exclusion principle where only one 
component of the pathway is mutated in a given tumor. RET  rearrangements, mainly, and 
less frequently, Neurotrophic Receptor Tyrosine Kinase (NTRK) and Anaplastic Lymphoma 
Kinase (ALK) rearrangements or RAS (26%)(252)  and BRAF activating point mutations are 
some of the main alterations, although BRAF accounts mostly 60% of the mutations.  
 
FTC main drivers are RAS mutations accounting around 40% of them (252), mostly activating 
PI3K/AKT signalling pathway to promote tumorigenesis and PAX8/PPARγ rearrangements. 
 
PDTC and ATC have a high mutation rate for RAS (53%) (252) that together with other 
alterations such as telomerase reverse transcriptase (TERT) (253) and eukaryotic translation 
initiation factor 1A in chromosome X (EIF1AX) (254) mutations confer worse prognosis, 
which also occurs in PTCs. ATC has also TP53 frequently mutated, which confer 
aggressiveness if co-occurring with RAS. Moreover β-catenin is also frequently mutated in 
these tumors together with mutations in genes encoding components of the SWI/SNF 
chromatin remodeling complex, mostly in ATC (36%), including AT- Rich Interacting 
Domain-containing proteins 1A, 1B, 2 and 5B (ARID1A, ARID1B, ARID2 and ARID5B) 
(245, 248).  
 
Mutations in genes encoding members of the PI3K/AKT/mTOR pathway were also seen more 
frequently in ATCs than PDTCs mainly in PIK3CA and PTEN genes, which could also be 
epigenetically regulated altering its function in thyroid cancer (245). Moreover, loss of 
expression of thyroid differentiation markers, such as PAX8, is one of the hallmarks of 
advanced thyroid cancers causing loss of NIS expression leading to resistance to radioiodine 
therapy (245, 255). 
 
1.5.4.1 Oncogenic rearrangements  
 
RET is a versatile receptor tyrosine-protein kinase that binds ligands from the Glial Derived 
Neurotropic Factor (GDNF) family, triggering the phosphorylation of several proteins such 
as SRC, Signal Transducer and Activator of Transcription 3 (STAT3), Phospholipase C 
Gamma (PLCγ) and ENIGMA, plus the common RAS/ERK and PI3K/AKT signaling 
pathways. Therefore, it participates in numerous cellular processes such as proliferation, 
migration and differentiation (256, 257). RET rearrangements, mainly RET/PTC1 and 
RET/PTC3, that are a fusions of the tyrosine kinase domain of RET to Coiled-Coil Domain 
Containing 6 (CCDC6) or Nuclear Receptor Co-Activator 4 (NCOA4) respectively, the later 
being of worse prognosis (258).  As pointed before, RET rearrangements are very common in 
PTC, although they can also be found in thyroid adenomas (259), in FTC but in a less 
prevalence, in 14% of PDTC and are completely absent in ATCs (245). 
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RET, NTRK and ALK rearrangements are genetic events that occur mainly in PTC. Although 
they have the potential to activate pathways such as the PI3K-AKT axis, their oncogenic 
potential in the thyroid has been mostly related to the activation of the RAS-ERK pathway 
(260, 261). 
 
Another common rearrangement is the PAX8/PPARγ which is mainly found in FTC (262, 
263).  
 
1.5.4.2   Mutations 
 
1.5.4.2.1 BRAF 
 
The most common BRAF mutation, accounting for 95% of the total, is a Valine 600 (V) 
change to a glutamic acid (E) (BRAFV600E) in the activation loop, promoting BRAF 
constitutive activation independent of RAS and with no requirement for dimerization. The 
V600E mutation also increases BRAF kinase activity up to 500-fold as compared to wild-type 
BRAF (264, 265). Data from the TCGA network surveying a large panel of PTC, confirmed 
that PTC with BRAFV600E mutations are associated with a undifferentiation state and higher 
ERK activation than tumors harboring RAS mutations (248). Co-occurrence of BRAF and 
TERT synergistically increase the aggressiveness of the tumor (266). It must be said that 
TERT mutations are found at a relatively low prevalence in PTC (around 11%), but its higher 
in metastatic PTC, PDTC (30–40%) and ATC (30–70%) (267, 268). A less common BRAF 
mutation, K601E, has been detected in benign thyroid adenomas and in the follicular variant 
of PTC, strikingly showing a RAS-like behavior (269, 270).  
 
1.5.4.2.2 PI3K/AKT  
 
PI3K/AKT activation is thought to be critical in FTC initiation through mutations in RAS or 
inactivating mutations in the tumor suppression gene PTEN, or by activating mutations in the 
PIK3CA and AKT1 genes. Some patients with PTC and FTC may progress to RAI-refractory 
metastatic disease, and these tumors are particularly enriched with mutations in BRAF and 
RAS coexisting with PIK3CA or AKT1 (271, 272). Moreover, thyroid cancer progression and 
dedifferentiation to PDTC and ATC also involve a number of additional mutations that affect 
other cell signaling pathways such as p53 and WNT/β-CATENIN (273, 274). 
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histo-
types 
RET/PTC 
Gene 
fusion 
BRAF 
(V600E) 
mutations 
 
RAS 
mutations 
PAX8/PPARγ 
Gene fusion 
CTNNB1 
(B 
catenin) 
mutation 
TERT 
mutations 
TP53 
mutations 
FA 0% 0% 17-43% 8% 0% 0% 0% 
PTC 13-43% 30-69% 0-21% 0.3% 0% 9% 0-5% 
FTC 0% 0% 40-53% 39% 0% 15% 0-9% 
PDC 0-13% 0-13% 18-55% 0% 25% 40% 17-38% 
ATC 0% 10-35% 4-60% 0% 66% 73% 60-88% 
Table 1.4. Thyroid cancer histological types and their frequency of some of their most common 
mutations. Adapted from Kakudo et al “Thyroid Follicular Cell Neoplasms in Multistep 
Carcinogenesis” Journal of Basic & Clinical medicine 2015 4(1):13-21 
1.5.4.2.3  RAS 
 
RAS is one of the most frequently mutated oncogenes in cancer and is activated in one-third 
of all human tumors. RAS activating mutations in thyroid epithelial cells were first reported 
in the 1980s and have been directly implicated as early frequent events in transformation and 
proliferation of thyroid carcinoma (275). RAS represents the second most common genetic 
mutation identified in thyroid cancer and includes the 3 isoforms: N-RAS, K-RAS, and H-
RAS. Single base missense mutations, leading to a constitutively activation of RAS by locking 
it in a GTP-bound active form, are mainly in codons 12/ 13 which affect the guanosine 
triphosphate (GTP)-biding domain, and in 61, which alters the GTPase domain (252).  
N-RAS mutations in codon 61 are the main RAS alterations found in thyroid cancers, and 
substitution from a glutamine (Q) to an arginine (R) is the most common. It is followed by H-
RAS mutations in codon 61, K-RAS mutations in codons 12/13 and H-RAS mutations in 
codon 12. However, N-RAS has been mainly found in well-differentiated carcinomas whereas 
K-RAS mutated in codon 12/13 and H-RAS mutated in codon 12 have been found mainly in 
PDTC and ATC, although they can also be found in PTC and FTC. Overall this suggest that 
different mutations can be related to some extent with patient outcomes (252, 276). There are 
some discrepancies related to the overall frequency of RAS mutations (ranging from 7 to 62%) 
and their prevalence in specific thyroid tumors (219, 277, 278). It is well accepted that RAS 
mutations, although common in follicular adenomas or in well-differentiated carcinomas 
(follicular or papillary), have higher prevalence in poorly differentiated and anaplastic 
carcinoma. See (table 1.4).  
In thyroid cells, RAS mainly activates PI3K/AKT, a critical event in FTC initiation, rather than 
RAS-ERK signalling that is more related with BRAF driven oncogenicity (279).  
1. Introduction  
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Several studies have related RAS with high rates of mortality (276, 280) and distant metastasis 
(281, 282). However, a high number of follicular adenomas (FA) have RAS mutations and 
some of them will never progress to thyroid cancer, which makes difficult to propose RAS as 
a risk factor and further research is necessary to elucidate this baffling behavior. Although 
some research has been done in this matter, showing RAS co-occurrence with TERT 
promoter and EIF1AX mutations frequently associated with a worse prognosis than tumors 
harboring only RAS mutations (245). However, not all RAS mutated ATC co-occur together 
with TERT or EIF1AX mutations and therefore are unable to fully explain RAS seemly 
changing behavior. 
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2.   OBJETIVES 
 
RAS is commonly mutated in thyroid cancer. In consequence, considerable efforts have been 
made in order to apply RAS mutations as molecular markers to the clinical management of 
thyroid nodules and cancer, as new guidelines are heading to more conservative treatments. 
However, no good marker has been found yet. Moreover, due to RAS presence in benign 
adenomas and its uncertain role in the clinical outcome of thyroid cancer more research is 
needed. Since RAS has recently been found to be present and functional in different 
subcellular localizations as at lipids rafts, disordered membrane, the Golgi Complex and 
endoplasmic reticulum and has been shown to modulate exosomes biogenesis and cargo, we 
wanted to explore their implications in thyroid tumorigenesis. Thus, the aims of this thesis are:  
 
1. Study how RAS at its different subcellular locations contribute to thyroid  
tumorigenesis  
 
2. Find new markers to rule out indeterminate thyroid nodules risk of malignancy and 
thyroid cancer aggressiveness 
 
3. Adress the relevance of exosomes in thyroid cancer tumorigenesis mediated by RAS at 
its different sublocalizations 
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3.   MATERIAL AND METHODS 
3.1   DNA purification and plasmid description  
3.1.1   Plasmidic DNA purification from bacterial cultures 
 
A bacterial competent colony (DH5α, a E. Coli strain engineered to maximize transformation 
efficiency) containing the plasmid of interest was inoculated in four 5 ml Lysogeny Broth (LB) 
containing tubes with their specific resistance antibiotic, ampicillin or kanamycin. They were 
left shaking at 200 rpm at 37ºC Over-Night (ON). The bacterial culture was harvested by 
centrifugation at 8000 rpm for 2 minutes at room temperature and we Plasmidic DNA was 
extracted using GeneJET Plasmid Miniprep Kit (Thermo Fisher). In order to resuspend the 
cells we added 250 µL of Resuspension Solution and vortexed, 250 µL of Lysis Solution was 
then used to lyse bacteria then 350 µL of Neutralization Solution was added and centrifuged 
at 13,000 rpm for 5 minutes.  
The supernatant was then transferred to a Thermo Scientific GeneJET Spin Column and 
centrifuged at 13,000 rpm for 1 minute. After that, columns were washed twice with 500 µL.  
To elute the purified DNA 40 µL of Elution Buffer was added to the column and incubated 2 
minutes. Finally, it was centrifuged for 2 minutes at 10,000 rpm and the flow-through 
containing the Plasmidic DNA was collected.  
 
3.1.2   Plasmids 
 
Plasmid Brief description 
pCEFL Plasmid used as an expression vector 
 
 
pCEFL-HA*-HRAS-G12V 
H-RASv12 construct presents H-RAS 
mutated in Glycine 12, presenting a valine 
instead and its located in every 
compartment of the cell. HA HA was used 
as a Tag to detect protein expression by 
western blotting. 
 
pCEFL-M1-HA*-HRAS-G12V SS 
This construct tethers H-RASv12 to ER. 
HA was used as a Tag to detect protein 
expression by western blotting. 
 
pCEFL-LCK-HA*-HRAS-G12V SS 
This plasmid locates H-RASv12 in Lipids 
Rafts. HA was used as a Tag to detect 
protein expression by western blotting. 
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pCEFL-CD8-HA*-HRAS-G12V SS 
This construct directs H-RASv12 to 
disordered membrane, also known, al bulk 
membrane. HA was used as a Tag to detect 
protein expression by western blotting. 
 
pCEFL-KDELN-HA*-HRAS-G12V SS 
Thanks to this plasmid H-RASv12 is 
located in cis face of Golgi Complex. HA 
was used as a Tag to detect protein 
expression by western blotting. 
 
pCEFL-HA*-NRAS- G12V 
This plasmid present N-RAS mutated at 
position 12 (G>V). HA was used as a Tag 
to detect protein expression by western 
blotting. 
 
pCEFL-M1-HA*-NRAS- G12V S 
This construct tethers N-RAS mutated at 
position 12 (G>V) to ER. HA was used as 
a Tag to detect protein expression by 
western blotting. 
 
pCEFL-LCK-HA*-NRAS- G12V S 
This plasmid locates N-RAS mutated at 
position 12 (G>V) in Lipids Rafts. HA was 
used as a Tag to detect protein expression 
by western blotting. 
 
pCEFL-CD8-HA*-NRAS- G12V S 
This construct directs N-RAS mutated at 
position 12 (G>V) to disordered 
membrane, also known, al bulk membrane. 
HA was used as a Tag to detect protein 
expression by western blotting. 
 
pCEFL-KDELN-HA*-NRAS- G12V S 
Thanks to this plasmid N-RAS mutated at 
position 12 (G>V) is tethered to the cis  
face of Golgi Complex. HA was used as a 
Tag to detect protein expression by western 
blotting. 
 
pCEFL-HA*-KRAS-G12V 
This plasmid presents K-RAS mutated at 
position 12 (G>V). HA was used as a Tag 
to detect protein expression by western 
blotting. 
pCEFL-M1-HA*-KRAS-G12V This construct tethers K-RAS mutated at 
position 12 (G>V) to ER. HA was used as 
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a Tag to detect protein expression by 
western blotting. 
pCEFL-CD8-HA*-KRAS-G12V This construct directs K-RAS mutated at 
position 12 (G>V) to disordered 
membrane, also known, al bulk membrane. 
HA was used as a Tag to detect protein 
expression by western blotting. 
pCEFL-FLAG-CDC25 RASGRF1 CDC25 domain, known to  
specifically activate endogenous H-RAS 
(283). FLAG was used as a Tag to detect 
protein expression by western blotting. 
pCEFL-M1-FLAG-CDC25 RASGRF1 CDC25 domain, known to  
specifically activate endogenous H-RAS 
(283). M1 protein tethered it to 
endoplasmic reticulum. FLAG was used as 
a Tag to detect protein expression by 
western blotting. 
 
pCEFL-LCK-FLAG-CDC25 
RASGRF1 CDC25 domain, known to  
specifically activate endogenous H-RAS 
(283). LCK protein tethered it to lipids raft. 
FLAG was used as a Tag to detect protein 
expression by western blotting. 
 
pCEFL-CD8-FLAG-CDC25 
RASGRF1 CDC25 domain, known to  
specifically activate endogenous H-RAS 
(283). CD8 protein tethered it to 
disordered membrane. FLAG was used as a 
Tag to detect protein expression by western 
blotting. 
 
pCEFL- KDELN-FLAG-CDC25 
RASGRF1 CDC25 domain, known to  
specifically activate endogenous H-RAS 
(283). KDELN protein tethered it to Golgi 
Complex. FLAG was used as a Tag to 
detect protein expression by western 
blotting. 
 
pCEFL-FLAG-APT1 
This construct carries the acyl-protein 
thioesterase-1, APT1, an enzyme that 
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removes palmitate for diverse palmitoyl 
protein substrates, as N-RAS and H-RAS. 
FLAG was used as a Tag to detect protein 
expression by western blotting. 
 
Table 3.1: Plasmid names and description. 
 
To investigate whether RAS subcellular locations affects thyroid tumorigenesis we used a wide 
number of constructs that tether H-RAS-G12V (For now on H-RASv12), N-RAS-G12V (For 
now on N-RASv12) or K-RAS-G12V (For now on K-RASv12) to its different subcellular 
locations. All these constructs have a resistance for geneticin.  
 
Constructs were already described and used in our laboratory (110, 284) and have the 
following characteristics:  
 
SS and S: In order to tether RAS to its different locations, we generated palmitoylation-
deficient H-RASv12, N-RASv12 and K-RASv12 by mutating cysteines 181 and 184 in H-RAS, 
cysteine 181 in N-RAS or 180 in K-RAS to serines. In consequence, RAS is not longer 
efficiently retained at the PM and exists in a dynamic equilibrium shuttling between the ER 
and cytoplasmic pools. The palmitoylation signal was then substituted by the following cues at 
RAS N-terminus that specifically direct H-RASv12 SS, N-RASv12 S or K-RASv12 S to the 
desired locations: 
 
- The avian infectious bronchitis virus M protein (M1): When RAS is fused in its N-
terminus amino acids 1 to 66 of M1 is delivered to the ER (3)(285). 
 
- KDEL receptor (KDELr) N193D: N193D was introduced in KDELr in order to avoid 
its recycle to the ER. This mutation then prevents KDELr redistribution to the ER 
and renders it a resident Golgi protein (110, 286). 
 
- CD8α: The transmembrane domain of the CD8α receptor directs proteins to bulk 
membrane (DM) (284, 287). 
 
- LCK: LCK myristoylation signal that when placed in RAS N-terminus is able to anchor 
it effectively to lipids rafts (110). 
 
CDC25 constructs: All CDC25 constructs are composed of RASGRF1 CDC25 domain fused 
to the sub-localization-defining cues. Herrero A. and colleagues determined that the CDC25 
domain has a high specificity for activating endogenous HRAS (HRAS-GTP) but not NRAS 
and KRAS (283).  
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Moreover, apart from these tethering signals all of our constructs have a tag epitope that can 
be the amino acids 98-106 of the Human influenza hemagglutinin (HA), or FLAG that consist 
of eight amino acids, DYKDDDDK, to enable the detection of these proteins (288, 289). 
When HA presents * means that HA ATG initiation codon has been deleted in order to avoid 
reading lecture frame errors.  
 
3.2   Tissue Culture 
 
3.2.1 IMMORTALIZED CELL LINES 
 
3.2.1.1 Wild type cells 
 
PCCL3 are well differentiated rat thyroid follicular cells that were firstly isolated from 18 
months donor rats and were spontaneously immortalized. Their doubling time is 24 hours 
(290). 
Culture Medium:  
- 1 L of sterile milliQ water mixed with one vial of Nutrient Mixture F-10 Ham powder 
(Sigma). 
 
- 2,69 g of sodium bicarbonate (Sigma)  
 
- 5% Calf Serum (Gibco)  
 
- Hormones and their working solutions:  
 
- Gly-His-Lys acetate Salt (Sigma) (20 ng/ml) 
- Hydrocortisone (Sigma) (10 ng/ml) 
- Somatostatin (Sigma) (10 ng/mL) 
- Insulin from bovine pancreas (Sigma) (10 µg/mL) 
- Human apo-Transferrin (Sigma) (5 µg/mL) 
- TSH (Sigma) (0.5U/µL) 
 
- 1% Penicillin-Streptomycin (10,000 U/mL) (Sigma) 
 
- 1% MEM Non-essential amino acid solution (100X) 
 
- 1% Amphotericin B (250 µg/mL) (Gibco) 
 
- 1% Glutamine 100X (Gibco) 
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Final pH should be 7.4. The whole media is passed through a 22 µm filter vacuum cup in order 
to avoid any contamination.  
Basal media:. This media does not contain any hormones, calf serum, glutamine and MEM 
Non-essential amino acids.  
Since there are no untransformed cell lines from human origin and several groups have been 
using them extensively to explore the effects of different oncogenes in vitro (291-293), we have 
chosen PCCL3 as our reference cell line to study RAS sublocalizations effects. 
 
3.2.1.2 Human Anaplastic thyroid cancer cell lines 
- C643 is a human anaplastic thyroid cancer cell line isolated from a 76-year-old male. They 
have mutations in H-RAS in position 13 (G13C) and it is heterozygous for TERT (228 C>T). 
This last mutation is located at its promoter (268, 294, 295).  
- HTH83 is another human anaplastic thyroid cancer cell line isolated from a male age 66. 
They have a mutation in H-RAS changing a Glutamine in 61 position for an Arginine. 
Moreover, it is heterozygous for TERT (228 C>T) (268, 294, 295).  
Culture Medium: They both were grown in Dulbecco´s Modified Eagle Medium (DMEM) 
(Thermo Fisher) supplemented with 10% Fetal Bovine Serum (Gibco) and 1% Penicillin-
Streptomycin (10,000 U/mL) (Thermo Fisher). 
Basal medium: DMEM culture media without Fetal Bovine Serum. 
All cells were grown at a 37ºC and 5% CO2 incubator. 
 
3.2.2   CELLULAR TRANSFECTIONS 
 
3.2.2.1   Lipofectamine LTX 
 
PCCL3 were transfected with the different plasmids described before, using Lipofectamine 
LTX (Thermo Fisher). Cells were seeded to be 80% confluent at transfection. 14 µL of LTX 
was diluted in 500 µL Opti-MEM medium (Thermo Fisher). Then, 3.5µg of DNA was diluted 
in another eppendorf tube containing 500 µL Opti-MEM medium and 18 µL of PLUS 
Reagent was added. DNA was added to the Lipofectamine LTX Reagent tube and was 
incubated at room temperature for 5 minutes. Meanwhile PCCL3 cells were washed twice with 
Phosphate-Buffered Saline (PBS) 1X and the DNA-lipid complex was added to cells. Next 
day, media was completed and cells were incubated for 3 days at 37ºC. A control plate 
of PCCL3 transfected with a Green Fluorescent Protein (GFP) was analyzed under a 
Leica microscope to determine transfection efficiency. Generally, a 70% efficiency was 
achieved. Cells were then selected with Geneticin (G418 (Sigma) 200 µg/ml. 
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3.2.2.2 Lipofectamine 3000  
 
SiRNA transfection was done using lipofectamine 3000 (Thermo Fisher). PCCL3, C643 or 
HTH83 cells were plated so they were around 80% confluent at the time of transfection. 12µL 
of Lipofectamine 3000 Reagent was added to Opti-MEM medium (Thermo Fisher). Then, 
diluted Small Interfering RNA (siRNA) (10 µM/ml) was added to the lipofectamine 3000 tube 
(1:1 ratio) and incubated for 10 minutes. During that time, cells were washed twice in PBS 1X 
and mixture was added. Cells were left ON with the mixture and media was completed. At 36 
hours transfected cells were collected to perform the chick embryo assays or they were left 3 
days for other in vitro assays.   
 
SiRNA Company (Catalog) 
LYPLA1 siRNA (Human) 10 µM Santa Cruz Biotechnology (sc-77637) 
 
Table 3.2: SiRNA description and Company. 
 
3.2.3 PROLIFERATION ASSAYS 
 
3.2.3.1 AlamarBlue proliferation assay  
To perform proliferation assays we used AlamarBlue Cell Viability Reagent (Thermo Fisher) 
that has as active component a non-toxic, cell-permeable non-fluorescent blue compound 
called Resazourin. This molecule can be reduce by several mitochondrial reductases 
(NADPH, NADH, FADH) as it acts as an intermediate electron acceptor in the electron 
transport change and as well by cytochromes and other enzymes as flavin reductase or 
NAD(P)H: quinone oxidoreductase. This indicates viability and indirectly number of cells by 
giving rise to a red highly fluorescent compound that is Resorufin. In consequence this change 
of color can be measure using absorbance-based place readers using 600 nm as a reference 
wavelength and monitoring reagent absorbance at 570 nm (296). 
We plated 6,000 cells per well in a corning 96-well plate in 100 µL complete medium and led 
them seat overnight. Then, complete medium was changed to 90 µL starving medium for 12 
hours. After that time, 10 µL of room temperature AlamarBlue Reagent was added and 
incubated in the dark at 37ºC, in the same cell incubator, for 12 hours. Then, absorbance was 
read as explained above.  
3.2.3.2 IncuCyte proliferation Assays 
 
In a 96-well plate, 3 x 103 PCCL3 cells transfected with the different HRASG12V constructs 
in 100 μl of starving medium were mixed with 104 freshly prepared EVs isolated by size 
exclusion (material and methods 3.8.1.1) in starving medium per cell (about the same number 
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of EVs secreted by each PCCL3 cell in 24 hour) for 30 minutes at 37ºC. Growth was followed 
over a period of three days by live image acquisition using the IncuCyte ZOOM® analysis 
system (10x magnification; Essen Bioscience) to automatically detect cell edges and to 
generate a confluence mask for cell coverage area calculation. Each biological replicate is 
represented as mean of at least 8 technical replicates.  
 
3.2.4 IN VITRO MIGRATION ASSAY 
 
Cell migration was measured using transwell chambers (Corning, USA) containing 24 well 
inserts with 8 µm pores. 10,000 cells were dyed with 10µM Green Cell Tracker (Thermo 
Fisher) for 30 minutes and placed in transwell chambers with 100 µL of basal medium. Wells 
containing transwell chambers were filled with 100 µL of complete media. After 24 hours cells 
in the upper chamber were removed and the remaining cells were seen using a Leica 
fluorescence microscope. Cells were quantified in five randomly selected fields for three 
independent experiments. The average of cell count per field was presented and compared 
between the different cells.    
 
3.2.5 Electron microscopy 
 
We first removed media from a 100 mm plate and washed cells twice with 1X PBS. After that, 
we fixed them with 5 ml of 3% glutaraldehyde in Phosphate Buffer 0.12 M (Buffer 3) for 30 
minutes at room temperature.  
After, 4 ml were removed, and cells were collected and centrifuged 5 minutes at 7,000 rpm at 
4ºC. We then leaved cells in post-fixation for 1-2 hours and centrifuged them at 14,000 rpm at 
4ºC. Supernatant was then removed and 1 ml of Phosphate buffer 0.12 M (Buffer 2) was 
added. Three 15 minutes changes were done (it can be stored at 4ºC in this solution several 
days). Supernatant was again removed. and pellet was fixed with Osmium Tetroxide 2-4 hours 
with agitation at room temperature protected from light. 
Then, pellets were washed with wash solution pH 4,5-4,6 twice for 15 minutes at 4ºC. Pellets 
were contrasted with uranyl acetate 90 minutes at 4ºC. Again, two 15 minutes washes at 4ºC 
were done with wash solution.  
The next step is dehydration: 
 
-Acetone 15%......5 seconds 
-Acetone 30%......10 minutes 
-Acetone 50%......10 minutes 
-Acetone 70%......10 minutes 
-Acetone 80%......15 minutes 
-Acetone 95%......4 times for 15 minutes 
-Acetone 100% without water ...3 times for 15 minutes 
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The last acetone was then substituted by 50% acetone 100% and B mixture. Pellets are there 
for several hours. After, this is changed to ascendant concentrations of B mixture. (25% (100% 
acetone) and 75% mixture B, 10% (100% acetone) and 90% mixture B) every 2-3 hours. Then 
they are left in mixture B over-night. The following morning, mixture B is renewed and is left 
for 2 hours and we proceeded to pellet inclusion. 
 
Buffers 
 
1. Phosphate solution (pH 7,2-7,4)  
NaH2PO4H20…………………..2,4g 
K2HPO4………………………...4g 
H20 (distilled)………………….100 ml 
 
2. Phosphate solution 0,12 M (pH 7,2-7,4) 
Phosphate solution 0,4 M………………3ml 
Distilled water…………………………...7ml 
 
3. 3% glutaraldehyde in 0,12 M Phosphate solution 
25% Glutaraldehyde 25% (Merk ZC755239546)………….1,2ml 
Phosphate solution 0,4M…………………………………….3 ml 
0,5% Cl2Ca (Sigma)……………………………………….....40µg 
Distilled water until reach…………………………………...10 ml 
 
3.3  Protein analysis 
 
3.3.1 SDS-PAGE AND WESTERN BLOTTING 
 
Cells were collected, washed twice in 1X PBS and lysed with the following lysis buffer: 
20 mM HEPES pH 7.5, 10 mM EGTA, 40 mM β-Glycerophosphate, 1% NP40, 2.5 mM 
MgCl2, 1 mM orthovanadate, 1 mM DTT and 10 µg/ml of aprotinin and leupeptin.  
Then, to remove cell debris lysates were centrifuged at 13,000 rpm for 10 minutes at 4ºC. After 
that, proteins samples were quantified using the Bradford Method. A Bovine Serum Albumin 
(BSA) standard curve was used to calibrate unknown concentrations. 
 
Laemli 5x tampon (100 mM Tris pH 6.8, 4% SDS, 20% glycerol, 20 mM DTT and 0.005% 
bromophenol) was added to 40 µg of proteins and heated at 95ºC for 5 minutes.  
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Antibody Species Dilution Company (Catalog) 
HRAS rabbit 1:4000 Abcam #ab96548 
TRANSFERRIN 
Receptor 
mouse 1:1000 Zymed 13-6890 
CAVEOLIN Mouse 1:1000 BD-transduction 
610058 
APT1 (LYPLA1) rabbit 1:500 Protein Tech 
Europe 16055-AP 
TUBULIN mouse 1:4000 Sigma #T8328 
Table.3.3: Primary antibodies used for immunoblotting. 
 
Proteins were resolved on sodium dodecyl sulfate-polyacrylamide (SDS) poli-acrylamide gels. 
SDS-PAGE gel was composed of a stacking part (4% acrylamide, 125 mM Tris-HCl pH 6.8, 
0.4% SDS, 0.1% Ammonium Persulfate (APS) and 0.1% Tetramethylethylenediamine 
(TEMED) in H20) and a resolving part (acrylamide, 375 mM Tris-HCl pH 8.8, 0.4% SDS, 
0.1% APS and 0.1% TEMED in H20) Then, proteins were electrophoretically transferred to 
Nitrocellulose membranes (Thermo Fisher) at 400 mA amperage (1 minute for each 1 kDa of 
the protein) at 4ºC in a Trizma base 25 mM and 192 mM Glycine solution. Membranes were 
then blocked in Tris Buffered Saline-Tween (TBS-T: 20 mM Tris, pH 7.4, 137 mM NaCl and 
0.05% tween) containing 5% BSA for 1 hour at room temperature. Blots were incubated O/N 
at 4ºC with the different antibodies (table 3.3) prepared in blocking solution. The day after, 
blots were washed (3 x 10´) with TBS-T and incubated for 1 hour with anti-rabbit 
Immunoglobulin (Ig) (Amersham Pharmacia) or anti-mouse Ig (Amersham Pharmacia) 
secondary antibodies (1:5000) in 1% milk in TBS-T. After that, membranes were washed with 
TBS-T 3 times for 10 minutes and blots were developed with an enhanced chemiluminescent 
system (ECL) and an autoradiography with Konica films was performed to detect proteins. 
 
3.3.2 EVS SDS-PAGE AND WESTERN BLOT 
 
EV preparations for western blot were assessed after normalization based on the amount of 
proteins in the EV-secreting cells from where they were isolated using cold RIPA buffer (10 
mM NaF, 40 mM -glycerophosphate, 200 µM sodium orthovanadate, Benzamidine 0,1 µg/µl, 
100 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, 1% NP-40, 0.1% SDS, 0.5% sodium 
deoxycholate in PBS 1X pH 7.4) supplemented with protease and phosphatase inhibitors (1 
µg/ml leupeptin, 4 µg/ml aprotinin) (Sigma). Protein concentration was measured by 
bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific).  
 
The standardized amount of EVs and total lysates were ultimately dissolved in either reduced 
4x Laemmli Sample Buffer (Bio-Rad) with 5% 2-mercaptoethanol or non-reducing sample 
buffer to asses CD63. Then, samples were heated to 95ºC for 10 minutes before loading. A 
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pre-stained protein ladder (Bio-Rad) was used for protein size control. Both cell lysates and 
EV preparations were electrophoretically separated using 10% mini-PROTEAN® precast 
gels (BioRad) at 140 Volts (V) by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE). Protein preparations were ultimately dissolved in either reduced (containing 
5% β-mercaptoethanol) or non-reduced (for CD63 detection) sample buffer and were heated 
to 90-100°C for 10 min before loading with a pre-stained protein ladder (Bio-Rad). Proteins 
were wet-transferred in cold to Polyvinylidene difluoride (PVDF) membranes at 100 V in 25 
mM Tris–HCl, 0.19 M glycine and 10% methanol for 1 hour using a Mini Trans-Blot Cell (Bio-
Rad). The membranes were then blocked with either 5% milk (optimal for CD63 detection) 
or 5% BSA in TBS buffer with Tween-20 (TBST) for 45 minutes and incubated overnight at 
4°C with primary antibody (Table 3.4) diluted in blocking buffer. After 3 x 10 min washing 
steps with TBST, the membranes were probed with the relevant secondary antibodies for 1 h 
at 22°C (anti-mouse IgG (H+L) HRP conjugate (Promega #W4021, 1:10000), anti-rabbit IgG 
(H+L) HRP conjugate (Promega #W4011, 1:10000) following 3 x 10 min wash steps. The 
signals were detected using the enhanced chemiluminescent detection reagent (ClarityTM, 
BioRad) and the Touch Imaging System (BioRad).  
 
Antibody Species Dilution Company (Catalog) 
TUBULIN mouse 1:4000 Sigma #T8328 
SYNTENIN rabbit 1:500 Abcam #ab133267 
TSG101 rabbit 1:500 Abcam #ab125011 
CD63 mouse 1:1000 Abcam #ab108950 
ALIX mouse 1:500 Abcam #ab117600 
 
Table 3.4: Primary antibodies used to detect Extracellular Vesicles by immunobloting. 
 
3.3.3 GUAVA NEXIN ANNEXIN V ASSAY (APOPTOSIS ASSAY) 
The Guava Nexin Annexin V assay relies on a two-dye strategy to detect early and late 
apoptosis. To detect early apoptosis Annexin V is used due to its high affinity to phosphatidyl 
serine (PE) a component normally localized to the internal face of the cell membrane that 
after apoptotic signals translocates to the outer surface, when Annexin V can bind to it. The 
other dye is 7-AAD that is impermeable and capable to enter late-stage apoptotic and dead 
cells due to their impairment of their membranes.  
200,000 cells were seeded in 60-mm plates and after 48 hours adhered cells and medium 
containing cells was collected and centrifuged at 1200 rpm for 5 minutes. 1 µM of 
Staurosporine was added for 5 hours as a positive control, and we proceeded the same. Cells 
were then resuspended in 1% BSA in 1X PBS to achieve 4x105 cells/mL concentration. Then, 
100 µL of these suspensions were transferred to a dark tube containing 100 µL of guava Nexin 
Reagent (Millipore) thawed to room temperature. After that, samples were stained for 20 
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minutes at room temperature in the dark. Then, samples were acquired on a Guava Nexin 
System.  
Total apoptosis (Annexin V-PE (early) and 7-AAD + (late)) was determined and analyzed.  
 
3.3.4 PLASMA MEMBRANE FRACTIONATION TO DETECT ENDOGENOUS RAS 
LOCATION 
 
Four 100-mm dishes of C643 and HTH83 cells were grown to an 80-90% confluence. 
Cells were then washed with 1x PBS and were scraped with 1 ml PBS by centrifugation at 1500 
rpm for 5 minutes. 
 
Pellet was resuspended in 500 µL of TNET buffer (25 mM Tris-HCL pH 7.4, 150 mM NaCl, 
5mM EDTA, 0.01% Triton and 10µg/ml aprotinin and leupeptin) and homogenized, avoiding 
harsh conditions to limit breakage of lipids rafts microdomains, using a 25 Gauge (G) needle 
(15 passages) and maintained for 30 minutes at 4ºC in constant agitation.  
 
A discontinuous sucrose density gradient was prepared by layering successive solutions of 
decreasing sucrose densities upon one another in a 5 mL tube. The lysate was added to one 
volume of 90% sucrose made in TNET buffer without triton and mixed properly. This new 
(45%) solution was placed on the bottom of a 5 mL tube. Next, 3,4 mL of 35% sucrose-TNET 
buffer without triton was loaded slowly and steadily without disturbing the bottom fraction. 
After that, 1 mL of 16% sucrose-TNET was loaded on top of the gradient. Then, the tube was 
centrifuge using a MLS-50 Beckman swinging bucket rotor for 18 hours at 41,000 rpm. Twelve 
0,4 mL fractions were collected and prepared for analysis by SDS-PAGE and western blotting 
as described above.  
 
3.4   ANIMAL ASSAYS 
 
3.4.1 CHICK EMBRYO SPONTANEOUS METASTASIS MODEL 
 
Fertilized chicken eggs are incubated on their side in a rotating incubator at 37ºC and 65% 
humidity for 10 days, rotating three times per hour. On day 10 eggs were placed on their side 
on an egg rack and using a 30-gauge syringe needle a hole was made in the air sack which is 
located at the blunt end of the egg. Another hole was made near the allantoic vein, which was 
firstly localized using a light source contacting the eggshell, using a Dremel rotary tool kit 
without injuring the Chorioallantoic Membrane (CAM). Then, a third small hole was made 
using a 20-gauge syringe needle with a small hook made on the end. In order to drop the CAM 
from the shell, a mild vacuum was applied to the air sack hole working with an automatic 
pipette with a Tygon tube. Then, a square window around 1 cm2 was made with a cut off wheel 
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(Dremel) close to the bifurcation of the allantoid vein. After that, 25µL of the cell suspension 
containing 1x106 cells in starving medium were grafted nearby the allatoid vein bifurcation 
with a laboratory pipette without touching the CAM. Egg´s window was then sealed with tape 
and were left to grow for 6 days (C643 and HTH83) or 7 days (all PCCL3-derived cells) or 4 
days for all siRNA experiments on a stationary incubator. Then, tumors were excised and 
weighted and portions of distal CAM, liver and lungs were harvested and analyzed by 
quantitative Polymerase Chain Reaction (PCR)  to determine the number of rat (in case of 
PCCL3 cells) or human (C643 and HTH83) cells intravasated to the CAM and metastasized 
to the internal organs (297, 298).  
 
When tumors were treated with VEGF-B (LSBIO LS-G11679), 10 nM concentration was 
used. Treatment started at day 2 after cells were grafted and was renewed every 2 days. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Graphic representation of the chick embryo spontaneous metastasis assay.  Adapted from 
Liu, et al. (2013). “The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick 
Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma” 
Translational oncology. 6. 273-81. 10.1593/tlo.13175. 
 
3.4.2 EX OVO CAM MICROTUMOR MODEL 
 
Eggs were incubated lying horizontally in an incubator with a moving tray, rotating three times 
per hour. Humidity was kept at 65% and temperature at 37ºC. After 3 days of incubation, eggs 
were removed from the incubator and the content of the eggs were transferred to sterile plastic 
weigh boats, checking that the embryo is visible and on the top of the yolk sac. They are then 
covered with a square Petri dish and placed in a stationary incubator until day 10 when 
embryos were grafted on several places (4-6), always close to small vessels, with 20,000 cells 
drawing on the square Petri dish the site of inoculation. The cells at a 90% confluence in 100-
mm plates were previously labeled with 10 µg of green cell tracker CMFDA (5-
chloromethylfluorescein diacetate) dye (Thermo Fisher) for 30 minutes with new media. After 
5 days Rhodamine (Thermo Fisher) was injected into the main CAM vessel in order to 
                1x106 cells 
Air Bubble 
Basement Membrane 
qPCR analysis for rat or 
human DNA 
10 days chick embryos 
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visualize vessels and pieces of CAM containing the microtumors were harvested and fixed for 
10 minutes with 4% Paraformaldehyde (PFA). After that, CAM was immediately visualized 
under a 25% water objective using a Leica microscope.  
 
 
 
Figure 3.2: Ex ovo CAM microtumor model. (A) 3 days embryo (B) 7 days embryo (day of grafting) (C) 
12 days embryo (harvest day). 
 
 
3.5   DNA and RNA analysis  
 
3.5.1 GENOMIC DNA EXTRACTION FROM CHICK EMBRYOS AND 
QUANTIFICATION 
 
To extract genomic DNA from the different organs we used the Gentra PureGen Tissue Kit 
from QUIAGEN. Following manufactures instructions 600 µL of lysis buffer from CAM or 
400 µL for lungs, liver or brain containing 1 µg/ml Proteinase K was added to every organ 
harvested and was homogenize using a Polytron and was incubated over night at 65ºC. Next 
day, 200 µL protein precipitation buffer was added and properly mixed. Then, samples were 
centrifugated at 13,000 rpm for 5 minutes. The supernatant was then collected and transfer to 
a tube containing 1 volume of Isopropanol and was allowed to settle for 5 minutes in order to 
allow DNA precipitation. Afterwards, a 13,000 rpm 5 minutes centrifugation was performed, 
and the pellet was kept and washed twice with 200 µL of ethanol 70% (13,000 rpm 5 minutes). 
Pellet was then dried for 5 minutes and resuspended with 200 µL hydration buffer.  
 
In order to quantify the amount of DNA contained in each sample we used NanoDropTM 
2000c (Thermo Fisher) making sure that 260/280 ratio was around 1.8. 
 
3.5.2 REAL TIME qPCR 
 
In order to detect rat or human cells in the different tissues harvested we used primers (Sigma) 
for rat β-actin or for human Alu sequence (299) (Table 3.5), which are transposable elements, 
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around 300 nucleotides in length, that account for more than 10% of human genome and are 
not present in chicken.  
 
Primers name Sequence 
Forward rat primers (light myosin chain) 5´CAAAAATGGAGCTGCGCAGGC 3´ 
Reverse rat primers (light myosin chain) 5´CGCCAGCTGGTGGGGATTTTA 3´ 
Forward Alu (human) primers (299) 5’ ACGCCTGTAATCCCAGGACTT 3’ 
Reverse Alu (human) primers (299) 5´TCGCCCAGGTGGCTGGGGCA 3´ 
Table. 3.5: Primers and sequence used to assess rat or human cells presence in chick tissues. 
 
PCR reaction contained generally 30 ng of genomic DNA as template in a 20 µL reaction 
containing 10 µL of 2X PowerUp SYBR Green Master Mix (Thermo Fisher), 100 nM per 
primer (Alu primers) or 200 nM per primer (Rat primers) and DNAase free Water. PCR 
conditions were the following: 4 minutes 95ºC followed by 40 cycles of 30 seconds at 95ºC to 
denaturate DNA, 63ºC during 30 seconds for primers annealing and 30 seconds at 72ºC to 
allow DNA polymerase to start amplification.  
The number of human or rat cells were determined by the measurement of the triplicated Ct 
values against a standard curve generated by DNA extraction of a specific known number of 
human or rat cells (100, 1000 and 10,000 cells).  
 
3.5.3 Tumoral RNA extraction and quantification  
 
To analyzed gene expression frozen tumors were harvested and cut in really small pieces, on 
dry ice to avoid RNA degradation, and RNA extraction was done using the RNeasy Mini Kit 
(Quiagen). To do so, we introduced tumor pieces into 500 µL of RLT buffer and we 
homogenized them using a 20 G syringe. Then, samples were centrifuged for 3 minutes at 
13,000 rpm and the supernatant was removed and transferred to a new eppendorf tube 
containing 500 µL of 70% ethanol. After that, 700 µL of the samples were transferred to a 
RNeasy spin column and centrifugated for 15 seconds at 12,000 rpm discarding the flow 
through. 700 µL of buffer RW1 were later added and centrifuged, as before. Then, 500 µL of 
Buffer RPE were added to the column and centrifuged. This step was done twice. The column 
was placed into a new 1.5 mL collection tube and 30 µL RNase-free water were added to elute 
RNA by centrifugation. RNA was then quantified using NanoDrop 1000 (Thermo Fisher). 
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3.5.4 CDNA SYNTHESIS AND QUANTITATIVE REVERSE TRANSCRIPTION (RT) 
PCR  
cDNA was produced from 1 µg of RNA using iScripttm Reverse Transcription Supermix 
(BioRad). Briefly, 4 µL of iScript RT supermix was added to a 20 µL final volume reaction 
containing 1 µg of RNA and a variable amount of Nuclease free water. Then the complete 
reaction mix was incubated in a thermal cycler using the following conditions:  
- Priming (5 minutes at 25ºC) 
- Reverse Transcription (20 minutes at 46ºC)  
- RT inactivation (1 minute at 95ºC) 
After that, qPCR was performed as described in 3.5.1 using the following primers: 
Primers name Sequence 
Forward VEGF-B primers rat (300) 5´GATCCAGTACCCGAGCAGTCA 3´ 
Reverse VEGF-B primers rat (300) 5´TGGCTTCACAGCACTCTCCTT 3´ 
Forward VEGF-A primers rat (300) 5´TAACGATGAAGCCCTGGAGTG 3´ 
Reverse VEGF-A primers rat (300) 5´ AGGTTTGATCCGCATGATCTG 3´ 
Table 3.6: VEGF-A and -B primers and sequence. 
 
3.6  Immunohistochemistry of chicken samples 
 
3.6.1 TISSUE INCLUSION IN PARAFFIN  
 
Tissues were fixed ON with 4% Paraformaldehyde (PFA) at 4ºC, washed in 1X PBS (3 times 
10´) and embedded in paraffin. Paraffin blocks were then prepared in a paraffin embedding 
station. 
Solution Time 
70% Ethanol 2 x 1 hour  
80% Ethanol 1 hour 
95% Ethanol 1 hour 
100% Ethanol 3 x 1 hour 
Xylene 3 x 1 hour 
Paraffin (60ºC) 2 x 1.5 hours 
                                                  Table 3.7: Paraffin processing of tissues. 
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3.6.2 IMMUNOHISTOCHEMISTRY (IHC)  
 
Once embedded in paraffin, 5µm sections were cut at the microtome and placed on Poly-L-
Lysine treated microscopes slides.  
Previous any staining, slides were deparaffinize and tissue was rehydrated. Firstly, slides were 
dried for 1 hour at 60ºC or O/N at 37ºC.  
Solution Time 
Xylene 3 x 5´ 
Tap water 5´ 
100% Ethanol 5’ 
90% Ethanol 5´ 
80% Ethanol 5´ 
70% Ethanol 5´ 
Tap water 5´ 
Table 3.8: Standard procedure to rehydrate histological sections. 
 
In order to allow the antibody to enter more easily to each cell, a permeabilization step was 
done, incubating specimens for 10 minutes with 0,1% IGEPAL (Sigma) in 1x Tris Buffered 
Saline (TBS). Then, slides were washed twice for 5 minutes with 1x TBS, and we procced to 
eliminate non-specific bindings using a serum free blocking reagent, background punisher 
(BIOCARE Medical) for 8 minutes. After that, a 1% Bovine Serum Albumin (BSA) 0.05% 
IGEPAL in 1x TBS solution containing a mouse anti-rat CD44 antibody (1:100) (Antibodies 
Online) or not (negative control), was incubated O/N at 4ºC in a humid chamber (to avoid 
evaporation). Next day, slides were washed in 1x TBS (3 x 10´) and endogenous peroxidase 
was quenched using 3x Hydrogen Peroxide (H2O2) in 1x TBS for 20 minutes.  
 
Then, specimens were washed in 1x TBS (3 x 10´) and incubated with an anti-mouse 
biotinylated secondary antibody (Vector Labs) diluted in 1% BSA 0.05% IGEPAL in 1x TBS 
(1:400) for 1 hour in a humid chamber. After that, slices were washed, as before, and  
specimens were incubated with Horseradish Peroxidase (HRP) Avidin D diluted in 1x TBS 
(1:500) for 30 minutes in a humid chamber. Slices were washed again and incubated with the 
substrate diaminobenzidine (DAB) (Gibco) for 5 minutes or until brownish color started to 
appear. Chromogenic reaction was stopped with H20. To finish specimens were stained with 
Hematoxylin (Sigma), dehydrated, cleared and mounted with DPX. Images were taken at a 
Zeiss Axio Scope A1 microscope using 10x, 20x or 40x objectives.   
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3.7 Oil red staining  
 
Fresh harvested tumors were snap-frozen, embedded in OCT (Thermo Fisher) and stored at 
-80ºC.  
 
Blocks were cut at the cryostat to obtain 10µm and placed on Poly-L-Lysine treated 
microscope slides. Then, sections were air dried, fixed with 4% PFA for 5 minutes and washed 
with tap water for 2 minutes. They were rinsed with 60% isopropanol and stained with freshly 
prepared Oil Red working solution for 5 minutes. They were again rinsed with 60% 
isopropanol and nuclei were stained with hematoxylin for 2 minutes and mounted using an 
aqueous mounting media.  
 
Reagent formulae:  
 
Oil Red stock: 0,5 g………...Oil Red (Sigma) 
                       100ml………... Isopropanol 
Oil Red was dissolve using a gentle heat.  
 
Oil Red working solution: 30 ml from the stock was diluted in 20 ml of distilled water. It was 
allowed to settle for 10 minutes and it was filtered into a Coplin jar and covered immediately.  
 
3.8   EXOSOME ISOLATION, DETERMINATION AND ANALYSIS  
 
3.8.1 Extracellular Vesicle Isolation   
 
PCCL3 cells were changed to its serum-free basal medium without hormones or essential 
amino acids, this time supplemented with 1% ITS (Insulin-Transferrin-Selenium; #41400045 
Life 429 Technologies) for 24 h. Generally, about 7 x 106 PCCL3 cells were seeded per 15 cm 
cell culture plate using 12 plates per condition. They were allowed to settle for 72 h in complete 
medium until they reach 80-90% confluence before changed to 1% ITS depleted medium for 
24 h to then proceed to EV collection. After that, culture medium was collected and pre-
cleared by centrifuging at 500g for 10 minutes at 4ºC and they were further centrifuge at 2000g 
for another 10 minutes at 4ºC to remove any cells, debris and large vesicles. The supernatant 
obtained was then pass through a 0.22 μm filter (Milex®). Thereafter, EV-containing filtrate 
was concentrate using a tangential flow filter (TFF) set-up with a 100 kDa membrane 
(Vivaflow 50R, Sartorius) using a 230V pump (Masterflex). After that, size exclusion specific 
protocol was followed. 
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3.8.1.1 Size exclusion 
  
Filtrate was concentrated to 5 ml and PBS was added to the TFF machine in order to collect 
the maximum of EVs that could have been left in the process getting 20 ml final volume. After 
that, it was further concentrated in 100kDa Amicon filters by sequential centrifugation at 
4000g for 10min at 4ºC to a final volume of 1 ml. This volume was then injected into a size-
exclusion column (column size 24 cm x 1 cm containing Sepharose 4B, 84nm pore size) set up 
in an AKTA start system (GE Healthcare Life Science) and eluted with PBS, collecting 30 x 1 
ml fractions. Fractions corresponding to the initial “EV peak” (fractions 3-5 for PCCL3) were 
pooled in 100kDa Amicon tubes by centrifuging at 2000 rpm at 4ºC to a final volume of 
approximately 100 μl for analysis and later fractions found before the protein peak (6-8), were 
also pool in 100 μl. 
 
3.8.2 Nanoparticle Tracker Analysis (NTA) (NanoSight®)  
 
NTA is a technique that allows EVs size and concentration distribution measurement in liquid 
suspension combining the properties of both laser light scattering microscopy and Brownian 
motion. We used the NS500 NanoSight® (Malvern Instruments Ltd, Malvern, UK) that allows 
to characterize particles from 10-2000 nm visualizing them by the light they scatter upon laser 
illumination. Thirty seconds videos were captured 3-5 times per EV sample at known dilution 
(normalized to protein mass of secreting cells). Particle concentrations were measured within 
the linear range of the NS500 between about 1-6 x 108 particles ml-1. Equipment settings for 
data acquisition were kept constant between measurements: camera level 14, threshold 5, 
minimum expected particle size 80 nm and screen gain 10.  Particle movement was analyzed 
by NTA software 2.3 (NanoSight Ltd.) to obtain particle size and concentration (301).  
 
3.9  BIOINFORMATIC ANALYSIS 
 
cBioPortal database for cancer genomics was used to perform an analysis of APT-1 alterations 
in thyroid cancer. We chose a 507 sample set from papillary thyroid carcinomas (TCGA) (302) 
and looked for APT-1 (LYPLA1), H-RAS and N-RAS alterations. We searched for 
mutations, amplifications, gains, shallow deletions, deep deletions and changes in mRNA 
levels. To define low mRNA expression levels we selected samples that have them less than -
2 standard deviations (SD) below the mean. To define high mRNA expression levels we select 
samples 2-fold greater than 2 SD above the mean.   
 
3.10   STATISTICAL ANALYSIS AND IMAGES PROCESSING   
 
Data was processed and analyzed using GraphPad Prism Software (GraphPad Software, Inc., 
San Diego, CA). Data is given as Mean ± SEM (bar graphs) or Mean ± SD (scatter graphs) 
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from a representative experiment or several normalized experiments. Two tailed unpaired 
Student’s t-test or Mann-Whitney test were used to determine differences between data sets 
and significance (*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001) 
 
The number of chick embryos and tissue samples analyzed, as well as the number of 
experiments performed, are indicated in the figure legends. 
 
Confocal images were processed and analyzed using Fiji-Image-J software.  
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4. RESULTS 
 
4.1 Role of RAS sublocalizations in thyroid tumorigenesis  
The first aim of this study was to investigate the tumorigenic potential in thyroid cells of RAS 
activated at its main subcellular locations; Disordered Membrane (DM), Lipids Rafts (LR), 
Endoplasmic Reticulum (ER) and Golgi Complex (GC); both in vitro and in vivo. 
For this purpose, we choose PCCL3 cells, which are spontaneously immortalized rat thyroid 
follicular cells; they do not have any known mutations; and have been widely used to study, in 
vitro, RAS, BRAF or RET/PTC signalling (291, 293, 303, 304).  
We generated different PCCL3 stable cell lines expressing RAS proteins at their different 
sublocalizations in the cell. To do so, we transfected them with pCEFL hemagglutinin (HA)-
tagged vectors harboring the targeting signals M1 (285), LCK, CD8α (287) or KDELr (286) 
placed N-terminal to H- , N- or K-RAS (In this case only M1 or CD8α), mutated in position 
12 (Gly>Val) (Fig. 4.1). M1 is the avian infectious bronchitis virus M protein that can deliver 
RAS to ER; LCK is a myristoylation signal that can anchor RAS to LR; CD8α is a receptor 
that can direct RAS to DM; and KDELr mutated in N193D which avoids KDEL receptor, 
recycling to ER making it a permanent resident at GC. These constructs have been successfully 
utilized in previous studies (110, 284, 305). PCCL3 were also transfected with an empty pCEFL 
plasmid to be used as a control (From now on we will refer to it as control cells). 
Figure 4.1: Expression levels of the targeted RAS proteins as determined by anti-H-RAS 
immunoblotting in total lysates from the PCCL3 cells lines stably expressing the RAS constructs. 
 
4.1.1 RAS ISOFORMS ACTIVATED AT DIFFERENT SUBCELLULAR 
LOCALIZATIONS DO NOT AFFECT THYROID CELLS PROLIFERATION BUT 
AFFECT APOPTOSIS  
Since mutant RAS has been widely described as a thyroid cancer driver, we wanted to know: 
i) if the different constitutively activated RAS proteins mutated in position 12 (Gly>Val) 
H-RAS 
30  - 
40  - 
50  - 
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could promote cell proliferation in PCCL3 cells and ii) if the effects were different depending 
on RAS localization within the cell. To asses this, we used the PCCL3 stable cell lines 
described above, which express mutant H-, N- or K-RAS targeted to the different subcellular 
locations where they are usually found under physiological conditions: ER, LR, DM and GC 
for H- and N-RAS and ER and DM for K-RAS.  
Cell proliferation, analyzed at 24 and 48 h using AlamarBlue Viability Assay, did not show 
substantial differences either compared to control cells or among RAS sublocalizations. 
Results were similar among the three RAS proteins (Fig. 4.2 A, C and E). Although, no major 
differences were seen in this respect, a high number of floating cells were observed in every 
RAS PCCL3 stable cell line suggesting some degree of cell death. Indeed, several groups have 
shown that H-RAS can induce apoptosis in PCCL3 cells by increasing genomic instability (291, 
306-308).  Additionally, our laboratory recently described that H-RAS signals from the GC 
were able to induce apoptosis in MCF-7 mammary epithelial cells (121). Therefore, to explore 
if GC RAS signals, as well as those from, ER, DM and LRs, could also induce apoptosis in 
thyroid PCCL3 cells, we performed a Guava Nexin Annexin V assay, using Staurosporine as a 
positive control. This cytometry assay is based in a two-dye strategy, where Annexin V binds 
to phosphatidyl serine (PE) to detect early apoptosis, and 7-AAD, which detects late-stage 
apoptotic and dead cells. In line with previous studies (291, 306-308), every RAS protein 
induced apoptosis, compared to control cells, particularly from the GC, as expected (Fig. 4.2 
B, D and F). The exception was LR signals that showed the same percentage of death as 
control cells in the case of N-RAS, or even reduced apoptotic rates, in the case of H-RAS (Fig. 
4.2 B and D). 
These results indicate that RAS proteins promote apoptosis in PCCL3 thyroid cells when 
active mainly at the GC but not from LR. 
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Figure 4.2: Cell proliferation and apoptosis responses to mutant RAS activation at its different 
subcellular locations in PCCL3 cells. (Control: pCEFL; Total: H-RASv12; M1: H-RASv12 at ER, LCK: 
H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-RASv12 at GC). Cell proliferation is presented 
as the rate of AlamarBlue Assay Reagent reduction at 24 and 48 h in (A) PCCL3 cells transfected with 
H-RASv12 (C) N-RASv12 or (E) KRASv12 constructs tethered to their different subcellular locations. 
Apoptosis was evaluated by annexin V detection using the Guava/nexin assay (B) Apoptosis in response 
to H-RASv12; (D) N-RASv12; or (F) KRASv12. Staurosporine (STAU) was used as a positive control. 
Results show Mean ± SEM (n=3) using two-tailed unpaired Student T-Test (*p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001). 
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4.1.2 H-RAS AFFECTS MIGRATION DIFFERENTLY DEPENDING ON ITS 
LOCALIZATION 
 
Since H-RAS oncogenic mutations have been widely related to migration and invasiveness 
(292, 309, 310), we sought to determine whether this could be differently modulated 
depending on its subcellular location. Using transwell assays to monitor migration we 
determined that RAS was able to promote migration from all its locations. It was found that 
when active in DM and GC H-RAS shower higher rates of migration, three to four times, than 
those detected from LR and ER (Fig. 4.3).  
 
 
 
 
 
 
 
       TOTAL                       M1                       LCK                       CD8                       KDEL 
 
 
Figure 4.3: Transwell migration assay. The different PCCL3 stable cell lines (Control: pCEFL; Total: 
H-RASv12; M1: H-RASv12 at ER, LCK: H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-
RASv12 at GC). were dyed with 10 µM cell Green tracker and 10,000 cells were placed in 8µm pores 
transwells. Migrated cells were observed after 24 hours using a 20x objective in a Leica fluorescence 
microscope. Data shows Mean ± SD of cells per field of three independent experiments. A double 
tailed unpaired Student T-test was utilized. *p<0.05, **p<0.01. 
 
4.1.3 SPATIALLY-DEFINED H-RAS AND N-RAS POOLS EXHIBIT DIFFERENT 
SPONTANEOUS METASTASIS POTENTIAL 
 
The chick embryo has been widely used to study tumor growth, intravasation and 
dissemination of different types of tumor cells (311-313). 
Since we did not see major changes in proliferation but observed differences in migration 
among H-RAS subcellular locations, we wanted to determine whether our cells could generate 
primary tumors and if they had the ability to metastasize in vivo. The chick embryo model 
overcomes many limitations for studying the metastatic process, thanks to the accessibility of 
the Chorioallantoic Membrane (CAM), the outermost, highly vascularized, extra-embryonic 
tissue located under the eggshell, where mammalian or rodent tumor cells can be xenografted. 
The chick embryo is naturally immunodeficient, so the CAM can support the engraftment of 
tumor cells, and most of the characteristics of the carcinogenic process such as: growth, 
invasion, angiogenesis and metastasis, can be recapitulated (299, 314-316).  
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1x106 cells were grafted onto the CAM of 10-days chick embryos and were left for 7 days, when 
sizable primary tumors were observed. Strikingly, although in vitro we were not able to see 
differences in proliferation, H- and N-RAS LR and ER pools evoked three- or two-fold bigger 
tumors, respectively, in comparison to the DM and GC ones. (Fig. 4.4 A and 4.6 A). We also 
analyzed whether tumor cells could intravasate into the CAM vasculature or colonize distant 
organs, such as the liver, the first organ cells reach once intravasation has occurred, and lungs, 
the most common place for thyroid cancer metastases.  
 
To analyze CAM intravasation, cells in distal CAM were detected by qPCR using specific rat 
primers. Surprisingly, the RAS sublocalizations yielding the smaller tumors (DM and GC), 
were the ones that presented higher number of embryos with cells in the distal CAM. 
However, irrespective of the % of chicks that exhibited distal CAM colonization, the total 
number of cells in the CAM was not different among the different subcellular locations 
(Fig.4.4 B,C and 4.6 B, C), although, N-RAS evoked almost twice the number of invading cells 
than H-RAS. 
 
Similarly, signaling from DM and the GC displayed a 2-3-fold increase in the % of chick 
embryos showing colonization in lungs, in comparison to ER or LR sublocalizations (Fig. 4.5 
C and 4.7 C) both from H- and N-RAS. Moreover, irrespective of the sublocalization H-
RASv12 showed almost six-fold more cells metastazing the lungs when compared to N-
RASv12 (Fig. 4.5 D and 4.7 D). In addition, H- and N-RASv12 DM and GC pools induced 
liver colonization (Fig. 4.6 A and 4.8 A), though, to a lesser extent than lungs and also half the 
number of invading cells (Fig. 4.5 B and 4.5 B). In striking contrast, cells with H-RASv12 at 
LR showed the same % of liver colonization as DM and GC (Fig. 4.5 A and 4.7 A). 
 
Altogether, our results show that H- and N-RAS sublocalizations play different roles in tumor 
growth and dissemination and suggest that small RAS positive thyroid nodules and tumors 
could be highly metastatic.   
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Figure 4.4: Metastatic potential of H-RAS sublocalizations in the chick embryo spontaneous metastasis 
model. PCCL3 cells:(Control: pCEFL; Total: H-RASv12; M1: H-RASv12 at ER, LCK: H-RASv12 at 
LR; CD8: H-RASv12 at DM; KDEL: H-RASv12 at GC). 1x106 cells from each PCCL3-derived cell 
lines were grafted on 10-days chick embryos. After seven days, the primary tumors were collected and 
weighed (mg) (Mean ± SD) (A), and the presence of rat cells in distal portions of the CAM were 
analyzed by qPCR showing the % of chicken displaying intravasation (distal CAM colonization) (Mean 
+ SEM) (B). In those cases, the relative numbers of rat cells (MEAN ± SEM) per 106 chicken cells was 
determined (C). Data from three independent experiments with 9 to 15 embryos per case. Statistical 
significance was determined in comparison to the lower value, when not specified. Groups were 
analyzed by a double tailed unpaired student T-test. *p<0.05, ***p<0.001 and ****p<0.0001.  
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Figure 4.5: Liver and lung colonization in the chick embryo spontaneous metastasis model by PCCL3 
stable cell lines expressing site-specific H-RASv12. PCCL3 cells:(Control: pCEFL; Total: H-RASv12; 
M1: H-RASv12 at ER, LCK: H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-RASv12 at GC).  
1x106 cells from each cell line were grafted on 10-days chick embryos. After seven days, liver and lungs 
were collected and the presence of rat cells was analyzed by qPCR showing (A) the % of chick embryos 
(Mean + SEM) exhibiting liver colonization or (C) lung colonization. (B) Average number (Mean + 
SEM) of rat cells found in liver or (D) in lungs. Data is from three independent experiments employing 
from 9 to 15 embryos per cell variant. Statistical significance was determined by a double tailed unpaired 
student T-test. *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 4.6: Metastatic potential of N-RAS sublocalizations in the chick embryo spontaneous metastasis 
model. PCCL3 cells: (Control: pCEFL; Total: N-RASv12; M1: N-RASv12 at ER, LCK: N-RASv12 at 
LR; CD8: N-RASv12 at DM; KDEL: N-RASv12 at GC). 1x106 cells from each PCCL3-derived cell lines 
were grafted on 10-days chick embryos. After seven days, the primary tumors were collected and 
weighed (mg) (Mean ± SD) (A), and the presence of rat cells in distal portions of the CAM were 
analyzed by qPCR showing the % of chicken displaying intravasation (distal CAM colonization) (Mean 
+ SEM) (B). In those cases, the relative numbers of rat cells (MEAN ± SEM) per 106 chicken cells was 
determined (C). Data from three independent experiments with 8 to 15 embryos per case.  Statistical 
significance was determined in comparison to the lower value, when not specified. Groups were 
analyzed by a double tailed unpaired Student T-test. *p<0.05, ***p<0.001 and ****p<0.0001.  
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Figure 4.7. Liver and lung colonization in the chick embryo spontaneous metastasis model by PCCL3 
stable cell lines expressing site-specific N-RASv12. PCCL3 cells: (Control: pCEFL; Total: N-RASv12; 
M1: N-RASv12 at ER, LCK: N-RASv12 at LR; CD8: N-RASv12 at DM; KDEL: N-RASv12 at GC).  
1x106 cells from each cell line were grafted on 10-days chick embryos. After seven days, liver and lungs 
were collected and the presence of rat cells was analyzed by qPCR showing (A) the % of chick embryos 
(Mean + SEM) exhibiting liver colonization or (C) lung colonization. (B) Average number (Mean + 
SEM) of rat cells found in liver or (D) in lungs. Data is from three independent experiments employing 
from 9 to 15 embryos per cell variant. Statistical significance was determined by a double tailed unpaired 
Student T-test (**p<0.01). 
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4.1.4 K-RAS SUBLOCALIZATION EFFECTS IN SPONTANEOUS METASTASIS  
 
K-RAS is mainly located at ER and DM (112). Since we saw opposing effects in growth and 
metastasis when looking at H- and N-RAS signals emanating from these sublocalizations, we 
hypothesized that this could also be case for K-RAS. However, KRAS ER and DM pools 
exhibited the same capacity for tumor growth (Fig. 4.8 A), intravasation and liver colonization 
(Fig. 4.8 B, C left). Strikingly, K-RAS signals from DM promoted more lung colonization, 
showing high amounts of invading cells (Fig. 4.8 B, C right).  
This data indicates that all RAS isoforms signaling from disorder membrane can induce high 
rates of lung metastases in our thyroid cancer model. 
 
Figure 4.8: Metastatic potential of K-RAS sublocalizations in the chick embryo spontaneous metastasis 
model. PCCL3 cells: (Control: pCEFL; Total: K-RASv12; M1: K-RASv12 at ER, CD8: K-RASv12 at 
DM). 1x106 cells from each PCCL3-derived cell lines were grafted on 10-days chick embryos. After 
seven days, the primary tumors were collected and weighed (mg) (Mean ± SD) (A), and the presence 
of rat cells in distal portions of the CAM were analyzed by qPCR showing the % of chicken displaying 
intravasation (distal CAM colonization) (left), liver (middle) or lung (right) colonization (Mean + SEM) 
(B). In those cases, the relative numbers of rat cells (MEAN ± SEM) per 106 chicken cells was 
determined (C). Presented data is from three independent experiments employing from 8 to 16 embryos per 
cell variant. Statistical significance was analyzed by a double tailed unpaired T-test. *p<0.05 and **p<0.01. 
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4.1.5 IMMUNOHISTOCHEMICAL ANALYSIS OF CAM, LIVER AND LUNG 
COLONIZATION  
 
Immunohistochemical staining with an anti-rat CD44 antibody was undertaken in order to 
study histologically PCCL3 colonization of distant organs. 
7 days after grafting only a small number of chick embryos grafted with cells expressing H-
RASv12 at ER, showed CAM invasion, consistent with the results obtained by qPCR (Fig. 
4.4). Strikingly, the few ones showing cells in distal CAM exhibited high vasculotropism (Fig. 
4. 9 B). Conversely, almost all tumors formed by H-RAS at DM (Fig. 4. 9 A) and at GC 
presented cell agregates that appeared to be expanding into the CAM mesoderm and all were 
close to blood vessels. Cells with H-RAS at LR showed distal CAM colonization in 50% of the 
chick embryos assessed, and their immunohistological characteristics were similar to H-RAS 
at DM and GC.  
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Immunohistological analysis of colonized organs. 1x 106 cells were grafted onto the CAM of 
10 days old chick embryos. After 7 days distal CAM, liver and lungs were collected and processed for 
immunohischemical analysis of rat cells. Rat cells were stained with an anti-RAT CD44 antibody (brown 
staining)(arrows) and tissues were counterstained with hematoxylin. (A) distal CAM showing big cell 
aggregates (arrow) in a chick embryo grafted with PCCL3 cells expressing H-RASv12-CD8. Picture was 
taken with an Axio Scanner microscope in order to see all the sample (5x) (B) PCCL3 cells expressing 
H-RASv12-M1 gathered around a vessel (arrow) in distal CAM (40x) (C) lungs of a chick embryo 
grafted with PCCL3 cells expressing RAS at LR (20x). (D and F) Lungs showing high amount of rat 
PCCL3 cells (arrows) expressing RAS in DM (D 10x) (G 20x) (E) Liver showing micrometastasis 
(arrow) and scattered H-RAS-LCK transfected PCCL3 cells (arrowhead) (20x). Scale bars are: 160µm 
in (A), 80µm in (D), 40µm in (C), (E) and (F), 20µm in (B). 
A. B. 
C. D. 
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All H-RAS sublocalizations, with exception of the ER, generated microfoci in livers composed 
of 8-20 cells, as well as scattered cells (Fig. 4.9 E). This suggests, together with qPCR data 
indicating small number of invading cells, that invading cells are not abundant and have a low 
potential to proliferate and form macroscopic metastasis in this organ.  
When lung immunostaining was analyzed we found that mainly H-RAS at DM and at the GC 
showed cells in this organ, including large metastatic foci, as opposed to the other H-RAS 
sublocalizations that did not evoke significant colonization (Fig. 4.9 D and F).  
Therefore, our immunohistological studies reinforce our previous qPCR results and confirm 
the high levels of metastasis induced by DM and GC H-RAS signals. In addition, the 
histological analyses suggested the close relationship between H-RAS-expressing cells and the 
CAM vasculature, surprisingly high in tumors with H-RAS active at the ER. 
 
4.1.6 ENDOGENOUS H-RAS ACTIVATION AT ITS DIFFERENT SUBCELLULAR 
LOCATIONS INDUCES TUMORS BUT NOT METASTASIS 
 
In order to ascertain that the observed effects were not a consequence of some artifact 
resulting from the expression of artificially-tethered RAS proteins at the different 
sublocalizations, it was necessary to analyze the effects of endogenous RAS activation at its 
different sublocalizations. We have developed constructs where the CDC25 domain of 
RASGRF1 was fused to the site-specific tethers (M1, LCK, CD8α and KDELr) to send it to 
the different cellular compartments where RAS resides, thereby activating the endogenous 
RAS pools (283).  
Therefore, we transfected PCCL3 cells with the different CDC25 constructs (CDC25, M1-
CDC25, LCK-CDC25, CD8-CDC25 and KDEL-CDC25) in order to activate endogenous 
RAS at ER, LR, DM or GC, respectively, and determine whether its site-specific activation 
mirrored the H-RASv12 effects observed in our model. To assess so, we grafted 1x106 cells 
onto the CAM of 10-days-old chick embryos and after 7 days we collected and weighted the 
tumors and analyzed distal CAM, liver and lungs by qPCR. We saw that the CDC25 constructs 
elicited similar effects in tumor formation as HRAS constructs (Fig. 4.10 A) but they caused 
little if any-CAM, liver and lung colonization. Only PCCL3 cells expressing CD8-CDC25 or 
KDEL-CDC25 showed some degrees of intravasation and lung colonization (Fig. 4.10 B, C).  
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Figure 4.10: Metastatic potential of PCCL3 cells expressing site-specific CDC25 domain in the chick 
embryo spontaneous metastasis model. PCCL3 cells: (Control: pCEFL; Total: H-RAS-CDC25; M1: H-
RAS-CDC25 at ER, LCK: H-RAS-CDC25 at LR; CD8: H-RAS-CDC25 at DM; KDEL: H-RAS-
CDC25 at GC). 1x106 cells from each PCCL3-derived cell lines were grafted on 10-days chick embryos. 
After seven days, the primary tumors were collected and weighed (mg) (Mean ± SD) (A), and the 
presence of rat cells in distal portions of the CAM were analyzed by qPCR showing the % of chicken 
displaying intravasation (distal CAM colonization) (left), liver (middle) or lung (right) colonization 
(Mean + SEM) (B). In those cases, the relative numbers of rat cells (MEAN ± SEM) per 106 chicken 
cells was determined (C). Data is from three independent experiments employing from 7 to 12 embryos 
per cell variant. Groups were analyzed by a double tailed unpaired Student T-test. *p<0.05, **p<0.01 
and ****p<0.0001. 
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4.2 APT-1 levels modify thyroid tumoral cells behavior  
 
4.2.1 APT-1 OVEREXPRESSION CORRELATES WITH BETTER PROGNOSIS IN 
THYROID CANCER  
 
Since high levels of APT-1 activity will result in RAS localizacing at LR (119), it was interesting 
to determine how APT-1 levels related to the evolution of thyroid tumors. Using the 
cBioPortal for Cancer Genomics database, we choose a 507 sample set from papillary thyroid 
carcinomas (TCGA) (302) and looked for APT-1 (LYPLA1) alterations, H-RAS and N-RAS 
alterations. We found that APT-1 was altered in 7% of the tumors, these were mainly showing 
high mRNA levels. Some tumors showed underexpression of APT-1 and only a few of them 
showed amplications or shallow deletions (Fig. 4.11). Moreover, some tumors over-expressing 
APT-1 also had missense mutations in N-RAS, but H-RAS alterations did not co-occur with 
APT-1 ones (Fig. 4.11).  
 
Figure 4.11: APT-1 (LYPLA1), H-RAS and N-RAS mutations, amplifications, gains, deletions and 
mRNA expression.  Data is been extracted from “cBioPortal for cancer genomics” using a database of 
507 samples of papillary thyroid carcinomas (TCGA) (302). 
When we looked at the overall survival of patients with either amplifications of high levels of 
APT-1 (5%). Interestingly, all of these patients (22) survived, whereas patients without APT-
1 alterations, exhibit a 80% survival after 14 years (Fig. 4.12 A). We also checked the survival 
of patients showing low levels of APT-1 mRNA and shallow deletions (6) without detecting 
differences (Fig. 4.12 B) although not significant due to the low amount of samples.  
 
 
Figure 4.12: Overall survival Kaplan-Meier Estimate. Using data extracted from “cBioPortal for cancer 
genomics” using a cohort of 507 samples of papillary thyroid carcinomas (TCGA) (302) we selected the 
samples with APT-1 overexpression, amplification and gains (22 samples) and checked for overall 
survival (A) or the samples with low levels of APT-1 mRNA or deletions (6 samples) and checked again 
for overall survival (B).  
APT1 amplifications, gains 
 and high mRNA levels 
No alterations in APT-1 No alterations in APT-1 
APT-1 deletions and 
 low mRNA levels 
A. B. 
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4.2.2 H-RAS LOCATION AT PLASMA MEMBRANE MICRODOMAINS IS RELATED 
TO APT-1 EXPRESSION LEVELS 
 
Since PCCL3 thyroid cells transfected with H-RAS tethered to LR and DM exhibit opposed 
effects in tumor proliferation and dissemination, we sought to determine if this was also the 
case in thyroid tumor cells harboring endogenous H-RAS at these different sublocalizations. 
We utilized C643 and HTH83 cell lines, both are derived from thyroid anaplastic carcinomas 
and have H-RAS mutations in position 13 (G13C) in C643 and in position 61 (Q61R) in 
HTH83 together with a mutation in TERT promoter (C228T) (294, 317). We monitored if H-
RAS sublocalizations differed in these cell lines, by membrane fractionation analyses. It was 
found that C643 cells harbored H-RAS at LR (Fig. 4.11 A) whereas in HTH83 cells H-RAS 
was located in DM (Fig. 4.13 B). This is a consequence of APT-1, an acyl thioesterase involved 
in H-RAS depalmitoylation (119), which is more expressed in C643 cells (Fig. 4.13 C). 
 
A.                                                   B.                                                                         C.                                                                   
                                                                       
  
 
 
 
Figure 4.13: H-RAS segregation in plasma membrane microdomains. H-RAS location at detergent-
resistant membrane domains (LRs, enriched in Caveolin-1) and detergent-soluble fractions (DM, enriched in 
transferrin receptor) in C643 (A) or HTH83 (B) human thyroid anaplastic carcinoma cell lines. (C) APT-1 
expression levels in lysates from C643 and HTH83 determined by immunoblotting. Protein levels were 
equalized using Bradford assay.  
 
4.2.3 OPPOSING EFFECTS ON TUMORIGENESIS BY ENDOGENOUS H-RAS AT LR 
AND DM  
 
To assess C643 and HTH83 cells tumorigenic behavior, we grafted 106 cells onto the CAM of 
10-days chick embryos and after 6 days we analyzed their tumor weight and distal CAM, liver 
and lung colonization. Interestingly, even though both cell lines are derived from anaplastic 
thyroid carcinomas they exhibited some crucial differences: C643 cells generated bigger 
tumors than HTH83 cells (Fig. 4.14 A), but induced less CAM intravasation and lung 
colonization, though, more liver colonization (Fig. 4.14 B). Even though, in all the positive 
cases the number of invading cells did not vary substantially (Fig. 4.14 C). These results are in 
consonance with the behavior of PCCL3 cells expressing H-RAS at LR or DM.  
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Figure 4.14: Tumorigenic behavior of the human anaplastic thyroid cancer cell lines, C643 and HTH83, 
in the chick embryo spontaneous metastasis model. 1x106 cells from each cell line were grafted on 10-
days chick embryos. After six days, the primary tumors were collected and weighed (mg) (Mean ± SD) 
(A) and the distal portions of the CAM were analyzed by qPCR showing the % of tumors that 
underwent spontaneous intravasation (Distal CAM) and liver and lung colonization (B); allowing us to 
determine the relative numbers of human cells (Mean ± SEM) per 106 chicken cells in distal CAM, 
liver and lungs (C). Data is from three independent experiments using from 8 to 16 embryos per cell 
variant. Statistical significance was analyzed by double tailed unpaired Student T-test. *p<0.05, 
**p<0.01 and ***p<0.001. 
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4.2.4 APT-1 KNOCKDOWN IN C643 CELLS TRANSLOCATES H-RAS TO DM AND 
GENERATES SMALLER TUMORS WITH HIGHER METASTATIC POTENTIAL 
 
To further substantiate the above findings, we downregulated APT-1 in C643 cells using a 
siRNA. We confirmed its knockdown (Fig. 4.15 A) and we performed a membrane 
fractionation and sucrose gradient to analyze H-RAS location at the plasma membrane. As 
we expected, APT-1 knockdown caused a H-RAS translocation from LR (Fig. 4.15 B) to DM 
(Fig 4.15 C). 
 
                                          A. 
                                         
 
 
 
 
B.                                                                              C. 
                                                                       
  
 
 
 
Figure 4.15: APT-1 siRNA knockdown effects in H-RAS micro localization in C643 cells. (A) siRNA- 
mediated knockdown of APT-1 in C643 cells. APT-1 expression levels determined by immunoblotting. 
Protein levels were normalized by Bradford assay. (B) H-RAS distribution at detergent resistant 
membrane domains (LRs, enriched in caveolin-1) and detergent soluble fractions (DM, enriched in 
transferrin receptor) in C643 cells (C) H-RAS distribution after APT-1 siRNA-mediated knockdown. 
 
We then, tested whether H-RAS diffusion from LR to DM in C643 cells was able to 
recapitulate HTH83 characteristics in tumor growth and dissemination. To do so, we grafted 
106 cells onto the CAM of 10-days chick embryos and after 5 days we collected the tumors and 
the different organs. We confirmed that APT-1 knock-down in C643 cells, matched HTH83 
behavior in tumor growth and metastasis, as they created smaller tumors (Fig.4.16 A) with 
higher rates of intravasation, with higher number of cells (Fig. 4.16 C), and colonized lungs 
but not liver (Fig. 4.16 B). Therefore, we can conclude that targeting APT-1 in C643 cells, 
resulting in RAS translocation to DM, generates smaller but more aggressive tumors than the 
parental cells.  
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Figure 4.16: Metastatic potential of C643 APT-1 knockdown (KD) cells in the chick embryo 
spontaneous metastasis model. (Control: C643 (blue); APT-1 KD: C643 cells with APT-1 knockdown 
(garnet)) C643 cells were transfected with an APT-1 siRNA and a day after 1x106 cells from each 
condition (Control and APT-1 KD) were grafted on day 10 chick embryos. After 5 days, the primary 
tumors were collected and weighed (mg) (Mean ± SD) (A) and the distal portions of the CAM were 
analyzed by qPCR showing the % of embryos that underwent spontaneous intravasation (distal CAM 
colonization) (MEAN ± SEM) (B); allowing us to determine the relative numbers of rat cells per 106 
chicken cells (MEAN ± SEM) (C). Data is from three independent experiments employing from 6 to 
12 embryos per cell variant. Statistical significance was analyzed by a double tailed unpaired T-test. 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
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4.2.5 APT-1 OVEREXPRESSION IN HTH83 CELLS TRANSLOCATES H-RAS FROM 
DM TO LRS GENERATING BIGGER TUMORS WITH LESS METASTATIC 
POTENTIAL 
 
After seeing the effects of APT-1 knockdown in C643 cells we sought to investigate whether 
APT-1 overexpression in HTH83 cells was able to recreate the opposite situation. 
To do so we transfected pCEFL-FLAG-APT-1 in HTH83 cells and we corroborated the 
increase of APT-1 protein levels by immunoblotting (Fig. 4.17 A) and analyzed the 
endogenous H-RAS location in the different membrane microdomains using a membrane 
fractioning in sucrose gradient by ultracentrifugation. Again, the modification of APT-1 levels, 
in this case overexpression, was able to partially redistribute, H-RAS from DM to LR. (Fig. 
4.17 B and C). 
 
                                                       A. 
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Figure 4.17: APT-1 overexpression effects in H-RAS plasma membrane microdomains distribution in 
HTH83 human thyroid anaplastic carcinoma cells. (A) pCEFL-FLAG-APT-1 was transfected in 
HTH83 cells with lipofectamine 3000 following manufacturer instructions. APT-1 proteins expression 
levels were then assessed by immunoblotting. (B) Oncogenic H-RAS distribution at detergent resistant 
membrane domains (LRs, enriched in caveolin-1) and detergent soluble fractions (DM, enriched in 
transferrin receptor) in HTH83 cells (C) H-RAS distribution in HTH83 cells with APT-1 
overexpressed.  
Although in HTH83 cells endogenous H-RAS did not fully diffuse to LRs after APT-1 
overexpression, this was sufficient to elicit a significant increase in tumor weight compared to 
HTH83 parental cells (control) (Fig. 4.18 A) and a decrease in distal CAM and lung 
colonization, but not liver (Fig. 4.18 B). No changes in the number of invading cells were seen 
in the positive cases (Fig. 4.18 C). Altogether, our data demonstrate that H-RAS 
sublocalizations critically influences thyroid cell oncogenic behavior. 
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Figure 4.18: Metastatic potential of HTH83 cells, overexpressing APT-1, in the chick embryo 
spontaneous metastasis model. (Control: HTH83 (greenish brown); APT-1: HTH83 cells stably 
expressing ectopic APT-1 (lilac)) 1x106 HTH83 cells were grafted on day 10-chick embryos. After 7 
days, the primary tumors were collected and weighed (mg) (Mean ± SD) (A) and the distal portions of 
the CAM were analyzed by qPCR showing the % of embryos (MEAN ± SEM) that underwent 
spontaneous intravasation (distal CAM colonization) and liver and lung colonization (B) allowing us to 
determine the relative numbers of human cells per 106 chicken cells (MEAN ± SEM) (C).  Data is from 
three independent experiments employing from 6 to 9 embryos per cell variant. Statistical significance 
was analyzed by a double tailed unpaired T-test. **p<0.01 and ****p<0.0001. 
 
 
 
 
 
 
 
 
4. Results 
 
123 
 
4.3 H-RAS sublocalizations notably affect tumor phenotype  
 
Given that H-RAS sublocalization can dramatically affect tumor growth and aggressiveness it 
was interesting to study their histological phenotype. To this end we grafted at several sites of 
the CAM of 7-days-old chick embryos grown since day 3 ex ovo, 20,000 green labeled PCCL3 
cells with H-RAS at its different sites. We also looked at C643 or HTH83 cells. After 5 days, 
Rodhamine was injected to visualized CAM blood vessels and the parts of the CAM 
containing tumors were fixed in 4% PFA and mounted.  
We found that cells transformed by H-RAS ER signals generated big round tumors in the 
proximity of major vessels, which reinforced previous results pointing out this cells 
vasculotropism, but few to-non cells were found intravasating (Fig. 4.19 A). H-RAS LR signals 
yielded the biggest tumors, as expected, showing a roundish shape with some cells migrating 
from the tumor core. Some necrotic areas were also present (arrow), which can be related to 
the high rate of proliferation (Fig. 4.19 B). Strikingly, tumors generated by C643 cells showed 
a similar phenotype to that one elicited by PCCL3 cells expressing H-RAS at LR, although 
more necrotic parts where observed (Fig. 4.19 C), in consonance with our previous results that 
demonstrated that C643 cells present H-RAS in LR (Fig. 4.13 A).  
 
Figure 4.19: Phenotype of the different microtumors formed by H-RAS at its different subcellular 
locations. C643, HTH83 or PCCL3 cells with total H-RAS or H-RAS activated at either ER (M1), LR 
(LCK), DM (CD8) or GC (KDEL) were pre-labeled with green fluorescence CellTracker and 20,000 
cells were placed on several parts of the CAM of live chick embryos grown ex ovo for 3 days. After 5 
days CAM vasculature was highlighted by injecting Rodhamine and CAM containing microtumors was 
fixed with 4% PFA. Then, samples were visualized in a Leica Confocal Microscope using a 25x water 
objective. 1 µm stacks were captured to visualize the whole thickness of the CAM and images were later 
reconstructed using Fiji Software. Cells (green), vessels (red), intravasated cells (yellow). Arrows show 
necrotic zones. 
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Regarding H-RAS DM-induced tumors they displayed some microfoci as well as high amounts 
of scattered cells, some of them already in the vessels lumen or intravasating, indicating high 
rates of invasion and intravasation (Fig. 4.19 D). This is in full agreement with our results in 
the chick embryo spontaneous metastasis model that identified this H-RAS sublocalization as 
the most metastatic. These results suggest that the small tumors found in the chick model 
could be due their highly ability to: i) migrate and scatter throughout the CAM and ii) 
intravasate. With respect to H-RAS at the GC, it also evokes microtumors but a high amount 
of scattered cells were also found. As before, some of these cells were already intravasated 
(Fig.4.19 E). Moreover, HTH83 cells which have mutant H-RAS active at DM showed the 
same phenotype as H-RASv12-CD8 expressing tumors, presenting mostly scattered cells, 
some of them intravasating (Fig. 4.19 F).   
These results suggest that H-RAS can differentially modulate tumor phenotype, cell invasion 
and vasculotropism depending on where it is activated within the cell. 
 
 
4.4   VEGF-B implications in H-RAS mediated tumorigenesis 
 
4.4.1 TUMORS GENERATED BY MUTANT H-RAS AT ER AND LR PRESENT LIPID 
DROPLETS 
Figure 4.20: Oil red lipid staining of tumor sections. (PCCL3 cells transfected with: Control: pCEFL; 
Total: H-RASv12; M1: H-RASv12 at ER, LCK: H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-
RASv12 at GC). 
When tumors generated by H-RAS at its different sublocalizations were stained with 
hematoxylin we observed particularly in the case of ER and LR H-RAS, empty rounded spaces 
inside some of the cells, which resembled lipids droplets, which are known to be dissolved by 
Xylene processing. To explore this possibility an oil red Staining was performed to reveal the 
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existence of neutral triglycerides and lipids. Strikingly, we found that mainly H-RASv12-M1 
and H-RASv12-LCK-expressing tumors stained positive por oil red (Fig.4.20). That made us 
wonder if H-RAS active at ER and LRs could regulate lipid uptake and storage.  
 
4.4.2 H-RAS ACTIVE AT ER AND LR GENERATES TUMORS EXPRESSING HIGH 
LEVELS OF VEGF-B  
 
VEGF-B is a poorly angiogenic member of the VEGF family that signals through VEGFR1 
and its coreceptor, neuropilin-1 (135). Recently, this growth factor has been related to energy 
metabolism, instructing endothelial cells to take up Long-Chain Fatty Acids (LCFAs) from 
the circulation, that are then uptaken by surrounding cells for use and storage as lipid droplets 
(137). Therefore, we hypothesized that this molecule could be responsible for the 
accumulation of the lipids shown in our tumors. 
To test our hypothesis, we extracted mRNA from the different tumors and we checked for 
VEGF-B mRNA levels using rat primers that recognized both VEGF-B isoforms. 
Interestingly, VEGF-B was upregulated in H-RASv12-M1 and H-RASv12-LCK-expressing 
tumors which correlates with the presence of lipid droplets in the cells (Fig 4.21 A). Moreover, 
C643 cells, that have H-RAS mainly in LRs also exhibited significantly higher levels of VEGF-
B when compared to HTH83 cells (Fig 4.21 B). Since VEGF-B is able to modulate VEGF-A-
induced pathological angiogenesis in some situations (136), we also tested for VEGF-A 
mRNA expression using primers that recognize all VEGF-A isoforms. We saw that H-
RASv12-CD8 and H-RASv12-KDEL-expressing tumors exhibited higher levels of VEGF-A 
compare to tumors generated by H-RAS active at LR and ER (Fig. 4.21 C). Indeed, VEGF-
A is known to promote angiogenesis and increase vessels leakage and permeability thus 
favoring metastasis (124) in agreement with our results showing that H-RASv12-CD8 and H-
RASv12-KDEL-expressing PCCL3 cells induced more metastatic tumors.  In consequence our 
results suggest that VEGFs expression could be modulating tumor behavior.   
Figure 4.21: Fold changes of the relative mRNA levels of VEGF-B and VEGF-A in the different 
tumors. (A) and (B) represent VEGF-B mRNA expression levels analyzed by qPCR in tumors with H-
RAS at its subcellular locations or C643 and HTH83 tumors, respectively, grown using the chick embryo 
spontaneous metastasis model (C) VEGF-A mRNA expression levels analyzed by qPCR. Data (A,C) 
are expressed as the fold change relative to CONTROL. 
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4.4.3 VEGF-B ADDITION TO H-RAS DM AND GC TUMORS ALTERS THEIR 
METASTATIC POTENTIAL 
 
Since H-RAS activated in LR and ER induces big tumors with low ability to colonize distant 
organs, and presents high levels of VEGF-B expression, we sought to elucidate whether 
VEGF-B was impairing tumor the ability to metastasize.  
We grafted 1x106 cells with active H-RAS present at either DM or GC, onto the CAM of 10- 
days old chick embryos. After two days, rat VEGF-B was added and renewed every two days. 
At day 7 tumors were collected and weighted and distant organ colonization was analyzed by 
qPCR. Interestingly we found that VEGF-B was capable of increasing the tumor size of H-
RAS DM and GC-generated tumors (Fig. 4.22 A) and of decreasing to a substantial extent, 
about 20%, their ability to intravasate (Fig. 4.22 B) and to colonize lungs (Fig. 4.22 D), though, 
no effects in liver colonization were observed (Fig 4.22 C). These results demonstrate that 
VEGFB impairs tumor cells ability to intravasate and invade distant organs. 
Altogether these results point out VEGF-B as a new possible biomarker to further stratify the 
risk of H-RAS-positive nodules or to assess the ability of already stablished tumors to colonize 
distant organs. Therefore, as for APT-1, a prospective or retrospective analysis of H-RAS 
mutant nodules and tumors should be carried out in order to relate the levels of VEGF-B in 
immunohistochemistry to the aggressiveness of tumors and thus, confirm our assumptions.  
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Figure 4.22: Effects of VEGF-B in tumor growth and metastasis. 1x106 cells were grafted on 10-days 
chick embryos. 10 nM of VEGF-B was added at day 2 and every two days it was renewed. After 7 days, 
primary tumors were collected and weighed (mg) (Mean ± SD)  (A) and the distal portions of the CAM 
were analyzed by qPCR showing the % of embryos (MEAN ± SEM) that underwent spontaneous 
intravasation (distal CAM colonization) (B left), liver (C left) or lung colonization (D left) allowing us 
to determine the respective relative numbers of rat cells per 106 chicken cells (B,C, D right). Data is 
from three independent experiments employing from 5 to 10 embryos per cell variant. Statistical 
significance of cells treated with VEGF-B was determined in comparison with their respective non-
treated counterparts. Groups were analyzed by a double tailed unpaired Student T-test. *p<0.1, 
**p<0.01, ***p<0.001 and ****p<0.0001. 
* 
*** 
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4.5 RAS sublocalizations implications in exosome secretion and its effects 
 
4.5.1 PCCL3 CELLS HAVE MULTIVESICULAR BODIES  
 
Exosomes are nanovesicles having a maximum size of 150 nm, that carry specific cargos, such 
as, DNA, RNA, proteins and lipids. The vast majority are formed in multivesicular bodies that 
release them once fused to the plasma membrane, although some of them can arise directly 
from the plasma membrane budding as microvesicles (150 nm-1 µm) (152). H-RASv12 has 
been shown to promote exosome secretion (173, 318), and it has also been found in them (177, 
319), conferring exosomes the ability to transform other cells. Therefore, to explore whether 
PCCL3 cells were able to secrete extracellular vesicles and if H-RASv12 sublocalizations could 
affect their formation or secretion, we looked for multivesicular bodies (MVBs) using 
transmission electron microscopy. We found MVBs in PCCL3 cells whether expressing H-
RAS or not, and independently of its sublocalizations (Fig. 4.23 B). Moreover, we saw high 
amount of plasma-membrane budding, a key step in microvesicles biogenesis and release so 
we could confirm that PCCL3 cells induce microvesicles formation and secretion (Fig. 4.23 
C).  
In addition, we found interesting features in the different cell lines:  
PCCL3 parental cells, as expected, showed a polarized state and since they are thyroid 
follicular cells, which are highly active transcriptomically, we found high amounts of free 
polyribosomes and a moderate plasma membrane budding (Fig. 4.23 A). 
PCCL3 cells expressing H-RAS showed high amounts of free polyribosomes and more 
compacted chromatin.  
H-RASv12-M1-expressing PCCL3 cells have high amounts of free polyribosomes 
multilamellar bodies, which are membrane-bound organelles. They vary in size from 100-2400 
nm, are composed of concentric membrane layers, and frequently exhibit an electron-dense 
core. Their main function is lipid storage and secretion and they have a lysosomal nature (320) 
(Fig. 4.23 C). In addition, heterochromatin is more condensed than the other cell lines (Fig. 
4.23 D).  
PCCL3 cells expressing H-RAS at LR presented high amount of membrane budding, have 
lots of free polyribosomes and they are still polarized (Fig. 4.23 F). PCCL3 cells with H-RAS 
at DM exhibited i) high membrane activity ii) high amounts of free polyribosomes iii) big and 
highly condensed nucleolus and iv) little heterochromatin (Fig. 4.23 G). These results coincide 
with the reduction in the levels of heterochromatin and an  increase in nucleolar size in cancer 
cells (321, 322) pointing out again that cells with H-RAS at DM show characteristics of 
aggressive cancers.    
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Figure 4.23: MVB presence in PCCL3 cells (A) PCCL3 parental cells (B) Multivesicular body (arrow) 
in cells with H-RAS at GC (C) (D) PCCL3 cells expressing mutant H-RAS at ER, heterochromatin is 
pointed out by arrows (E) multilamellar bodies present PCCL3 with active H-RAS at GC (F) cells with 
active H-RAS at LR (G) Cells with mutant H-RAS at DM, arrow point out the nucleolus (H) Necrotic 
cell (arrow) and multilamellar bodies (double arrow) in H-RASv12-KDEL expressing cells. 
PCCL3 cells expressing H-RAS at LR presented high amount of membrane budding, have 
lots of free polyribosomes and they are still polarized (Fig. 4.23 F).  
PCCL3 cells with H-RAS at DM exhibited i) high membrane activity ii) high amounts of free 
polyribosomes iii) big and highly condensed nucleolus and iv) little heterochromatin (Fig. 4.23 
G). These results coincide with the reduction in the levels of heterochromatin and an increase 
in nucleolar size in cancer cells (321, 322) pointing out again that cells with H-RAS at DM 
show characteristics of aggressive cancers.   
PCCL3 cells with H-RAS at the GC exhibited i) a hypertrophic GC with some dilated cisterns 
ii) lots of mitosis and iii) several necrotic cells (Fig. 4.23 H). In addition, as in cells with H-
RAS at ER, we saw a high amount of multilamellar bodies, some of them strikingly big (Fig. 
4.23 E). 
H. G. 
E. F. 
D. C. 
A. B. 
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To sum up, H-RAS expressing cells, as well as PCCL3 parental cells, present MVBs, plasma 
membrane budding known to be related to microvesicles secretion, and high amounts of free 
polyribosomes. Surprisingly H-RAS signaling from intracellular organelles, ER or the GC, 
induce multilamellar bodies (MLB) formation, suggesting that H-RAS might be altering 
cholesterol metabolism and autophagosome trafficking, since these alterations have been 
related to MLB appearance (323). 
 
4.5.2 H-RAS EXPRESSION IN PCCL3 CELLS AFFECTS EVs CHARACTERISTICS 
AND SECRETION DEPENDING ON ITS LOCATION  
 
Since we had confirmed MVBs presence inside the cells and some of them never reach the 
plasma membrane because they are recycled into lysosomes (324), we needed to check 
whether PCCL3 cells were actually able to secrete EVs. To reach our aim, we isolated EVs by 
size exclusion chromatography and EVs fractions 3-5, that correspond to the exosome peak, 
shown in the chromatogram (Fig. 4.24), were analyzed.  
Surprisingly, H-RAS activated in the different subcellular locations decreased ALIX-1 EV 
marker compare to PCCL3 parental cells and EVs secreted by cells expressing H-RASv12 at 
DM or GC were slightly enriched in SYNTENIN and mostly in TSG-101 (Fig. 4.25 B). 
Fractions 6-8 are the ones located previous to the protein peak, which is the high peak shown 
in the chromatogram (Fig. 4.24), and are known to also contain exosomes. Therefore, we also 
analyzed them by Western blotting and  
Figure 4.24: Size exclusion chromatogram (PCCL3 parental cells). Fractions T3-T5 (arrow) correspond 
to the exosome peak. Line shows fractions T6-T8. The 240 mAU peak corresponds to proteins present 
in supernatants. 
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we observed that although SYNTENIN and CD63 were all still markedly present in all cell 
lines, cells expressing HRAS at its different locations had almost undetectable levels of TSG-
101 and ALIX-1 but were still strongly present in PCCL3 parental cells (Fig. 4.25 C). 
Figure 4.25: EVs Immunoblotings showing (A) cells total lysates (B) EV markers in size exclusion 
fractions 3-5 (C) EV markers in size exclusion fractions 6-8. 
To investigate whether H-RAS was modulating the amount and the size of EVs depending on 
its sublocalizations, we analyzed EVs concentration by Nanoparticle Tracker Analysis using 
NanoSight. We saw that PCCL3 parental cells secreted the same amount of EVs as PCCL3 
cells with H-RAS at DM and the GC but strikingly more than cells with H-RAS signaling from 
the ER and LR. Results were similar for both the exosome peak (fractions 3-5) (Fig. 4.26) and 
6-8 fractions (Fig. 4.27). EVs size was also different between H-RAS sublocalizations and we 
saw that, like PCCL3 cells, cells with H-RAS at DM and the GC showed bigger EVs in the 
exosome peak but not in later fractions, when compared to EVs secreted from cells with H-
RAS active at ER or LR.  
Overall, this data suggests that H-RAS when present at different subcellular locations induce 
different pools of EVs, that might have distinct cargos. 
 
4.5.3 EVs SECRETED BY CELLS WITH H-RASV AT DM AND GC AFFECT CELL 
PROLIFERATION  
 
Since we demonstrated that EVs secreted by cells containing H-RAS at DM and GC are 
different from the ones secreted by cells with H-RAS at ER and LR, we sought to explore if 
they could have different effects in cell proliferation, in line with our previous findings. To 
analyze that, we first assessed cellular growth, acquiring live images for three days using the 
IncuCyte ZOOM® analysis system. This system takes four photos per well every two hours 
and uses a specific mask to detected cells silhouette, transforming it into a figure. We found 
that this method showed changes in proliferation that were not detected by AlamarBlue.  
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Figure 4.26: NanoSight tracker analysis measurement of particle size distribution and concentration in 
exosomes from fractions 3-5. (PCCL3 cells transfected with: Control: pCEFL; Total: H-RASv12; M1: 
H-RASv12 at ER, LCK: H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-RASv12 at GC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: NanoSight tracker analysis measurement of particle size distribution and concentration in 
exosomes from fractions 6-8. (PCCL3 cells transfected with: Control: pCEFL; Total: H-RASv12; M1: 
H-RASv12 at ER, LCK: H-RASv12 at LR; CD8: H-RASv12 at DM; KDEL: H-RASv12 at GC) 
CONTROL(6-8) TOTAL (6-8) 
CD8 (6-8) KDEL (6-8) LCK (6-8) 
M1 (6-8) 
Control (3-5) 
CD8 (3-5) 
TOTAL (3-5)  M1 (3-5) 
 LCK (3-5) KDEL (3-5) 
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In this case, cells with H-RAS at DM and GC displayed lower levels of proliferation compared 
to the other cells. However, as seen before, H-RASv12 in ER and LR presented similar 
proliferation rates as PCCL3 parental cells (Fig. 4.28 A).  
To investigate whether EVs secreted by cells containing H-RASv12 tethered to its different 
subcellular locations could influence cell proliferation differentially, we incubated 3,000 
recipient cells with 1,000 EVs (either using 3-5 or 6-8 fractions) collected from the different 
types of H-RAS-expressing cells for 30 minutes. EVs isolated by size exclusion were utilized 
and using the IncuCyte ZOOM analysis system we closely followed cell proliferation for 3 
days. We found that the EVs secreted by cells with H-RAS at DM and the GC could decrease 
proliferation of PCCL3 parental cells (Fig. 28 and 29 B) and cells containing active H-RAS at 
ER (Fig. 28 and 29 C) or LR (Fig. 28 and 29 D) after 24 hours, and more significantly after 72 
hours. This effect was more pronounced when exosome peak fractions 3-5 were used (Fig.28). 
Moreover, EVs secreted by cells with H-RAS at LR also diminished proliferation of PCCL3 
parental cells (Fig. 28 and 29 B) and of cells with H-RAS at ER (Fig. 28 and 29 C), although 
to a lesser than the other EVs. In contrast, EVs secreted by cells harboring H-RAS at LR (Fig. 
28 and 29 E and F) or ER (Fig. 28 and 29 E and F) did not promote proliferation of other 
cells. 
These results further indicate that H-RASv12 activated at different subcellular locations 
generate different EVs. 
 
4.5.4 EVs SECRETED BY PCCL3 CELLS EXPRESSING H-RAS AT DM INCREASE 
THE METASTATIC POTENTIAL OF CELLS EXPRESSING H-RAS AT ER OR LR 
AND DECREASE THEIR TUMOR SIZE 
 
Since we demonstrated that EVs isolated from PCCL3 cells expressing H-RASv12 at DM 
could decrease the proliferation rate of cells expressing H-RAS at other sublocalizations, we 
hypothesized that these EVs could also decrease their tumor size. To approach it, cells with 
H-RAS at ER and LR were incubated with EVs secreted from cells harboring H-RAS at DM. 
After that, cells were grafted onto the CAM of 10-days old chick embryos and after 7 days 
tumor weight was measured and distal CAM, liver and lungs colonization were analyzed.  
It was found that EVs derived from cells expressing H-RAS at DM were capable of reducing 
tumor growth promoted by H-RAS signals at ER (Fig. 30 A) and LR (Fig. 31 A) by 50% 
compared to EVs derived from control cells. More interestingly, these EVs were able to confer 
cells with H-RAS at ER (Fig.4.30 B) and LR (Fig.4.31 B) the capacity to intravasate and 
colonize distant organs as lungs (Fig.4.30 and 31 F) and liver (Fig 4.30 and 31 D). These effects 
were quite outstanding in lungs, where they were capable to almost triplicate H-RAS ER- 
mediated lung colonization and almost doubled H-RAS LR-mediated one. 
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 Figure 4.28: Effects of heterologous EVs on cellular proliferation (3-5). The indicated cells lines were 
incubated with EVs secreted by PCCL3 cells (fractions 3-5) parental or expressing H-RAS at its 
different localizations. 3,000 PCCL3 cells were incubated with 1x PBS (A) or with 1000 EVs/per cell for 
30 minutes before seeded and were grown for 72 hours. EVs used were obtained by size exclussion and 
fractions 3-5, which correspond to the exosome peak. (B) PCCL3 parental cells, or PCCL3 with (C) H-
RASv12 at ER (M1), (D) HRASv12 at LR (LCK), (E) HRASv12 at DM (CD8) and (F) HRASv12 at 
GC (KDEL) treated with EVs isolated from PCCL3 parental cells or PCCL3 cells expressing H-
RASv12 at either ER, LR, DM or GC. Data is from three independent experiments. Statistical 
significance was determined using a double tailed unpaired Student T-test **p<0.01, ***p<0.001 and 
****p<0.0001. 
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Figure 4.29: Effects of heterologous EVs on cellular proliferation (6-8). The indicated cells lines were 
incubated with EVs secreted by PCCL3 cells (fractions 6-8) parental or expressing H-RAS at its 
different localizations. 3,000 PCCL3 cells were incubated with 1x PBS (A) or with 1000 EVs/per cell for 
30 minutes before seeded and were grown for 72 hours. EVs used were obtained by size exclussion and 
fractions 6-8, which correspond to the exosome peak. (B) PCCL3 parental cells, or PCCL3 with (C) H-
RASv12 at ER (M1), (D) HRASv12 at LR (LCK), (E) HRASv12 at DM (CD8) and (F) HRASv12 at 
GC (KDEL) treated with EVs isolated from PCCL3 parental cells or PCCL3 cells expressing H-
RASv12 at either ER, LR, DM or GC. data is from three independent experiments. Statistical 
significance was determined in comparison using a double tailed unpaired Student T a double tailed 
unpaired T-test **p<0.01, ***p<0.001 and ****p<0.0001. 
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To sum up, these results suggest that H-RAS at DM can promote the secretion of EVs capable 
of i) changing tumoral behavior, ii) inducing intravasation and iii) shaping distant tumoral 
niches allowing cells to extravasate, survive and proliferate, growing micrometastases in these 
organs.  
 
4.5.5 EVs ISOLATED FROM PCCL3 CELLS EXPRESSING ONCOGENIC H-RAS AT 
GC MODIFY ER AND LR H-RAS ONCOGENIC POTENTIAL  
 
As EVs isolated from PCCL3 cells with oncogenic H-RAS at GC diminished ER and LR H-
RAS mediated proliferation in vitro, we sought to explore the possibility that these EVs were 
also capable of modifying the tumor size and the capacity to invade distant organs displayed 
by these cells. 
To explore this possibility, we incubated 1x106 PCCL3 cells expressing H-RASv12-M1 or H-
RASv12-LCK with 1000 EVs/per cell isolated from cells harboring RAS at GC, for 30 minutes. 
After this time, cells were grafted onto the CAM of 10 days old chick embryos and after 7 days 
tumoral weight was measured and distal CAM, liver and lungs colonization were analyzed by 
qPCR. Under these conditions we saw that GC RAS EVs decreased the size of LR H-RAS 
tumors but not those induced by ER H-RAS one, (Fig.30 and 31 A). Furthermore, GC H-
RAS-derived EVs promoted by 2-fold ER H-RAS induced-intravasation (Fig. 30 B) and 
almost tripled its liver and lung colonization in the chick embryo spontaneous metastasis 
model (Fig. 30 D and F). Regarding LR H-RAS, GC H-RAS-derived EVs increased by 30% 
their intravasation (Distal CAM colonization) (Fig. 31 B), by a 20% liver colonization (Fig. 31 
D) and shockingly double their ability to colonize lungs (Fig. 31 F). 
All together this data suggests that GC H-RAS-derived EVs and DM H-RAS-derived EVs, 
besides from being different in terms of the markers they exhibit, are capable to enhance ER 
and LR H-RAS metastatic potential, presumably by increasing their intravasation rate, by 
modifying cell organotropism or by preparing the pre-metastatic niche in lungs.  
 
4.5.6 EVs SECRETED BY H-RAS AT ER OR LR DO NOT MODIFY DM OR GC H-RAS 
METASTATIC POTENTIAL 
 
Although we did not see any changes in proliferation when EVs coming from PCCL3 cells 
with H-RAS activated in ER or LR were added to cells with H-RAS at DM or GC, we wanted 
to explore if they were capable of promoting cell intravasation and distant metastasis.  
We again followed the same experimental settings as above. However, this time we did not see 
any changes in tumor size (Fig. 32 and 33 A), intravasation (Fig. 32 and 33 B) or distant organs 
colonization (Fig. 32 and 33 D and F) when using EVs derived from cells with H-RAS at ER. 
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Conversely, we found that EVs isolated from cells with H-RAS active at LR increased GC 
RAS-promoted tumor size although they did not affect distant organs colonization (Fig. 4.33 
A).  
To sum up, these results show that extracellular vesicles isolated from cells expressing 
oncogenic H-RAS exhibit striking different effects, depending on its subcellular locations, that 
affected other RAS locations-mediated proliferation and metastasis.  
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Figure 4.30: Effects of heterologous EVs on the oncogenic potential of cells with H-RASv12 at ER. 
1x106 cells expressing H-RASv12 at ER (M1) were incubated with EVs secreted by PCCL3 cells 
(fractions 3-5 and 6-8 mixed) parental or expressing H-RAS at DM (CD8) or GC (KDEL) and were 
grafted on 10-days chick embryos. Seven days after, the primary tumors were collected and weighed 
(mg) (A) and the distal portions of the CAM were analyzed by qPCR showing the % of embryos that 
underwent spontaneous intravasation (distal CAM colonization) (B), liver (D) and lung colonization 
(F) allowing us to determine the relative numbers of rat cells  per 106 chicken cells in CAM (C), liver 
(C) or lungs (E). Error bars shows (Mean ± SD) in (A) and in the rest (MEAN ± SEM).  Data is from 
three independent experiments employing from 7 to 12 embryos per cell variant. Statistical significance 
was determined using a double tailed unpaired student T-test. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
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Figure 4.31: Effects of heterologous EVs on the oncogenic potential of cells with H-RASv12 at LR. 
1x106 cells expressing H-RASv12 at LR (LCK) were incubated with EVs secreted by PCCL3 cells 
(fractions 3-5 and 6-8 mixed) parental or expressing H-RAS at DM (CD8) or GC (KDEL) and were 
grafted on 10-days chick embryos. Seven days after, the primary tumors were collected and weighed 
(mg) (A) and the distal portions of the CAM were analyzed by qPCR showing the % of embryos that 
underwent spontaneous intravasation (distal CAM colonization) (B), liver colonization (D) and lung 
colonization (F) allowing us to determine the relative numbers of rat cells  per 106 chicken cells in CAM 
(C), liver (C) or lungs (E). Error bars shows (Mean ± SD) in (A) and in the rest (MEAN ± SEM).  
Data is from three independent experiments employing from 7 to 12 embryos per cell variant. Statistical 
significance was determined using a double tailed unpaired student T-test. *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. 
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Figure 4.32: Effects of heterologous EVs on the oncogenic potential of cells with H-RASv12 at DM. 
1x106 cells expressing H-RASv12 at DM (CD) were incubated with EVs secreted by PCCL3 cells 
(fractions 3-5 and 6-8 mixed) parental or expressing H-RAS at ER (M1) or LR (LCK) and were grafted 
on 10-days chick embryos. Seven days after, the primary tumors were collected and weighed (mg) (A) 
and the distal portions of the CAM were analyzed by qPCR showing the % of embryos that underwent 
spontaneous intravasation (distal CAM colonization) (B), liver colonization (D) and lung colonization 
(F) allowing us to determine the relative numbers of rat cells  per 106 chicken cells in CAM (C), liver 
(C) or lungs (E). Error bars shows (Mean ± SD) in (A) and in the rest (MEAN ± SEM).  Data is from 
three independent experiments employing from 7 to 12 embryos per cell variant. Statistical significance 
was determined using a double tailed unpaired student T-test. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
 
4. Results 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33: Effects of heterologous EVs on the oncogenic potential of cells with H-RASv12 at the GC. 
1x106 cells expressing H-RASv12 at the GC (KDEL) were incubated with EVs secreted by PCCL3 cells 
(fractions 3-5 and 6-8 mixed) parental or expressing H-RAS at  ER (M1) or LR (LCK) and were grafted 
on 10-days chick embryos. Seven days after, the primary tumors were collected and weighed (mg) (A) 
and the distal portions of the CAM were analyzed by qPCR showing the % of embryos that underwent 
spontaneous intravasation (distal CAM colonization) (B), liver colonization (D) and lung colonization 
(F) allowing us to determine the relative numbers of rat cells  per 106 chicken cells in CAM (C), liver 
(C) or lungs (E). Error bars shows (Mean ± SD) in (A) and in the rest (MEAN ± SEM).  Data is from 
three independent experiments employing from 7 to 12 embryos per cell variant. Statistical significance 
was determined using a double tailed unpaired student T-test. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001.
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5.   DISCUSSION:  
 
More than 50 years have passed since the first RAS protein was discovered but yet, our 
knowledge on RAS signaling and its role in tumorigenesis is still not fully understood.  Today 
we know that RAS is not exclusively in the inner leaflet of the plasma membrane, where it is 
present at LR and DM, but it is also present and functional at different subcellular 
localizations, as in ER and GC, contrasting the initial idea of a single source of RAS signals 
(101, 104, 325). However, little is known about how RAS sublocalization affects its oncogenic 
potential. It is well known that RAS mutations are found in many human cancers and that 
thyroid cancer is one of them. For instance, 26% of papillary thyroid carcinoma harbor RAS 
mutations, follicular thyroid carcinoma around 40% and anaplastic carcinoma about 53% 
(252). RAS mutations also occur in 20–25 % of benign Follicular Thyroid Adenoma (FTA).  
However, although in the last decade considerable effort has been made to 
correlate RAS mutations to the clinical management of thyroid nodules and thyroid cancer, 
most RAS-positive thyroid nodules are classified, using the Bethesda system, as indeterminate 
(326). Moreover, due to RAS uncertain role in the clinical outcome of thyroid cancer, it has 
been unclear how to appropriately use RAS status to assist the management of thyroid tumors. 
In consequence, new markers are needed to rule out RAS-positive thyroid nodule malignancy 
and to predict thyroid cancer aggressiveness and risk for local and distant invasion, since new 
thyroid cancer guidelines are heading to more conservative approaches.  
We therefore hypothesized that the different behavior of thyroid tumors, harboring RAS 
mutations, are related to RAS differential sublocalization in the cell, where it can modulate 
different proteins and genetic programs. In consequence, the aims of this thesis were to study 
if RAS sublocalizations modulate RAS oncogenic potential in thyroid cancer and to find new 
related markers to identify high risk thyroid nodules and cancers.  
 
5.1 Role of RAS sublocalizations in thyroid tumorigenesis 
Recently, our group casted some light for the first time in vivo on RAS sublocalization-
dependent oncogenic effects, demonstrating that RAS at the GC antagonize melanoma 
formation (121). Moreover, we determined that RAS signals emanating from the GC, and 
specifically from the cis-Golgi, can induce a potent apoptotic response, endorsing other recent 
findings that showed GC RAS signals antagonizing proliferation and differentiation (121) 
(305). However, this was only assessed in one experimental model and in a specific cancer 
type, melanoma, which makes it risky to extrapolate to other types of cancer.  
We generated PCCL3 rat thyroid follicular cell lines stably expressing the three RASv12 
isoforms in the different subcellular locations using vectors harboring targeting signals to 
direct them to ER, LR, DM or GC. 
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Using these cell lines, we investigated different in vitro parameters such as proliferation, 
apoptosis and migration. A number of important observations were noticed: i) Neither of the 
RAS isoforms induce PCCL3 cells proliferation, but H-RAS signals from DM and GC slightly 
decrease it, ii) all H-RAS, N-RAS and K-RAS sublocalizations promote to some extent 
apoptosis, particularly signals from the GC, iii) H-RAS signals from DM and GC are the most 
competent for inducing migration. 
Therefore, we posit that H-RAS in DM and GC is able to reduce proliferation rates and that 
H-RAS signals from LRs or ER do not induce proliferation. This could be due to RAS 
inducing apoptosis. It might be also explained due to a possible need for other type of cells in 
order to regulate proliferation cues. For instance, it has been seen that oncogenic K-RAS 
regulates tumor cell signaling via stromal cells dramatically changing tumor cell 
phosphoproteome resulting in increased cell proliferation and survival (327). 
In agreement with our findings regarding RAS inducing apoptosis, other authors have shown 
that H-RASv12 can induce programmed cell death in PCCL3 p53 wild-type cells through 
genome destabilization associated with the disruption of critical cell cycle checkpoints (308).  
We also monitored the oncogenic potential of H-RAS, N-RAS and K-RAS sublocalizations 
in vivo using the chick embryo spontaneous metastasis model. Interestingly, our study shows 
for the first time that, irrespective of its localization, H- and N-RASv12 signals have the same 
effects in growth and metastasis of thyroid tumor cells. Strikingly, when RAS signals come 
from DM and the GC they generate smaller tumors, compared to RAS in LRs and ER, but 
with higher rates of intravasation and distant organ colonization, mostly lungs. However, K-
RAS, that is only present in DM and ER, exhibits similar rates of tumor growth at both 
sublocalizations, although signals from DM were more effective for inducing lung metastasis.  
In addition, we demonstrated that DM H-RASv12 signals induce increased nucleolar size and 
condensation, a feature that has been recognized as a hallmark in a large number of tumor 
types (322, 328, 329). Also, cells with H-RAS at DM present a tremendous amount of free 
polyribosomes, that could be a consequence of by RAS induced modification of the nucleolar 
size. Conversely, data pointing to increased proliferation in cells with bigger nucleoli due to 
an increment in ribosome synthesis (330, 331), contradict our findings. However, since the 
nucleolus has recently been assigned a fundamental role in other processes, essential for 
tumoral cells, such as telomere function, regulation of cell-cycle progression, genome stability 
or biogenesis of multiple ribonucleoprotein particles (322, 329, 330), it is reasonable to 
speculate that nucleoli modified by RAS at DM could be relevant for its tumorigenic effects. 
Therefore, further work needs to be done in this respect to try to unravel how RAS at DM 
affects nucleoli and what are the consequences. 
Intriguingly, our GC results contradict previous findings from our group where it was 
demonstrated that RAS at the GC antagonizes melanoma progression via induction of PTPRκ 
that downregulates ERK activity (121). However, when PTPRκ was not present or was present 
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together with tp53 mutations, this led to a partial or total rescue of GC RAS transforming 
potential (121). In consequence, PTPRκ expression and tp53 status should be investigated in 
PCCL3. Moreover, PCCL3 cells that have H-RAS in GC exhibit a shocking high amount of 
mitosis and some necrotic and apoptotic cells.  This suggests that GC RAS signals might 
induce high rates of mitotic catastrophe in our model. Mitotic catastrophe is a regulated 
antiproliferative process that occurs during defective or failed mitosis. It works by detecting 
and removing mitotically defective cells to prevent of H-RAS-induced genome instability  
(332-334). Therefore, mitotic catastrophe could explain, at least in part, GC H-RAS reduced 
levels of cell proliferation and small tumor size, together with the induction of apoptosis.  
For the first time, as far as we know, we have demonstrated in the chick embryo model that 
GC RAS signals promote thyroid cell metastasis in lungs. However, little is known about how 
GC RAS could be evoking this effect. Some groups have shown the GC as a key regulator of 
directional cell migration and invasion (335, 336). Particularly, one study by Bisel and 
colleagues who showed that ERK activation from the GC, directly phosphorylates the Golgi 
matrix protein GRASP65, a promigratory signaling event (337). Moreover, previous results 
from our group demonstrated an increased JNK and RALGDS signals when RAS was present 
at the GC (110, 338). There are several studies pointing JNK being fundamental for cell 
migration and invasion (339) in different human cancer cells as pancreatic or gastric (90, 340, 
341). In consequence, JNK and RALGDS signaling pathway assessment is necessary and the 
use of specific inhibitors could give an insight into the role of this pathways in GC mediated 
thyroid tumorigenesis.  
Intriguingly, our results have pointed out that small H- and N-RAS positive tumors, which 
arise when RAS is present at DM or the GC, are the most invasive and metastatic ones, 
whereas bigger tumors, which have mutant RAS at LR or ER, shown little or no invasion and 
metastasis.  
This shocking and newfangled results suggest: i) a possible explanation for RAS variable 
behavior in human thyroid nodules and cancers, based on its sublocalizations, ii) that small 
thyroid nodules or cancers could be the most metastatic ones, which makes urgent the need 
for specific markers to predict how RAS-positive thyroid tumors are likely to evolve.  
In order to ascertain this last proposal, we analyzed oncogenic H-RAS locations in human 
anaplastic thyroid cell lines C643 and HTH83 both of which harbor mutant H-RAS. We 
demonstrate that C643 cells have mutant H-RAS mainly in LRs whereas HTH83 at DM. This 
differential H-RAS subcellular location is fundamental for their tumorigenic potential. 
Indeed, HTH83 cells show smaller tumors compared to C643 cells, but promote a more 
invasive phenotype leading to higher rates of metastasis. Furthermore, they endorse to a large 
extend to our results with PCCL3 cells expressing H-RAS site-specific constructs, though not 
completely. For instance, in C643, H-RAS signals from LRs promote higher rates of 
metastasis than our H-RASv12-LCK construct and H-RAS signals from DM in HTH83 cells 
5.    Discussion  
  
 
148 
 
promote bigger tumors than our PCCL3 cells with H-RASv12-CD8. This could be explained 
by the burden of mutations that these cells contain. For instance, both C643 and HTH83 have 
mutations in the telomerase reverse transcriptase TERT gene promoter. That creates binding 
sites for E-Twenty-Six (ETS) transcription factors, promoting TERT transcriptional activity 
resulting in increased telomerase activities. Interestingly, some ETS factors are targets of 
ERK(342-344), which suggest that TERT modulation by H-RAS might be crucial to reduce 
apoptosis, conferring them a unique survival advantage (345). Moreover, TERT promotes cell 
adhesion and migration, independently of telomerase activity (346) which can to some extend 
explain C643 higher rates of distant colonization when compared to H-RASv12-LCK 
expressing PCCL3 cells. In addition, C643 cells are mutated in p53 which avoids H-RAS 
induced apoptosis in PCCL3 thyroid cells (291, 306, 307). Furthermore, it is now known that 
mutant p53 proteins provoke activities that are different to those resulting from the simple 
loss of wild-type tumor-suppressing p53 function. Many of this newly unveiled functions enable 
tumor cells to survive, proliferate, invade adjacent tissues and metastasize, which could 
explain, for instance, HTH83 tumor size (347). Therefore, additional mutations might give 
C643 and HTH83 cells an advantage compare to our PCCL3 transfected cell lines, that do not 
harbor any mutations besides the expression of the different RAS constructs.  
 
5.2 APT-1 levels modify thyroid tumoral cells behavior 
Due to our results we propose that H-RAS location in different plasma membrane 
microdomains, a process in part controlled by APT-1, is also of primary importance in 
anaplastic cells tumorigenesis, as H-RAS lateral diffusion after APT-1 ablation or 
overexpression modifies tumor growth and distant organ colonization. Moreover, it will be 
interesting to investigate H-RAS localization at ER and GC in C643 cells and HTH83, since 
they could be also collaborating in their oncogenicity.  
Overall our data suggests that i) small RAS-positive tumors can be highly metastatic, ii) H-
RAS subcellular location plays a fundamental role in growth and metastasis iii) APT-1 
overexpression is linked to H-RAS location in LRs and recapitulates H-RASv12-LCK effects 
in PCCL3 cells in the chick embryo metastasis model; and that iiii) APT-1 ablation 
translocates H-RAS from LRs to DM and APT-1 overexpression leads to H-RAS lateral 
diffusion from DM to LRs, completely changing cell behavior in tumor formation, cellular 
intravasation and distal organ colonization. 
When we looked for APT-1 alterations in databases of thyroid tumors we found that this 
protein was mutated only in 0,2% of the 507 samples of papillary thyroid carcinomas(302). 
However, it displayed had alterations both in DNA, including amplifications, gains, shallow 
deletions and deep deletions; and in mRNA levels, high and low, in 7% of the cases. When we 
analyzed survival in samples with alterations that lead to an overexpression in APT-1 (22 
cases) we observed 100% survival. When we looked at survival in samples with alterations that 
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lead to a decrease in APT-1, we did not see changes. However, the low amount of samples, 
only 5, that showed these alterations preclude us from making any assumptions. Surprinsingly, 
APT-1 alterations did not co-occurred with H-RAS alterations although they did at some 
extent with N-RAS suggesting that other depalmytoilases or palmytoilases could be involved 
in H-RAS and N-RAS, location at its different subcellular locations in thyroid cells, thus 
affecting its oncogenic potential. We propose that APT-1 even by regulating wild type RAS 
location, could be affecting tumor cells behavior. For instance, we have looked at another 
tumor type, melanoma, that harbors more alterations in APT-1 in order to get a clearer 
picture. Indeed, in cBioPortal database of 479 clinical samples we found that APT-1 was 
amplified in 2.7% of the melanoma cases. When we looked for samples presenting high 
mRNA levels, gains and amplifications of APT-1 we found that 39% of the samples showed 
these alterations (Fig. 5.1). We also looked for samples presenting low mRNA levels, shallow 
and deep deletions of APT-1 and we found that 11% of the samples presented them (Fig. 5.2). 
We also cheeked for co-occurrences with H-RAS and N-RAS mutations and we saw that 
almost half of the cases showing H-RAS mutations co-occurred with APT-1 altered mRNA 
expression. The same was observed for N-RAS (Fig. 5.3).  
We then looked for estimate survival and we found that patients exhibiting amplifications, 
gains or an increase in APT-1 mRNA levels, which, presumably promote the presence of RAS 
at LR, have a greater overall survival, around 11 months, compare to patients that did not 
have APT-1 alterations (Fig. 5.4 A). When we looked for the estimate survival of patients 
showing deletions or low mRNA levels of APT-1 we found that they have a lower overall 
survival, around 15 months compare to a group without these alterations (Fig. 5.4 A). 
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Figure 5.4: Overall survival Kaplan-Meier Estimate. Using data extracted from “cBioPortal for cancer 
genomics” using a cohort of 479 samples of skin cutaneous melanoma (TCGA) we selected the samples 
with APT-1 overexpression, amplification and gains (22 samples) and checked for overall survival (A) 
or the samples with low levels of APT-1 mRNA or deletions (6 samples) and checked again for overall 
survival (B).  
 
This data suggests that APT-1 might be crucial for RAS effects by affecting its subcellular 
location, reinforcing our findings. One explanation for our lack of alterations in APT-1 in 
thyroid cancer might be that the available database includes only papillary carcinomas and not  
other types, such as follicular thyroid carcinomas or anaplastic carcinomas, which harbor more 
RAS mutations. But no mRNA data was available for these tumors. Therefore, we can not 
conclude that APT-1 is not crucial for RAS driven thyroid tumorigenesis. In addition, we can 
speculate that APT-1 might also be to some extent modifying tumor behavior by altering wild 
type RAS subcellular location.  
However, APT-1 also has other substrates so we cannot solely attribute the consequences of 
its alterations to RAS segregation at plasma-membrane microdomains. Nevertheless, it is 
reasonable to speculate that APT-1 immunohistochemical assessment in FNA samples from 
RAS positive thyroid nodules might be a potential new marker to better rule out malignancy 
and risk of locoregional recurrence and distal metastasis. Moreover, it could also be used in 
other cancers as such as melanoma although more research in this respect is needed.   
New American Thyroid Association guidelines controversially recommends not to study 
nodules <1cm and advice for a partial thyroidectomy in RAS-positive papillary and follicular 
tumors between 1-4 cm (348). In spite that partial thyroidectomy has been chosen to avoid 
surgery complications and a life time of hormone supplementations, it worryingly alters the 
correct follow-up of these patients, which might lead to late diagnosis of locoregional or 
distant metastasis that otherwise would have been found earlier. However, although, these 
recommendations have been done due to little changes in overall survival (36), our results 
suggest that small H- and N-RAS-positive thyroid nodules and cancers could benefit from a 
total thyroidectomy and closer follow-up. Although it is necessary to work with clinical 
samples, we suggest that small thyroid nodules could benefit from FNA RAS status analysis. 
Moreover, we think that until good markers are found, RAS positive thyroid nodules should 
APT1 amplifications and  
high mRNA levels 
No alterations  No alterations  
APT-1 deletions and 
 low mRNA levels 
A. B. 
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not be limited to a partial thyroidectomy as the new 2015 ATA guidelines advice, and that the 
previous management, that was total thyroidectomy, should be recommended for the possible 
risks that small H- and N-RAS-positive thyroid nodules have to be cancerous and to 
metastasize.  
 
5.3 Endomembrane H-RAS signals promote MLB formation 
Our results show that cells that present H-RAS active in endomembranes, ER or GC, present 
a high amount of MLBs. Multilamellar bodies (MLBs) are membrane-bound cellular 
organelles of lysosomal nature, which vary in size from 100-2400 nm, they are composed of 
concentric membrane layers, and frequently exhibit an electron-dense core.  MLBs are found 
in numerous cell types, where they participate in lipid storage and secretion (349). Besides, 
lamellar bodies provide lipids and proteins to form the skin barrier (350). MLBs are also 
associated with various lysosomal storage diseases such as Fabry´s or Niemman-Pick 
syndromes, due to deficiencies in various lysosomal degradative enzymes and aberrant 
lysosomal accumulation of lipids. Multilamellar bodies can be formed from the Golgi Complex 
(320, 351, 352) or from endoplasmic reticulum (353) although their main way of formation is 
via autophagy (320). Our results lead us to speculate that H-RAS signals from 
endomembranes might alter lipid metabolism. leading to their accumulation in lysosomes and 
giving rise to MLBs. Long term culture of A549 a non-small cell lung cancer cell line, known 
to be K-RAS mutant, promote MLBs formation (354). We could speculate this is a 
consequence of mutant K-RAS presence at the ER. Therefore, further work needs to be done 
in order to relate endomembrane H-RAS signals to lipid disfunction and MLBs formation.   
 
5.4   VEGF-B implications in H-RAS mediated tumorigenesis 
 
Vascular endothelial growth factor B (VEGF-B) controls lipid accumulation in tissues by 
stimulating fatty acid transport through endothelial cells (137). Given that our frozen sections 
analysis demonstrates higher levels of fatty acids storages in H-RAS-M1 and H-RAS-LCK 
evoke tumors we studied the expression of VEGF-B as induced by the different H-RASv12 
subcellular locations and its role in tumor growth and metastasis. To date, there are no data 
with regards to the expression of VEGF-B in thyroid cancer. In the chick embryo model, we 
found that VEGF-B was highly expressed in cells harboring H-RASv12-M1 and H-RASv12-
LCK but not those with H-RASv12-CD8 or H-RASv12-KDEL. In agreement with these 
results C643 cells, that has H-RAS at LR, presented significantly higher levels of VEGF-B 
when compare to HTH83 cells with H-RAS at DM. Therefore, it was tempting to speculate 
that RAS sublocalizations may regulate VEGF-B secretion leading to fatty acids uptake and 
storage in thyroid cells tumors. Although VEGF-B over expression has been detected in a 
wide variety of tumors such as breast carcinoma, melanoma (139, 355), colorectal cancer (356), 
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oral squamous cell carcinomas (357), little is known about its implications. We observed that 
VEGF-B addition to H-RASv12-CD8 and H-RASv12-KDEL expressing cells, in vivo, using 
the chick embryo metastasis model, increased tumor weight but decreased cell intravasation 
and lungs colonization. VEGF-B does not induce angiogenesis (126, 134, 135) but it is capable 
of antagonizing VEGF-A-induced abnormal formation of leaky and permeable vessels (136). 
Therefore, since H-RAS signals in DM and GC induce high levels of VEGF-A we propose 
that VEGF-B might be stabilizing abnormal vessel formation, which would lead to organized, 
stable intra-tumoral vessels, showing less leakage and permeability, leading to high availability 
of nutrients, increasing cell growth and hindering cell intravasation that, in consequence, 
decreases metastasis.  
Only a few papers have addressed VEGF-B implications in cancer (139, 140, 355, 356) and 
none of them are in thyroid cancer. Studies using transgenic expression of VEGF-B in the 
RIP1-Tag2 mouse model of pancreatic neuroendocrine tumorigenesis retarded tumor growth 
(358). Moreover, another study has observed that colorectal tumors expressing high levels of 
VEGF-B were more metastatic, although primary tumors growth was largely impaired (356). 
Similarly, VEGF-B in a VEGF-A–null colorectal tumor resulted in attenuated primary tumor 
growth but substantial pulmonary metastases (139). Our results show the opposite for thyroid 
cancer so we can speculate that it is something tissue dependent, although more research is 
needed in this topic. Moreover, we should use a specific VEGF-B siRNA or shRNA to 
determine if its knockdown can increase metastasis. 
 
Since VEGF-B is upregulated in the less metastatic tumors we think that its 
immunohistochemical analysis, together with APT-1, should be assessed in human thyroid 
cancer samples in order to try to correlate their overexpression with tumor aggressiveness. If 
confirmed, they could be included in RAS positive thyroid nodules assessment to better 
stratify and manage patients. 
 
5.5  RAS sublocalizations implications in exosome secretion and its effects 
Exosomes are spherical to cup-shaped nanovesicles between 40-100 nm of endocytic origin, 
that are secreted by many cells including cancer cells. Indeed, H-RAS and K-RAS mutations 
in kidney cells or colon cancer cells alter exosomes cargo compared to wt cells, augmenting 
invasiveness (183, 186). Furthermore, mutant H-RAS genomic DNA is present in exosomes, 
relating to higher rates of invasion (177-179). But the most intriguing finding has been RAS 
co-precipitation with ESCRT-associated proteins ALIX and VSP4A, implicated in exosomes 
biogenesis, in glioblastoma EVs (181). Although further work needs to be done in that respect, 
these findings also relate RAS with EVs biogenesis. In consequence, we wanted to explore if 
RAS subcellular locations affected EV secretion.  
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Exosome biogenesis starts within the endosomal system; early endosomes mature into late 
endosomes or multivesicular bodies (MVBs) where intraluminal vesicles ILVs are formed 
through endosomal membrane invagination (152, 359). To first try to address exosome 
presence in our different RAS cell lines we looked for MVBs using transmission electron 
microscopy, which is the only technique that allows to visualize them. Our results show that all 
PCCL3 cells, parental and transfected with HRASv12 tethered to the different subcellular 
locations, present MVBs, which suggested that these cells secrete exosomes. However, some 
MVBs never reach the plasma membrane and are recycled into lysosomes (324). In 
consequence, exosome isolation by stablished methods such ultracentrifugation or size 
exclusion chromatography, was necessary to indirectly determine whether our MVBs fused to 
the membrane and released exosomes.  
ESCRT machinery is important in exosome biogenesis. ESCRT consist of four different 
protein complexes; ESCRT-0, -I, -II, -III and the associated proteins (VPS4, VTA1, ALIX) 
(152, 359). Some are widely used exosome markers, such as ALIX that can bind SYNTENIN 
and TSG-101, an ESCRT-I member, among others. Moreover, although not ESCRT related 
the presence of at least one tetraspanins, such as CD63, CD9 or CD81, is fundamental to 
define vesicles as exosomes. In our study we checked for these markers in order to confirm 
exosome secretion. Our results indicate that all cells lines including PCCL3 parental cells 
secrete exosomes since all, markers, ALIX, TSG-101, SYNTENIN and CD-63, are present. 
However, some differences between the different cell lines were seen. Parental cells and H-
RASv12-M1- and H-RASv12-LCK-expressing cells, which are the less metastatic, showed 
higher levels of ALIX but lower levels of SYNTENIN and TSG-101, compared to H-RASv12-
CD8 and H-RASv12-KDEL expressing cells. It is thus reasonable to speculate that RAS 
sublocalizations generate heterogeneous exosomes subpopulations. Indeed, the ESCRT 
biogenesis pathway is not the only one involved in exosome biogenesis since simultaneously 
silencing of key subunits of all four ESCRT-complexes, ILVs are still formed in MVBs (360). 
In consequence, it might be possible that H-RAS could be triggering at distinct exosome 
biogenesis pathways depending on its sublocalization. Interestingly, it has been described that 
ALIX silencing alters exosome protein composition without affecting their secretion (361). 
Therefore, one hypothesis that can derived from our last observation is that in H-RASv12-
CD8 and H-RASv12-KDEL expressing cells downregulation of ALIX could be affecting their 
cargo, generating different exosome populations. Therefore, we find of crucial interest to 
perform transcriptomic and proteomics analysis of the different exosomes in the future in 
order to confirm it.  
TSG-101, although being a ubiquitously-expressed exosome marker, is found at different 
concentrations among different prostate and breast cancer cell lines EVs, suggesting that 
that EVs biogenesis, or protein sorting mechanisms, may be different among those cell lines 
(362). Moreover, since TSG101 depletion reduces exosome secretion (152) we looked at 
exosome concentration using Nanoparticle Tracking analysis, that also analyzed their size. Our 
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results match these previous affirmations. Cells with H-RAS at ER and LR, that have lower 
levels of TSG101, manifest lower exosome secretion. Conversely, PCCL3 cells and H-RASv12-
CD8- and H-RAS-KDEL-expressing cells, which presents higher levels of TSG-101, showed 
higher exosome levels. Again, we can speculate that RAS sublocalizations could be either 
triggering different exosome biogenesis pathways or/and modifying exosome cargo. To assess 
so in the future, we could inhibit different biogenesis pathways such as the ESCRT one, and 
analyze their effects in exosomes. Furthermore, these results again reinforce the urgent need 
to analyze exosome cargo mainly by transcriptomics and proteomics.miRNA, small non-
coding RNA and ribosomal RNA, content could also be investigated as well as lipid 
composition by lipidomics.  
When we looked at the size of the exosome peak EVs (fractions 3-5), we saw that H-RASv12-
CD8 and H-RASv12-KDEL expressing cells derived EVs are bigger. This can suggest that we 
could be having a higher amount of microvesicles in these sets, or that they showed more 
protein aggregates since Nanoparticle Tracking analysis is not able to distinguish between 
exosomes, microvesicles or protein aggregates. 
Extracellular vesicles are key mediators in cell to cell colonization and have been shown to 
enhance tumor growth, angiogenesis, immune cell responses, survival, cell migration and 
invasion (318, 363, 364). To check whether exosomes could modify proliferation or tumor 
growth in our cells, we tested if EVs isolated form the different RAS-expressing cell lines could 
alter tumor behavior. Our studies show that DM and GC H-RAS-derived EVs reduce 
proliferation of cells with H-RAS at ER and LR in vitro and tumor growth in vivo. However, 
other cells EVs did not promote proliferation of cells with H-RAS at DM or LR. These 
findings contradict previous studies pointing EVs to be major tumor enhancers (365). 
However, little has been done in thyroid cancer in this respect and most findings have only 
associated thyroid-derived EVs as potent inductors of Epithelial-Mesenchymal Transition 
(EMT) (319, 366). Indeed, one study has shown that exosomes derived form a papillary 
thyroid carcinoma cell line, after Transforming Growth factor (TGF) -β1 treatment, 
transferred to other cells long non coding RNAs with some EMT transcriptional factors 
such as SLUG or SOX2 (319, 366).  
In other cancer types it has been shown that tumor derived exosomes (TDEs) can provide 
autocrine and paracrine signals programming cancer cells to invade surrounding stromal 
tissue, to allow intravasation and to enter the circulation (367-370). Moreover, TDEs can 
educate non-cancer cells in distant organs by metabolic reprogramming, recruiting immune 
cells and other stromal cells stablishing a supportive microenvironment, also known as 
metastatic niche formation, that facilitates tumor cell arrest, extravasation and later 
colonization (364, 371). In consequence, tumor cells organotropism is also shaped by TDEs. 
For example, EVs from pancreatic ductal adenocarcinoma cells can create an ideal fibrotic 
liver pre-metastatic niche by transferring Migration Inhibitory Factor (MIF) to Kupffer cells 
in the liver (170) (372). Another study showed that highly metastatic melanoma cells release 
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EVs, which increased vascular leakiness and enhanced metastasis of melanoma cells 
orthotopically injected into mice (373).  
To check whether exosomes from the most aggressive H-RAS sublocalization (DM and GC) 
transferred their ability to colonize lungs to cells wit H-RAS at LR and ER we incubated the 
corresponding EVs with cells harboring site-specific H-RAS with low metastatic potential. We 
found that EVs isolated from the most metastatic cells can induce lung colonization of 
previously low metastatic cells. However, EVs derived from the less metastatic cells could not 
stop GC or DM H-RAS signals to promote lung colonization, suggesting that EVs derived 
from LR and ER RAS-expressing cells are not the responsible for these cells inability to 
colonize distant organs. It is then reasonable to propose that H-RASv12-CD8 or H-RASv12-
KDEL expressing cells-derived EVs could be capable of modulating organotropism and 
shaping of the pre-metastatic niche. In this regard, as EVs in lung can be uptaken by either 
endothelial cells or fibroblasts (374, 375) new investigations are needed to fully confirm their 
uptake and its consequences. 
Additionally, although mutant K-RAS can be transferred via exosomes in a colon cancer 
model (186), our model cannot assess RAS transference to other cells since our constructs do 
not recapitulate physiological conditions. Therefore, we cannot affirm either that thyroid cell 
exosomes will be able to introduce mutant H-RAS into their EVs or that this possible situation 
will lead to increase tumor and/or normal cells proliferation.  
Besides EVs favoring pre-metastatic niche formation, EVs have also been linked to cancer 
cells organotropism. It has been shown that priming a mouse with EVs derived from a specific 
cancer cell line that normally metastasizes to the lungs, can redirect a bone-metastasizing cell 
to the lungs (171). It has been suggested that integrins were responsible for specific organ 
colonization.  Integrin α6 was linked to lung metastasis, whereas integrins αv and β5 were 
implicated in liver metastasis (152, 171). For instance, Integrin α 6 shows a 73.3 % homology 
between Rattus Norvegicus and Gallus Gallus using BLAST analysis. Although these 
differences in their sequence, main biding sites might remain unaltered during evolution. 
Therefore, we think that integrin α 6 expression should be checked among our different EVs 
to see whether their express it to different levels and if it is implicated in lung tropism and 
metastasis.  
Additionally, we have demonstrated that cells with LRs H-RAS signals have certain tropism 
to colonize liver, since they exhibit higher rates of colonization compared to other H-RAS 
sublocalizations. However, when we looked livers by immunohistochemistry small number of 
cells were present showing only small cells foci. These results can be explained since liver is 
the first organ that intravasated cells reach once entering chick embryo circulation. In 
consequence, since all potential metastatic cells will firstly arrive there, and due the permeable 
nature of liver sinusoids vessels, which facilitate cells extravasation (376, 377), it can be 
speculated that although H-RASv12-LCK-expressing cells might have a weak tropism to 
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chicken liver it may not be relevant in humans. Indeed, human thyroid tumors are unlikely to 
metastasize in liver but mainly invade regional lymph nodes and lungs due to their relative 
closeness and vascularization (348). Therefore, our results suggest LRs H-RAS signals to not 
be crucial in liver or lung metastasis in humans and that LRs H-RAS cells-secreted EVs cannot 
induce higher rates of liver colonization in H-RASv12-CD8 or H-RASv12-KDEL expressing 
cells.  
To sum up, our results suggest for the first time, that RAS sublocalizations have a key role in 
exosome biogenesis by using different pathways that affect the amount, the size and cargo 
loading of exosomes. As a result of exosome heterogeneity, EVs released by PCCL3 with 
mutant H-RAS at GC or DM, display similar characteristics, and can induce a decrease in H-
RAS LR and ER mediated proliferation in vitro and in vivo. More interestingly, these EVs 
can transfer lung metastatic properties, suggesting that they can be educating the lung pre-
metastatic niche although they might also be increasing cell migration and invasion. This part 
of the project is just currently starting but shows novel and exciting data that needs to be 
further explored. Moreover, if different cargos are found between EVs secreted by either H-
RAS at DM and GC, vs,  H-RAS at ER and LR, they could be monitored in patients liquid 
biopsies which could save patients discomfort and it would possibly help to detect early 
recurrences and metastasis, even in patients that only undergo a partial thyroidectomy.  
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6.   CONCLUSIONS 
 
1. Tumor size in tumors induced by H-RAS and N-RAS site specific signals does not 
correlate with metastatic potential. 
 
2. The ability to colonize lungs is given by mainly by RAS signals coming from DM  
 
3. APT-1 levels modify thyroid tumor cells behavior with respect to their proliferation 
and metastatic potential by regulating RAS segregation in plasma-membrane 
microdomains 
 
4. Tumors with H-RAS at LR and ER accumulate lipids and it relates with high VEGF-
B expression levels 
 
5. VEGF-B can alter tumor size and the metastatic potential of cells expressing RAS at 
DM and GC 
 
6. PCCL3 cells expressing H-RASv12 at its different sublocalizations secrete different 
populations of EVs   
 
7. Depending on RAS sublocalization, the generated EVs can alter tumor behavior 
distinctively 
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